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Abstract 
The differentiation of stem cells into multiple lineages has been 
explored in vascular regenerative medicine and tissue engineering. However, in 
the case of smooth muscle cells (SMC), issues exist concerning inefficient rates 
of differentiation and a lack of understanding of the molecular mechanisms 
underpinning smooth muscle phenotype development. In stem cells, multiple 
repressors potentially downregulate myocardin, the potent SRF coactivator 
induced SMC transcription including Krüppel like zinc finger transcription factor-
4 (KLF4). This thesis aimed to explore the role of KLF4 in the regulation of 
myocardin gene expression in human smooth muscle stem/progenitor cells 
(hSMSPC), a novel circulating stem cell identified in our laboratory which 
expresses low levels of myocardin and higher levels of KLF4. hSMSPC cells 
cultured in SmGM2 1% FBS with TGF-β1 (5 ng/ml “differentiation media”) show 
limited SMC cell differentiation potential. Furthermore, myocardin transduced 
hSMSPC cells cultured in differentiation media induced myofilamentous SMC 
like cells with expression of SM markers. Five potential KLF4 binding sites were 
identified in silico within 3.9Kb upstream of the translational start site of the 
human myocardin promoter. Chromatin immunoprecipitation assays verified that 
endogenous KLF4 binds the human myocardin promoter at -3702bp with 
respect to the translation start site (-1). Transduction of lentiviral vectors 
encoding either myocardin cDNA (LV_myocardin) or KLF4 targeting shRNA 
(LV_shKLF4 B) induced human myocardin promoter activity in hSMSPCs. 
Silencing of KLF4 expression in differentiation media induced smooth muscle 
like morphology by day 5 in culture and increased overtime with expression of 
SMC markers in hSMSPCs. Implantation of silastic tubes into the rat peritoneal 
cavity induces formation of a tissue capsule structure which may be used as 
vascular grafts. Rat SMSPCs integrate into, strengthen and enhance the SMC 
component of such tubular capsules. These data demonstrate that KLF4 directly 
represses myocardin gene expression in hSMSPCs, which when differentiated, 
provide a potential source of SMCs in the development of autologous vascular 
grafts in regenerative medicine.  
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1. Review of literature 
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1.1. Introduction 
Cardiovascular disease (CVD) remains a leading cause of death in the 
Western world as well as in developing countries [1, 2]. Atherosclerosis, a major 
component of CVD, is caused by the accumulation of fatty materials, inflammatory 
macrophages and smooth muscle cells [3]. Vascular smooth muscle cells (VSMCs) 
line the walls of blood vessels and are spindle shaped cells range from 5-10μm in 
diameter which maintain the shape and tone of blood vessels. VSMCs are 
surrounded by basement membrane sheets of extra cellular matrix (ECM). ECM 
acts as scaffold for cell adhesion and plays a major role in cell differentiation, cell 
migration and cell proliferation. The major components of basement membrane are 
laminin, collagen IV and heparan sulphate proteoglycan perlecan [4]. Collagen IV 
maintains structural stability of ECM and heparan sulphate proteoglycan bridges 
laminin and collagen IV and also interacts with soluble growth factors [5].  
1.2.  Role of smooth muscle cells in Atherosclerosis 
The arterial vessel wall is made of three layers, tunica intima (inner layer), 
tunica media (middle layer) and tunica adventitia (outer layer). The intimal layer 
consists of endothelial cells that line the lumen. The middle layer comprises smooth 
muscle cell, which controls vascular constriction and vasodilation whereas the outer 
layer includes connective tissue and its function is to attach the vessels to the 
neighbouring tissue [6].  
Atherosclerosis (from Greek origin athere –meaning gruel, or wax and 
sclerosis - hardening) of arteries is the most common cause for heart attacks and 
stroke. The major factor responsible for this pathological process is apo-B 
containing lipoprotein retention and subsequent recruitment of smooth muscle cells 
and inflammatory macrophages and T-lymphocytes to the arterial wall [7, 8].  SMC 
accumulates in the intimal region, secretes extracellular matrix including collagen, 
elastin and proteoglycans leads to fibrous tissue formation, which is the 
characteristic component of the developing lesion [7]. Plaque rupture of the thin 
fibrous cap mediates plaque instability and perpetuates thrombosis which results in 
complete occlusion of artery leading to myocardial infarction [9-11]. SMC 
accumulation in the intimal region heals the ruptured plaque and also leads to 
intimal hyperplasia. This healing process narrows the artery and mediates arterial 
stenosis [12]. The developmental stages of atherosclerotic plaque are shown in 
Fig.1.1. 
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Figure 1-1. Developmental stages of atherosclerotic plaque.  
A) Normal arterial wall showing inner layer with endothelial cells, elastic lamina and middle 
layer with smooth muscle cells. B) Artery with plaque development due to accumulation of 
LDL cholesterol recruitment of macrophages and smooth muscle cells results C) Artery with 
plaque rupture and thrombosis. 
1.3. SMC in Vasculogenesis 
Embryonic blood vessel formation involves vasculogenesis, which is the 
spontaneous organisation of blood vessel by endothelial cell differentiation from 
mesoderm. This endothelium monolayer recruits primitive SMC precursor cells from 
mesenchyme which differentiate into VSMCs and form a multilayered vessel wall 
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[13]. VSMCs in association with vascular endothelium produce extracellular matrix 
within the vessel wall and form mature blood vessels [14]. In normal arteries, the 
medial layer is composed of layers of contractile smooth muscle cells. During 
development, the smooth muscle cells are fibroblast like with larger endoplasmic 
reticulum, prominent golgi complex and lesser myofilament [15]. When the vessel 
matures, smooth muscle cells secrete more extracellular components [16]  results in 
decrease in organelles size and increase in myofilament of the cell [15]. These 
studies suggest that SMC plays a major role in vasculogenesis as well as in 
development of vascular diseases. 
1.4. Smooth muscle markers 
Mature medial contractile SMCs express a range of unique smooth muscle 
lineage specific proteins including SM α actin [17], SM22α [18], SM1 and SM2 
myosin [16], calponin, and h-caldesmon [16]. However, in response to various 
environmental cues such as vascular injury, cytokines and extracellular matrix, the 
differentiated SMC switch to a highly proliferative phenotype [19] characterised by a 
drastic decrease in expression of smooth muscle markers such as SM α actin [17, 
20], SM22α [18], SM1 and SM2 myosin [18], calponin, and h-caldesmon [21, 22] 
(Fig.1.2), suggesting that identification of these multifunctional SMCs will be 
possible only through a clear understanding of the transcriptional regulation of 
smooth muscle marker genes. 
 
Figure 1-2. Phenotypic switching of vascular smooth muscle cells between contractile 
and synthetic state. 
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1.4.1. SM α actin  
Actin is the most abundant cellular protein which is involved in cytoskeletal 
organisation and muscular contraction in the eukaryotic cell [23]. Actin is highly 
conserved across species, exists as six different isoforms [24] coded by separate 
genes and grouped into three classes α, β and γ based on their isoelectric point 
[25]. Alpha actins (α-skeletal, α-aortic smooth, α-cardiac and γ2-enteric smooth) are 
specific to muscle whereas beta and gamma isoforms (β- and γ1 –cytoplasmic) are 
prominent in non muscle. Vascular smooth muscle cells predominantly express 
alpha type SM α actin [25] and vimentin whereas other smooth muscle cell types in 
digestive, respiratory and urinary tracts express gamma type SM α actin and desmin 
[26]. SM α actin is 43 kDa protein encoded by ACTA2 gene and its main function is 
to generate force in VSMCs during contraction [27, 28]. SM α actin is the early 
marker expressed in differentiated SMCs which arise from mesenchyme during 
vasculogenesis [29]. In early vasculature, β-actin content is higher than α actin. As 
vessels mature, the SM α actin content increases significantly and occupies 70% of 
actin content in VSMCs [30]. SM α actin has also shown to be expressed in 
pericytes [31], myofibroblasts [32] and tumours [33]. In spite of their abundance and 
early occurrence during differentiation, SM α actin is not an exclusive marker for 
vascular smooth muscle cell lineage due to their expression in other cell types. 
1.4.2. Smooth muscle myosin heavy chain (SMMHC) 
Myosins are motor proteins involved in muscular contraction. Myosins are 
classified into 20 different classes [34] based on phylogenetic analysis of a 
conserved domain [35]. Different myosins show variation in their tail domain 
whereas head domain sequences are highly conserved among them. The class II 
myosins in human have 15 genes, six skeletal myosin heavy chains [36], two 
cardiac myosin heavy chains, one smooth muscle myosin heavy chain and  two 
non-muscle myosin II heavy, respectively [37]. Myosin is a hexamer protein made of 
two myosin heavy chains and two set of myosin light chains [38]. 
Smooth muscle myosin heavy chain (200-204 kDa protein) is one of the  
exclusive markers for vascular smooth muscle cells [39]. In situ hybridization studies 
in mice demonstrated that the expression of SMMHC was confined to smooth 
muscle tissues and was first detected in the developing aorta at 10.5 postcoitum [39, 
40]. Furthermore, the expression of MHC isoforms was not detected in cells other 
than smooth muscle lineage [39], suggesting that SMMHC can be used as an 
exclusive markers for SMCs 
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Previous studies have identified many isoforms of smooth muscle myosin 
heavy chain generated via alternate splicing of single gene (MYH11). Alternate 
splicing in the 3’ region produces SM2 (200kDa) and SM1 (204 kDa) isoforms [40, 
41] whereas alternate splicing in the 5’ region coupled with insertion of exon 5b 
(seven - amino acid insert) at the 25-50 kDa junction of the myosin produces SMB 
isoform and without exon 5b insertion produces SMA isoform [42, 43]. The use of 
both splicing sites produces four different isoforms SM1A, SM1B, SM2A and SM2B 
[44]. The presence of a seven amino acid insert sequence in SM1B is associated 
with higher actin activated ATPase activity, suggesting that presence of SM1B may 
contribute to varying functional properties of SMCs in different tissues [45].  
A number of studies demonstrate that the expressions of SMMHC isoforms 
are differentially regulated during development of SMCs in a tissue specific manner 
[46]. The SMB isoform showed a predominant expression in all stages of bladder 
development. The expression of the SMB isoform was detected at 1 week in 
neonatal rat aorta but the transcript level decreased to an almost undetectable level 
in the adult aorta [46]. VSMC in aorta express both SM1 and SM2 isoforms [40, 47] 
which are developmentally regulated; the SM1 isoform is expressed in VSMC from 
the late fetal stage throughout adult, whereas the SM2 isoform expression appears 
only in fully differentiated SMCs after birth [21, 48]. VSMCs isolated from aorta 
continue to express only the SM1 isoform but the expression of SM2 isoform is 
downregulated in culture [49, 50]. During atherosclerotic lesion development, 
phenotypic modulation of VSMCs was accompanied by reduction in SM2 isoform 
with marked increase in SMB isoform [21]. Taken together, these studies suggest 
that the expression of smooth muscle myosin heavy chain (SMMHC) is 
developmentally regulated and smooth muscle myosin heavy chain (SMMHC) 
isoforms can be used as exclusive markers to study VSMC differentiation as well as 
for atherosclerosis [51]. 
1.4.3. Calponin 
Calponin (CNN) is a troponin –T like myofibrillar thin filament 28-34 kDa 
protein and was originally isolated from chicken gizzard smooth muscle and bovine 
aorta [52, 53]. Calponin is involved in stabilization of cytoskeletal actin [54] and 
regulation of smooth muscle contraction [55].  Three isoforms of calponin, named 
h1, h2 and acidic calponin have been identified in smooth muscle cells [56] and are 
found to be transcribed from three different genes [57]. Calponin family protein 
consists of three domains, the N-terminal calponin domain, the middle actin binding 
domain and the C-terminal domain. Calponin isoforms are distinguished from each 
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other by their unique C-terminal tails [58]. Based on the isoelectric points (pls), 
calponin isoforms are categorised as basic or h1-calponin (CNN1) with pI = 8.5–9.2, 
acidic calponin (CNN3) with pI of 5.5 to 5.8 and neutral or h2 calponin (CNN2) with 
pI = 7.2–7.6, respectively. [59, 60]. Two dimensional gel electrophoresis analyses 
has identified a spliced variant of α calponin named β calponin (28 kDa protein) and 
its expression was predominantly detected in urogenital tract smooth muscle cells 
[61]. Neutral (h2 calponin) [57] and acidic calponin (h3 calponin) [56] are encoded 
by two different genes and are expressed in lower levels in smooth muscle and non 
muscle cells. Neutral calponin (CNN2) has been found to be expressed in heart [62] 
and in remodelling smooth muscle cells [60]. However, acidic calponin (CNN3) was 
expressed predominantly in rat brain [56] and shown to facilitate wound healing 
activity by extracellular-signal-regulated kinases 1/2 (ERK1\2) activation and 
enhance cell motility in fibroblast [63]. 
Basic calponin (CNN1) is the most abundant form present in differentiated 
smooth muscle cells [61] and modulates contraction of smooth muscle cells [55]. In 
contrast, expression of h2 calponin is detected in non muscle cells such as heart 
[62], endothelial cells and fibroblast [64]. Of note, h2 calponin has also been 
detected at elevated levels in remodelling and growing SMCs in culture [60]. 
 Calponin binds to F-actin and regulates actin myosin interaction by 
blocking the activation of myosin ATPase in calcium dependent manner. An 
increase in intracellular calcium levels activates the calcium calmodulin complex 
formation. This complex binds to calponin and releases the actin molecule to 
interact with phosphorylated myosin resulting smooth muscle contraction [55]. 
Calponin phosphorylation by calcium calmodulin kinase II also disassociates actin 
and induces smooth muscle contraction in calcium independent manner [55]. The 
basic h1-calponin (CNN1) is predominantly smooth muscle specific and its 
expression is strongly downregulated in dedifferentiated SMCs and passaged 
VSMCs in culture [61, 65]. 
Gimona [66] and co workers investigated changes in calponin expression 
in smooth muscle cells from chicken gizzard and non muscle tissues during 
development based on monoclonal antibody for calponin. Results revealed that 
SMCs from chicken gizzard expressed increased differentiation linked calponin 
expression. In contrast, tissues from non muscles such as chicken skeletal muscles, 
kidney, spleen, liver and cardiac muscles showed no calponin expression [66], 
suggesting that calponin expression may be used as index to measure  smooth 
muscle differentiation. 
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Expression of h1-calponin is developmentally regulated in VSMCs. In 
developing dorsal aorta, cardiac outflow and tubular heart calponin was detected in 
E9.5 murine embryos [67]. Expression of h1-calponin increased drastically in 
vascular smooth muscle cells whereas expression of h1-calponin progressively 
decreased to undetectable levels in heart [67], suggesting that the expression of h1-
calponin may be used as an indicator for contractile SMC phenotype.  
In summary, these studies indicate that smooth muscle markers and their 
isoforms may be used for assessing the various stages of differentiation/proliferation 
of the smooth muscle cells. 
1.5. VSMC and phenotypic modulation 
VSMCs present in the arterial media are maintained at the  G0/G1 resting 
phase of the cell cycle and exhibit high level of contractile smooth muscle marker 
genes[68]. However, in response to vascular injury and subsequent release of 
growth factors, VSMCs attain a highly proliferative synthetic phenotype [69]. This 
process which changes the contractile to a synthetic state is called phenotypic 
modulation or SMC plasticity [70, 71] (Fig.1.2). 
Smooth muscle cells are the major extracellular matrix generators in blood 
vessels [14]. During blood vessel development, the immature SMCs are in a 
dynamic state with high proliferation and migration potential [72]. As vessels mature, 
the SMCs becomes quiescent [73] and fully differentiated with characterised 
expression of contractile phenotypic markers. SMC phenotype can switch between 
the dynamic and quiescent state upon local environmental cues. Unlike the cardiac 
and skeletal muscle, the SMC are not terminally differentiated. Phenotypic 
modulation of SMCs occurs during pathological conditions and helps SMCs to attain 
the highly dynamic state to exhibit multiple states of growth and differentiation. The 
sequence of events that takes place during pathological intimal thickening 
resembles the neonatal intimal thickening during development which explains that 
intrinsic migration potential of SMC may not be age related [74] but its migratory 
potential is controlled by local environment. The decision to undergo phenotypic 
modulation is aided by different growth factors produced in the cellular environment.  
Therefore a key for understanding the SMC differentiation and phenotypic 
modulation is to identify transcription factors that regulate smooth muscle specific 
genes that results in the distinct phenotype of the VSMC [22, 75].  
The expression of skeletal and cardiac muscle specific genes is 
developmentally regulated [76] and many master control genes have been identified 
9 
 
which alone control the skeletal muscle lineage [75]. Skeletal and cardiac muscles 
express overlapping sets of muscle specific genes. Skeletal muscle specific 
transcription is activated by MyoD family of regulatory factors whereas 
cardiomyocytes have unique cell type specific helix-loop-helix (HLH) protein for 
activation of cardiac muscle specific gene activation [76]. MyoD family proteins 
belong to the basic-helix-loop-helix (bHLH) transcription factor. They include MyoD, 
myogenic factor 5 (Myf5), myogenin, and myogenic regulatory factors 4 (MRF4) and 
they  share 80% homology within a segment of 70 amino acids that contain a basic 
region and a helix-loop-helix conformation [77]. HLH motif dimerization brings the 
basic region together and forms the DNA binding domain which recognizes the dyad 
symmetrical DNA sequences CANNTG ( N is nucleotide) called  E boxes [78], found 
in 5’ flanking regions of skeletal muscle specific genes and activate transcription in 
association with ubiquitous bHLH proteins referred as E proteins [79, 80]. Over 
expression of the MyoD family genes in non muscle cells can activate a skeletal 
muscle differentiation is program in non muscle cells [80]. Specificity of MyoD in 
skeletal muscle specific gene transcription referred to a master regulatory gene. 
Inhibitor of DNA-binding/differentiation (Id) protein, an inhibitor for differentiation also 
belongs to the HLH family of protein. Id proteins lack the DNA binding domain but 
they can negatively regulate the function of MyoD protein through the formation of 
non functional heterodimer.  Id expression is high during proliferation of skeletal 
muscle and down regulated during differentiation [81]. Thus, skeletal muscle 
development and differentiation is well defined and its transcription machinery is 
controlled by a master regulatory gene. 
 In contrast, SMC transcription is not controlled by a master transcription 
factor. Moreover, in response to various cytokine stimuli SMC undergoes 
dedifferentiation from its contractile phenotype to synthetic phenotype which is the 
underlying mechanism for many vascular diseases. This is described as phenotypic 
modulation of SMC which is accompanied by downregulation of differentiation 
markers SM  actin, SMMHC and SM22 . The key challenge in the SMC field is to 
determine transcriptional regulation of SMC under various physiological and 
pathological conditions. Extensive research has been carried out in the last decade 
in identifying transcriptional regulators of SMC. 
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1.6. Transcriptional regulation of smooth muscle cells 
1.6.1. CArG Element 
Comparative promoter analysis of the human, mouse and chicken cardiac 
 actin gene showed the presence of common motif coined as the CCArGG box 
(CC (A/G-rich) GG which is conserved in evolution [82]. From here, CCArGG box 
abbreviated as CArG box. CArG boxes are found in muscle restricted genes and 
growth related genes which are controlled by SRF. The CArG box was identified as 
a core sequence of the serum response element (SRE) in the c-fos gene [83] with a 
single CArG box in its promoter region whereas most smooth muscle markers have 
at least two CArG boxes located in their promoter and first intronic regions [84-87]. 
CArG boxes are located in the promoter region of smooth muscle (SM  actin, 
SM22 , SMMHC, telokin, calponin etc), cardiac (cardiac α actin, βMHC and 
dystrophin [82, 88-90] and skeletal muscle  actin genes [91]. They are also located 
in many immediate early genes including erg1, erg2 and β actin [92]. 
The SM α actin promoter has three CArG elements CArG A, CArG B and 
intronic CArG located at -62, -112 and +1001 bp, respectively. The spacing and 
phasing of the SM α actin CArG element are important for its promoter function. The 
CArG A and CArG B are located in close proximity with 40 bp distance between 
them on the same side of the DNA helix. Changes in the distance between CArG 
element and phase of CArG element may abrogate the SM α actin promoter activity, 
suggesting that spacing between the paired CArG elements are critical for SRF and 
its cofactor binding/interaction in SMC promoter transactivation [93]. 
SMC subtypes use distinct transcriptional control for activation of smooth 
muscle specific genes. SMMHC gene expression is highly restricted to SMC and 
expressed throughout development and maturation [39]. SMMHC has three CArG 
boxes in its promoter region and is used distinctly in SMC subtypes. Transgenic 
mice harboring a conserved SMMHC promoter reporter construct (–4200 to +11600 
region of SMMHC gene) showed that SMC specific expression of SMMHC gene 
requires 4.2 Kb of the 5’ flanking sequence, the entire first exon and 11.5 Kb of the 
first intronic sequence in all subtypes of SMCs. CArG2 box located at -1231bp and 
the intronic CArG element is an absolute necessity for SMMHC expression in large 
blood vessel whereas it has minor role in controlling expression of SMCs in 
gastrointestinal and urinary tract SMCs.  Thus, SMMHC gene expression is 
differentially regulated by the presence of multiple CArG elements within its 
promoter region in SMC subtypes.  [86]. Similarly, transcription of SM22   in cardiac 
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and smooth muscle cells is dependent on presence of two CArG boxes in its 
promoter region. SM  actin gene has three CArG elements located within -2.6/+2.8 
Kb of the promoter enhancer region. [94]. Taken together, location and number of 
CArG box present in the promoter region determines the tissue specific expression 
in SMC subtypes. 
Smooth muscle marker CArG elements are degenerate compared with the 
conserved consensus CArG element of c-fos promoter [95, 96]. The SM marker 
CArG element has G or C substitution within their A/T cores and highly conserved in 
evolution [95, 97] and plays a major role in SMC selective regulation during 
development and vascular injury. The G/C substitution in CArG elements mediate 
reduced SRF binding in SMC as compared to c-fos CArG element with high SRF 
binding affinity [95, 96, 98]. Smooth muscle genes showed a significant 
transcriptional repression seven days after vascular injury and their expression level 
returned to nearly equal to control level by 14 after vascular injury [98, 99]. 
Substitution of consensus CArG elements from c-fos to both 5’ CArG elements of 
SM  actin promoter showed no difference in SMC specific expression whereas the 
transgenic mice showed an attenuated SM  actin expression level after vascular 
injury. In addition, the SRF expression level was increased but expression of 
myocardin was decreased within three days and returned to nearly equal to control 
level by seven days after carotid injury [98]. Further, myocardin increased SRF 
interaction with CArG element of SM  actin promoter but not of c-fos promoter 
region, suggesting that G/C substitution within 5’CArG element (CArG degeneracy) 
within the SMC promoters and decreased myocardin expression level plays a critical 
role in phenotypic switching of SMC in response to vascular injury [98]. 
1.6.2. Serum response factor (SRF) 
SRF, a MADS ( MCM1, Agamous, Deficiens, SRF) box transcription factor 
is expressed in a wide range of cell types and was first identified as SRE binding 
protein by its ability to activate c-fos gene upon serum stimulation [100]. SRF has 
four isoforms known as SRF-L, SRF-M, SRF-S and SRF-I generated through 
alternative splicing and its expression is regulated in a tissue specific manner. SRF-
M and SRF-L are expressed at similar levels in differentiated smooth muscle and 
skeletal muscles but SRF-L is predominantly expressed in other tissues. SRF-S and 
SRF-I expression are exclusive to differentiated VSMC and embryo respectively 
[101]. SRF binds on CArG box [102] as homodimer [100] and recruits a variety of 
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transcriptional cofactors and activates transcription of most of the muscle specific 
gene expression [103], [104]. 
The c-fos CArG element has a higher SRF binding affinity compared to 
many SMC CArG elements. SRF binding affinity is dependent on the G/C 
nucleotides within the 5’ CArG element. For example, the SM  actin CArG element 
contains a single G or C substitution in A/T rich region of CArG element found to be 
responsible for its low SRF binding affinity. SMC with abundant SRF enhances its 
binding affinity to degenerative CArG elements [95, 105]. SRF activity can be 
modulated through its prolonged DNA binding to CArG element [106]. 
Homeodomain protein MHox induced by angiotensin II mediates SRF binding to SM 
 actin CArG element [107]. Another, homeodomain protein Barx2b, found to 
enhance SRF binding to telokin CArG element [108]. In contrast, homeodomain – 
only protein (HOP) physically associates with SRF and inhibits the SRF to bind to 
CArG element [109, 110]. Thus, SRF protein: protein interaction can modulate SRF 
binding to CArG element. 
SRF is a weak transcriptional activator but it’s able to interact with over 60 
cofactors and attain its strong transcriptional activator potential in a tissue specific 
manner. SRF directs the gene expression mainly through two signalling pathways 
[111, 112]. First, the classical pathway involves growth factor stimulation 
phosphorylation of SRF through mitogen-activated protein kinases (MAPKinase) 
pathway which results in growth related genes activation [113, 114] and the second 
is the Ras homolog gene family, member A (RhoA) pathway of actin dynamics [115], 
which involves nuclear translocation of myocardin related transcription factor A 
(MRTF-A) in response to F actin and activation of SRF dependent genes [116]. 
Furthermore, SRF dependent growth related genes encode for protein that activates 
cell cycle genes [117]. Thus SRF is an indirect controller of cell growth and the 
contractile apparatus. Presence of an Ets (E-twenty six) binding sequence 
(GGAA/T) adjacent to CArG element in most of the smooth muscle marker gene 
promoters and in growth related genes enables SRF to toggle between programs of 
differentiation and cellular growth. Stimulation of MAPKinase signalling cascade by 
epidermal growth factor (EGF) phosphorylates SRF [118] which interacts with 
ternary complex factor (TCF) and activates transcription of c-fos gene via SRE 
element. In addition to SRF, c-fos activation involves other transcription factor 
interaction with SRF and SRE [119]. ETS domain-containing protein, Elk-1 is one 
such factor which forms a ternary complex with SRF bound to SRE element and 
activates c-fos gene in response to protein kinase C dependent signalling [120]. Elk-
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1 is member of the ternary complex factor (TCF) subfamily of the ETS domain 
transcription factor and is activated via phosphorylation of MAPK pathway [121]. Elk-
1 contains conserved N terminal ETS domain with high sequence specific DNA 
binding potential [122, 123], the B–Box which directs protein: protein interaction with 
SRF [124] and the C terminal transactivation domain target for phosphorylation by 
MAPK pathway [125, 126]. The Elk-1 association with SRF is stabilized by additional 
binding of its ETS domain to ETS sequences. [121, 127]. MAPKK, kinase of 
mitogen-activated protein kinase 1/2 (MEK 1/2) dependent phosphorylation of ERK-
1/2 phosphorylates Elk-1 and stimulates its interaction with SRF [128]. 
Phosphorylated Elk (Elk-p) then competes with myocardin for the SRF docking site 
which displaces myocardin and downregulates smooth muscle gene expression 
[127]. In addition, Elk-1 binding to Ets binding sequences adjacent to CArG box 
partially blocks myocardin association with SRF [129]. Thus, SRF modulates genes 
involved in growth and differentiation of smooth muscle cells through changing its 
interaction with Elk-1 and myocardin. 
SRF plays a critical role in embryogenesis during mesoderm differentiation 
[130] and transcriptional regulation of cardiac muscle genes. SRF null embryos 
failed to develop beyond E6.0 and showed lethality with impaired mesoderm 
development. SRF-/- embryonic stem cells in mouse showed defects in muscle 
specific gene expression and in immediate early genes [131, 132]. Inactivation of 
SRF in cardiomyocytes attenuates the sarcomeric proteins necessary for its 
contractility [133]. In mouse, cardiac and smooth muscle specific deletion of SRF 
results in lethality. Skeletal muscle specific SRF knockout leads to perinatal lethality 
with severe skeletal muscle myopathy in mice [134]. Taken together, these data 
suggest that SRF is critical for regulation of cardiac, smooth and skeletal 
transcriptional regulation.  
The structure and function of chromatin is predominantly through 
posttranslational modification of histone lysine residues methylation and acetylation 
by histone acetyltransferase (HAT) and histone methyltransferase (HMT) activity 
[135]. The acetylation process unwinds the chromatin whereas methylation can 
serve as a docking site for transcription factors on chromatin [136, 137]. This 
epigenetic mechanism is well documented in regulation of SMC-specific SRF 
binding to CArG elements. SMC specific SRF activation is also determined by an 
epigenetic control mechanism through posttranscriptional histone modification which 
includes methylation and acetylation of histone H3 and H4 residues. Myocardin 
utilizes smooth muscle specific epigenetic element (H3K4dMe) and controls SRF 
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binding to CArG box DNA. Presence of SMC restricted myocardin and H3K4Me 
mediates SRF to activate smooth muscle specific genes [138]. In contrast, upon 
vascular injury, KLF4 binds to the evolutionary conserved TCE elements adjacent to 
CArG box [139, 140] which recruits HDCA2 to deacetylate histone H4 [141] and 
repress myocardin/SRF activation of smooth muscle specific genes. 
In summary, posttranscriptional modification, associated with positive and 
negative cofactors, binding affinity to CArG box, the presence of different isoforms 
explain how SRF can activate a wide range of genes involving exclusive events like 
growth and differentiation [93, 103]. 
1.6.3. Myocardin 
The major breakthrough in understanding gene regulation in SMC was the 
identification of a novel and potent transcriptional cofactor; named myocardin using 
bioinformatics based screening of unknown cardiac specific genes.  Myocardin 
belongs to SAP domain family of nuclear proteins and is highly expressed in 
developing cardiac and smooth muscle tissue [142]. In mouse embryos, myocardin 
expression was first detectable in the cardiac crescent at E7.75 stage whose 
expression is concurrent to other earliest cardiac specific marker, Nkx2.5 gene. 
Myocardin appears at E13.5 within smooth muscle cells lining the walls of the 
esophagus, aortic arch arteries and pulmonary outflow tract but myocardin 
expression was undetectable in skeletal muscle at any stage of embryonic 
development [142]. Myocardin is a highly potent cofactor for SRF and its expression 
is predominantly nuclear localised. Myocardin strongly transactivates cardiac 
specific promoters of SM22 , atrial natriuretic factor (ANF), myosin light chain 
(MLC-2V), and MHC genes and smooth muscle specific promoters of SM  actin, 
SMMHC, calponin and telokin. [142]. SRF expression remains the same with 
phenotypic modulation from aortic media to cultured SMC whereas myocardin 
expression was attenuated in cultured SMC which shows a possible role of 
myocardin in modulation of smooth muscle transcription [143]. 
The human myocardin gene has five different splice variants (Myocd_v1, 
Myocd_v2, Myocd_v3, Myocd_v4 and Myocd_v5) encoded by a single gene with 15 
exons [144] located on chromosome 17p11.2 and shows 74% homology to mouse 
myocardin gene [145]. Myocardin has unusually long 3’ UTR region (>4kb) and 
intron 1 exhibits high homology between species which suggests the presence of 
regulatory sequences in the control of gene expression. The presence of different 
splice variants differentiates the function of myocardin between cardiac and smooth 
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muscle cells. Splice variants Myocd_v1 and Myocd_v2 were specific to cardiac 
lineage whereas Myocd_v3 and Myocd_v4 were specific to smooth muscle cells. 
Alternate splicing of exon 2a and exon 10a yields cardiac and smooth muscle 
specific splice variants. The cardiac specific myocardin variant Myocd_v1 is the 
longest transcript coding for a protein with 983 amino acids whereas another cardiac 
specific variants Myocd_v2 lacks exon 10a (48 amino acid) with 935 amino acids. 
Both the cardiac variants have 79 amino acids extension for myocyte enhancer 
factor-2 (MEF2) binding site in its C-terminal region.  
 
The smooth muscle specific myocardin also has two splice variants; both 
include exon 2a in their transcripts [146]. Inclusion of exon 2a introduces the stop 
codon and generates in a truncated 79 amino acid protein and the presence of start 
codon in exon 4 encodes the most abundant smooth muscle specific myocardin 
Myocd_v3 with 904 amino acids. The rare smooth muscle specific variant Myocd_v4 
(856 amino acids) has no exon 10a in its coding region. Exon 10a is rich in proline 
and serine residues and its role in signalling should be further investigated. 
Recently, Myocd_v5 (807 amino acid) variant has been identified in transactivation 
of SMC gamma actin promoter (Acta2) in association with Nkx3.1 homeodomain 
protein [144].  
The N terminus of smooth muscle specific variants has two conserved 
RPEL (Arg-Pro-X-X-X-Glu-Leu) domains whereas cardiac variants have three RPEL 
domains. A seven residue sequence called B1 domain, which is between the basic 
region and glutamine rich Q domain [142, 147], mediates binding to SRF [148]. The 
SAP domain with 35-amino acids controls nuclear organisation, chromatin dynamics 
and apoptosis [149]. A Leucine zipper domain follows the SAP domain which is 
involved in homo-heterodimerization of myocardin family members in RhoA/actin 
dependent signalling process [116, 150] (Fig.1.3).  The C–terminus of myocardin 
has strong transactivation (TAD) domain [151]. Myocardin and MRTFs (MRTF-A 
and MRTF–B) has similar protein structure with 35% overall protein homology. The 
basic, Q and SAP domain of MRTFs possess high sequence homology (60%) 
whereas TAD (28%) shows very low level sequence identity to myocardin [152]. 
SRF has been found to interact with other transcription factors like Nkx2.5 
[153] and GATA4 [154] to activate cardiac specific genes. However, the protein-
protein interaction between SRF and myocardin differs from SRF other factors 
interaction with SRF dependent transcription Moreover, SRF was unable to form a 
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stable ternary complex either with Nkx2.5 or GATA4 which results in relatively 
modest transcription activation as compared to myocardin [142].  
Myocardin interacts with another MADS box protein other than SRF. MEF2 
family transcription factors controls cardiomyocytes differentiation [155]. Expression 
of MEF2 single gene is sufficient to commit to cardiac lineage in drosophila [156, 
157]. MEF2 contains MADS domain homology to SRF and binding site CTA (A/T) 
4TAG similar to CArG box [142]. MEF2 binds to 79 amino acids NTD (N-terminal 
domain) of cardiac specific myocardin and activates cardiac specific genes [146] 
(Fig.1.3). Myocardin uses different domains to interact with two MADS box proteins 
(SRF and MEF2) to activate cardiac and smooth muscle lineage genes.  
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Myocardin deficient mice created by homologous recombination die by 
embryonic day (E) 10.5 due to delayed development and pericardial effusion [158]. 
The mutant homologous mouse has no evidence for VSMC differentiation but has 
normal cardiac development which indicates that myocardin is necessary for VSMC 
differentiation. Cardiomyocyte-restricted null mutation in mice developed 
cardiomyopathy accompanied by defects in cardiomyocytes structural organisation 
and apoptosis [159]. In xenopus, expression of dominant negative myocardin mutant 
in the dorsal vegetal blastomere shows defects in cardiac lineage [142] suggesting 
that myocardin is used differentially by VSMC and cardiomyocytes [160], myocardin 
is an absolute requirement for VSMC differentiation whereas it is necessary for 
maintenance of differentiated cardiomyocytes survival.  
In most of the muscle as well as growth related genes, the CArG box 
resides within 2-3 kb of the translation start site (TSS) and relatively close to the 
RNA polymerase II holoenzyme.  SRF binds to the CArG box and creates an acute 
bend on the genomic DNA which enables SRF to establish multi-protein complexes 
with other transcription factors [106, 161]. Such structure on the DNA across CArG 
box helps myocardin to interact with SRF through its Q region and transactivates 
smooth muscle gene transcription [106, 161]. Myocardin transactivates the SM 
calponin promoter with three conserved intronic CArG [162] elements resulting in 10 
fold increase in SMC and mutation in CArG elements abolished myocardin induced 
transactivation showing the requirement of functionally active CArG bound SRF for 
its promoter activation [143]. These results suggest that activation of SM marker by 
myocardin is SRF- CArG dependent manner.  
Myocardin, the promyogenic activator in association with p300, histone 
acetyltransferase and histone deacetylase 5 (HDAC5), a class II HDAC, modulates 
the SMC transcription. The p300 binds to the transactivation domain from 713 to 
935 residues whereas the HDAC5 binds to 268 to 328 residues near to the N 
terminus of myocardin [163]. Chromatin immunoprecipitation assay in myocardin 
expressed 10T1/2 cells showed the evidence for histone H3 acetylation of CArG box 
located in SM α actin and SM22α promoter regions and the cotransfection of 
myocardin and p300 resulted in activation of 4X CArG luciferase reporters linked to 
SM22α promoter in COS cells [163]. In addition p300 enhanced the transcriptional 
activity of UAS luciferase reporter by GAL-4 DNA binding domain fused myocardin 
(GAL-4-Myo) and HDAC5, strongly repressed the p300 induced GAL-4-myocardin 
transcriptional activity. Chromatin immunoprecipitation (ChIP) of both p300 and 
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HDAC5 in the presence of myocardin indicated that they interact with separate 
domains, these results suggests that myocardin in association with the p300 
(acetylation) and HDAC5 (deacetylation) can modulate the CArG-SRF dependent 
SMC transcription [163]. 
It is interesting to note that the non SMC L6 cell line, expresses neither 
myocardin nor SMC markers. Ectopic expression of myocardin induced the 
expression of calponin, SM  actin and ANF as measured by RT-PCR, suggesting 
that myocardin can activate the smooth muscle differentiation program in non SMC 
[143]. 
1.6.4. Krüppel like transcription factor 4 (KLF4) 
Multiple repressor proteins interact with myocardin and suppress 
myocardin induced transactivation [164] either by blocking myocardin SRF 
interaction [165] or by mediating posttranslational modification of myocardin and 
further degradation by proteasome [166]. KLF4 is one of the most studied repressor 
proteins associated with suppression of myocardin induced SMC transcription [167].  
In general, the structure of eukaryotic transcription factors consists of DNA 
binding and transactivation domains, the later having binding sites for coactivators. 
Transcription factors are classified into super classes based on the DNA binding 
domains into 1) basic domain 2) zinc coordinating DNA binding domain 3) helix-turn 
helix and 4) beta scaffolding factors with minor groove contacts [168, 169].  KLFs 
are a subfamily belonging to class Cys2His2 zinc finger transcription factor and they 
are highly conserved among mammals [170]. The KLFs are named after the 
drosophila segmentation gene Krüppel (Cripple in German), with which their DNA 
binding domain show homology. [171]. KLFs contain a highly conserved 
characteristic C-terminal binding domains with three C2H2 zinc fingers, each 
chelating a zinc ion in the middle, co-ordinated by two cysteine and two histidine 
residues  [172]. KLFs have a highly conserved H/C link, a seven sequence residue 
TGEKP(Y/F)X between the zinc fingers [173]. The DNA binding specificity is 
directed by three critical residues within each zinc finger [171]. In contrast, the N-
terminal transactivation domains of KLF are highly divergent, vary significantly and 
allow them to bind with various coactivators such as cAMP response element 
binding protein (CBP), p300, and p300/CBP- associated factor (P/CAF) and 
corepressors like histone deacetylase (HDAC) resulting in its functional diversity and 
specificity [170].  
KLF4 (GKLF- Gut-Krüppel like Factor) is a zinc finger transcription factor 
belonging to the Krüppel like factor family transcription factors. KLF4  is expressed 
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in variety of tissues and plays a major role in proliferation, differentiation, 
development and apoptosis [174]. KLF4 was first identified and characterised 
independently by two groups, named as GKLF [175] and EZF [176] (renamed as 
KLF4) due to its high expression in epithelial lining of intestine and skin, 
respectively. KLF4 is also expressed in lung, testis, thymus, cornea, cardiac 
myocytes and lymphocytes. [174]. The human KLF4 (54 kDa) protein is encoded by 
KLF4 gene locus located on 9q31 [175]. KLF4 null mouse die shortly after birth due 
to dehydration and defects in barrier function of the skin. [177].  In addition, KLF4 
homologous mice showed a loss of goblet cells from the colon [178], suggesting that 
KLF4 plays a critical role in epithelial and colonic cell differentiation. 
1.6.4.1. Structure of KLF4 
KLF4 protein has three distinct domains such as N-terminal activator 
domain, a central repressor domain and the C-terminal DNA binding domain [176, 
179]. KLF4 has two potent nuclear localisation signals (NLS), first NLSs is located in 
the 5’ basic region (immediately amino terminal to the zinc fingers) which includes 
four arginine and lysine within a hexapeptide, (PKRGRR) between 385-390 amino 
acid residues. The second NLS resides within the zinc fingers, since the one and 
half amino terminal zinc finger itself confers a nuclear localisation signal in KLF4 
[180]. In addition, KLF4  has a PEST ( proline (P),glutamine (G),serine (S) and 
threonine (T)) sequence acting as a signal peptide for ubiquitin-mediated 
proteasomal degradation associated with the intracellular short half lives (t1/2 ~120 
minutes) of proteins. KLF4 contains a PEST domain (113 to 132 aa) located 
between the transcriptional activation and inhibitory domain (Fig 1.4) with high PEST 
score of 5.8 and relatively short half life [175, 181]. 
The zinc finger region of KLF4 shares a high degree of sequence 
homology with LKLF (lung Krüppel like factor) at 92%, EKLF (Erythroid Krüppel like 
Factor) at 84% and BTEB2 (KLF5) at 82% respectively. KLF4 also has 52% of 
sequence homology to Sp1 transcription factor [175]. Furthermore, KLF4 bind to 
GC-rich (5’–GGG GCG GGG-3’) sites on DNA which is similar to KLF5 and 
specificity protein (SP1) binding site. However, the amino acid sequence outside the 
zinc finger domain have no homology with other KLFs, suggesting that the KLFs can 
recognise same binding sequences on DNA but exert different functions due to the 
coregulator recruitment coupled to their divergent N terminal transactivation domain 
[175]. 
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1.6.4.2. Mechanism of KLF4 activation and repression 
The N terminal region of KLF4 is rich in proline, serine, threonine and 
acidic amino acid residues associated with activation or repression of transcription 
[182]. Presence of acidic residues in the N-terminal region enhances binding of 
p300/CBP coactivators. KLF4 binds to the GC rich region within the promoter of 
target genes and recruits the coactivators like p300/CBP proteins which have 
catalytic histone acetyltransferase (HAT) activity. The p300 protein directly 
acetylates KLF4 at Lys 225 and Lys 229 amino acid residues and neighbouring H4 
histones on the promoter resulting in transcriptional activation of target genes [183]. 
Furthermore, mutation analysis of two lysine to arginine residues attenuates the 
transactivation potential of KLF4 indicating that acetylation of KLF4 itself is important 
for its transcriptional activity. KLF4 binds to IAP (Intestinal Alkaline Phosphatase) 
promoter and recruits p300, transcriptional coactivator which mediate histone H4 
acetylation and transactivation of the target gene [183]. However, KLF4 can function 
as a transcriptional repressor either by simple competition with an activator for DNA 
binding known as passive repression or by recruitment of corepressors such as 
HDAC histone deacetylase to the promoter region and downregulate the target gene 
transcription. On Sp1, which can autoregulate its own promoter, KLF4 binds a 
sequence overlapping the Sp1 binding site and displaces Sp1 from its promoter 
element resulting in repression of the target gene [184]. In addition, KLF4 interacts 
with and recruits co-repressors HDAC1 and HDAC2 histone deacetylase to the 
CD11d promoter (leukocyte integrin gene) [185] and HDAC3 to the cyclin D1 
promoter and represses their transcriptional activity [183]. KLF4 also represses 
Cytochrome p450 1A1 (CYP1A1) and cyclin gene such as cyclin D, Cyclin B1, and 
cyclin E [186]. These studies indicate that KLF4 can act as activator and repressor 
of transcription depending on promoter and cellular context of the target gene. 
Expression of KLF4 is highly regulated and is stimulated upon various 
stimuli such as serum starvation, contact inhibition, DNA damage, sodium butyrate 
and oxidative stress [187]. KLF4 expression was induced in response to DNA 
damage and mediates G1/S phase cell cycle arrest in p53 dependent manner. KLF4 
has been shown to physically interact with p53 and transactivates the cyclin-
dependent kinase (cdk) inhibitor p21WAF1/CIP1, which binds to G1 cyclin-cdk 
complexes and inhibits DNA synthesis [188]. In addition, endogenous expression of 
KLF4 in cultured cells has been shown to inhibit DNA synthesis and cell proliferation 
[175]. These results indicate that KLF4 can act as a negative regulator of cell cycle 
and cell proliferation. 
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1.6.4.3. Expression and function of KLF4 in Smooth muscle cells 
KLF4 is expressed at low levels in normal VSMC whereas its expression 
gets rapidly induced in rat carotid arteries following balloon angioplasty and in 
dedifferentiated vascular smooth muscle cells [139, 167, 189, 190]. KLF4 is a 
pleiotropic transcriptional regulator having both activating and repressing actions on 
gene expression [191]. KLF4 interacts with p65, the NF-κB subunit and 
transactivates inflammatory genes, but also competes with TGF-β effectors Smad3 
for its coactivator p300 and inhibits TGF-β induced anti-inflammatory signaling. 
[192]. Likewise, KLF4 exhibits pleiotropic effects (anti proliferative and anti 
differentiation effects) on VSMCs [193]. KLF4 recruits HDAC2 and suppresses 
myocardin induced activation of CArG dependent SMC marker genes through 
induction of CArG hypoacetylation which causes decrease SRF binding to CArG 
elements and smooth muscle marker transcription [138, 167] (Fig. 1.5). In VSMCs, 
KLF4 participates in growth arrest, through induction of p53 expression, followed by 
upregulation of p21 WAF/Cip1, a suppressor of cell cycle progression [194], suggesting 
that KLF4 has a pleiotropic effect on VSMC proliferation and differentiation. 
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Of significance, the first seven base pairs (GAGTGGG) of TCE consensus 
sequence contains binding motif for KLF4 that is completely conserved in both rat 
and mouse SM22α and SM α actin promoters [139]. KLF4 was identified as a trans-
acting factor that binds to TCE regions within SM22α and SM α actin promoters 
based on yeast one hybrid cloning analysis and electrophoretic mobility shift assays 
[139]. KLF4 binding to TCE regions negatively regulates TGF-β1-induced SM gene 
transcription whereas KLF5, another KLF family transcription factor, induces rather 
than represses TGF-β1 mediated SM promoter function [139]. Ectopic expression of 
KLF4 eliminates TGF-β1 induced SM22α and SM α actin promoter activity. 
However, TGF-β1 (2.5ng/ml) stimulation decreased the endogenous expression of 
KLF4 in cultured SMCs with no detectable KLF4 binding on the TCE region. [139]. 
These studies demonstrate that KLF4 act as a TCE-repressor for SMC 
differentiation, TGF-β1 downregulates KLF4 expression and transactivates SM gene 
expression.  
KLF4 is regulated by multiple posttranslational modifications including 
phosphorylation [195], acetylation [183], sumoylation [196, 197] and ubiquitination 
[198]. KLF4 is degraded by ubiquitin-mediated proteolysis in response to TGF-β1 
induced transcriptional activation [198]. TGF-β1 signaling pathway is also closely 
regulated by proteolysis including its own downstream modulators TGF-β receptors 
and Smads [199]. Several studies reported the role of E3 ligases including Smurfs 
[200], cdh1/Anaphase promoting complex (APC) [201] and Carboxyl terminus of 
hsp70-interacting protein) ligase, CHIP [202] in regulation of TGF-β1 signaling 
pathway. TGF-β1 (2ng/ml) rapidly downregulates the expression of KLF4 without 
altering its mRNA level in Mv1Lu (mink lung epithelial cells) cells. Furthermore, 
KLF4 has two conserved destruction boxes for cdh1/APC E3 ligases. Exogenous 
expression of cdh1 has shown to downregulate the expression of KLF4 protein and 
facilitates ubiquitination. Mutation analysis in these destruction boxes attenuates 
both cdh1 and TGF-β1 mediated KLF4 downregulation. These studies suggest that 
KLF4 is tagged by polyubiquitin catalysed by cdh1/APC E3 ligases and targeted for 
degradation in response to TGF-β1 induced transcriptional activation [198]. 
1.7. Roles for miRNA in SMC differentiation. 
MicroRNA (miRNA) is short (~ 21-25bp) non coding RNA molecules that 
act as post transcriptional regulators in eukaryotes. The miRNAs bind to 
complementary sequences in the 3’UTR region on target mRNAs, results in 
degradation and mediates translation repression of target gene expression [203, 
204].  The miRNAs are transcribed as longer hairpin loop primary transcripts and 
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processed by the RNase enzyme complex Drosha-DGCR-8 followed by dicer to 
yield mature single stranded miRNAs [205]. Recently, many studies have revealed 
key roles for miRNA in the control of cardiac [206] and smooth muscle development 
and remodelling upon vascular injury[207]. Among these, the miR-143 and miR-145 
are highly specific to adult SMC lineage and involved in maintenance of contractile 
SMC phenotype [208]. The miR 143 /145 genes lie within 1.7 kb on mouse 
chromosome 18 and transcribed as a single bicistronic precursor with no homology 
between them, suggesting that they can act on different target sequences [209]. 
miRNA microarray hybridization assays in SMC enriched organs revealed that miR 
143/145 gene cluster expression was confined to SMC during embryonic 
development. During postnatal development, the miR 143/145 gene cluster 
expression is downregulated in the heart but persists in vascular and visceral SMCs 
[209]. However, the expression of miR 143/145 gets downregulated in neointimal 
lesions following vascular injury as well as in atherosclerotic plaques. Cordes et al., 
[208] provide seminal evidence suggesting that miR-143/miR-145 control SMC fate 
and plasticity. They demonstrated that miR-145 promotes VSMC differentiation 
through increasing the expression of myocardin protein and miR-143 suppresses 
the expression of Elk-1, a key competitor for myocardin binding to SRF on SMC 
genes. 
Furthermore, putative binding regions for miR-145 were identified in the 3’ 
untranslated region (3’UTR) of myocardin and KLF4. Similarly, putative binding site 
for miR-143 was identified in 3’UTR of Elk-1. Luciferase based 3’UTR reporter 
assays showed that miR-145 enhances myocardin activity while miR-143 and miR-
145 represses the expression of Elk-1 and KLF4, respectively which mediates the 
highly proliferative synthetic SMC phenotype. These results demonstrate that SMC 
phenotypic modulation was regulated by SMC enriched microRNAs, miR-143 and 
miR–145. [208]. 
The miR143/145 gene cluster has a conserved CArG element located 
between –3.2 to -4.2 Kb upstream of the gene and has been shown to be regulated 
by SRF and myocardin [209].  The miR 143/145 double knockout (dKO) mice were 
viable but displayed thinning of vessel wall with increased synthetic SMCs in the 
vessel wall. In addition, the dKO mice showed drastic reduction in blood pressure 
and reduced vascular tone compared with wild type mice, suggesting that miR 
143/145 regulates the actin dynamics and are necessary for normal contractility of 
arteries in vivo [209].  Emerging evidence has reported that TGF-β1 activates miR 
143/145 in human coronary smooth muscle cells (hCASMC) [210]. TGF-β1 induces 
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p38 MAPK and Smad pathways which then synergistically activates miR 143/145 
expression in Smad, myocardin, SRF-CArG dependent manner. Of note, TGF-β1 
induced myocardin and SRF expression gets downregulated by p38 MAPK inhibitor 
SB 203580 treatment, siRNA mediated knockdown of myocardin and SRF 
abrogated the TGF-β1 induced miR-143/145 expression. These results demonstrate 
a novel mechanism underlying TGF-β1 mediated SMC differentiation [210]. 
Recently, TGF-β family growth factors TGF-β1 and BMP4 were found to 
repress the expression of KLF4 through induction of miR-143/145 in VSMCs. Both 
TGF-β1 and BMP4 induce miR-143/145 expression but utilize distinct SRF 
cofactors; BMP4 requires MRTF-A while TGF-β1 requires myocardin for activation 
of CArG dependent miR-143/145 transcription and repression of KLF4 expression 
[211] (Fig.1.6). BMP4 stimulation mediates Rho signalling which enhances actin 
polymerisation and translocation of MRTF-A into nucleus where MRTF activates 
CArG-SRF dependent transcription of smooth muscle contractile proteins [116, 212]. 
In contrast, TGF-β1 activates myocardin/Smad proteins which synergistically 
upregulates smooth muscle genes. TGF-β1 facilitates Smad binding to TCE region 
on smooth muscle marker promoters and myocardin to CArG-SRF and activates 
transcription of SM markers [211, 213] (Fig.1.6). Various studies have identified 
other candidate miRNAs involved in SMC differentiation and proliferation. For 
instance, miR-26a [214], miR-1 [215] and miR-10a [216] were shown to be 
upregulated in SMC differentiation phenotype whereas miR-21 [217] and miR-
221/222 [218, 219] were found to be upregulated in SMC synthetic phenotype. 
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Figure 1-6. Signaling pathways involved in the regulation of KLF4 expression through 
induction of miR-145 expression in VSMCs. 
 BMP4 induce MRTF-A through RhoA signaling and TGF-β1 induces myocardin through 
Smad2/3 signaling.which enhances smooth muscle gene transcription in VSMCs. Both 
BMP4 and TGF-β1 signaling pathways induce miR-145 which downregulates KLF4 protein 
expression.  
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1.8. Cytokines 
SMCs are not terminally differentiated but they retain remarkable plasticity 
undergoing reversible phenotypic changes in response to the local environment 
cues [75] which includes mechanical force [220], extra cellular components [221], 
reactive oxygen species [222], and cytokines like TGF 1 [223, 224], PDGF-BB  and 
thrombin [225]. SMCs have diverse embryological origin which contribute to their 
heterogeneity in population [226].  
SMC derived from neural crest and mesenchymal origin shows clear 
difference in serum independent growth properties in response to TGF- 1 treatment 
[227]. SMCs derived from neural crest were stimulated to proliferate following TGF-
1 treatment whereas this treatment inhibits mesenchymal derived SMC growth 
[227]. Similarly, PDGF-BB promotes SRF-dependent smooth muscle marker 
expression in proepicardial derived SMCs than those from other lineages [228], 
suggesting that the heterogeneity in SMC lineage is responsible for their lineage 
dependent variation in growth and differentiation properties upon growth modifiers. 
1.8.1. TGF- 1 
TGF- 1 belongs to the transforming growth factor beta superfamily of 
proteins including activins, inhibins, bone morphogenetic proteins which are involved 
in cellular proliferation, growth, differentiation and apoptosis [229]. TGF- 1 null 
embryos showed lethality around 10.5 day post coitus (dpc) with defects in yolk sac 
vasculature and endothelial development [229] indicates the critical role of TGF- 1 
in promotion of differentiation during embryogenesis.  
TGF- 1 has three isoforms, TGF- 1, TGF- 2 and TGF- 3 which are 
produced in dimeric latent forms and processed extracellularly to their active forms 
[230]. Endothelial cells, smooth muscle cells, macrophages and lymphocytes 
interact with TGF- 1 through the type I and type II transmembrane serine/threonine 
kinase receptors. TGF-  isoforms have high affinity for type II receptors. Binding of 
TGF-  on type II receptors, recruits the type I and forms complex, which results in 
phosphorylation and conformational change of type I receptor [230]. Further signal 
propagation to the nucleus occurs through the phosphorylation of Smads, TGF- 1 
effectors by type I receptors. The Smads are classified into three types i) receptor 
regulated Smads (Smad1, Smad2, Smad3, Smad5 and Smad8), ii) Common Smad 
(Smad4) and iii) inhibitory Smads (Smad6 and Smad7) [231]. 
VSMC express many type I and type II receptors [232], whereas TGF- 1 
signaling in VSMC is predominately mediated via Activin-like kinases 5 (ALK5)/T RII 
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complex and subsequent signal propagation occurs through various signalling 
cascades including Smad 2/3, kinases such as p38 mitogen activated protein kinase 
(MAPK), p42/44, and Jun amino-terminal kinases (JNK) signalling cascades [233] 
[230].  
TGF- 1 can act as a bimodal (inhibition and stimulation) regulator, 
depending on its concentration in SMC [234]. TGF- 1 in low concentration (1-2 
fg/cell), stimulates cell proliferation whereas at higher concentrations, it inhibits cell 
proliferation in SMC [232].  Interaction between EC and SMC or EC and 
undifferentiated mesenchymal cells  activates the latent TGF- 1, induces 
differentiation of mesenchymal cells to SMC/pericyte lineage and inhibits EC 
proliferation and migration [235], suggesting that effects of TGF- 1 vary depending 
on its concentration and cell type.  
Mutation analysis of TGF- 1 revealed that nearly 50% of TGF- 1 
homozygous and heterozygous mutant mouse embryos die in utero by E9.5 –E10.5 
due to abnormalities in yolk sac with delayed vasculogenesis [229]. A similar 
embryonic lethality was exhibited in the TGF-  type II receptor null mutant mice 
[236]; suggesting that fetal death is due to lack of endothelial differentiation and 
capillary tube formation which occurred before the recruitment of VSMCs.  There is 
emerging evidence to show that TGF- 1 can upregulate various smooth muscle 
differentiation markers in cultured SMCs [237, 238]. In addition, TGF- 1 has been 
shown to induce smooth muscle differentiation in neural crest cells as well as in 
neural cell derived Monc-1 cells [239]. Furthermore, co-culture studies of mouse 
embryonic multipotent 10T1/2 cells with endothelial cells have shown to induce SMC 
differentiation in 10T1/2 cells [240]. 
 Sinha et al [241] demonstrate that mouse ESC-EB expresses SMC 
specific genes including SM  actin, SM22 , SMMHC, myocardin and smoothelin. 
However, adenoviral mediated attenuation of TGF-  type II receptor expression 
(which is specific to endogenous TGF- 1 expression) completely eliminates SM 
marker expression in embryonic stem cell (ESC)-derived embryoid bodies (EBs). 
Additional studies with siRNA repression of Smad2 and Smad3 have shown that the 
expression of SM  actin, an early SM marker is dependent on both Smad2 and 
Smad3 whereas the expression of SMMHC, late SM markers is dependent only on 
Smad3.  These studies provide a direct evidence for TGF- 1 signaling through 
Smad2 and Smad3 in smooth muscle differentiation from embryonic stem cells but 
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also provide evidence for differential TGF- -Smad signalling involved in expression 
of early vs. late smooth muscle genes [241]. 
1.8.2. PDGF-BB 
Platelet derived growth factor (PDGF) family consists of three isoforms 
made from pairwise combination of PDGF A and PDGF-B chains named as PDGF-
AA, PDGF-BB and PDGF-AB. Among the isoforms, PDGF–BB is a powerful 
chemoattractant and mitogen followed by PDGF AB and PDGF-AA. The PDGF 
receptor binds to similar ligands, which is made of dimers of  and  subtypes of the 
PDGF tyrosine kinase receptor. The  receptor binds both the A and B chains of 
PDGF whereas   receptor selectively binds only B chain of PDGF ligand. In the 
vascular wall, the main function of PDGF is the paracrine recruitment of mural 
precursor cells to the vessel wall and stimulation of endothelial cells proliferation by 
autocrine process [235].  
PDGF-BB represses the expression of SM  actin and SMMHC and with 
prolonged treatment induces the phenotypic modulation in SMCs but has no effect 
on -actin content [242]. However, withdrawal of PDGF-BB reversed the PDGF-BB 
induced repression, suggesting PDGF-BB acts as negative regulator for smooth 
muscle specific marker differentiation [243]. In contrast, SMC from proepicardial 
origin [244] or mononuclear cells [245] isolated from blood plated on collagen with 
PDGF-BB treatment favours the SMC differentiation; indicating that depending on 
SMC lineage PDGF-BB can act as positive or negative regulatory agent on control 
of SMC differentiation. 
1.9. SMC differentiation from stem/progenitor cell sources  
The variation in VSMC population and involvement of progenitor cells in 
vascular diseases necessitates improved understanding of the signaling pathways 
that induce differentiation of these vascular progenitor cells towards SMC specific 
lineage [224, 240, 246]. To date, several progenitor cells were capable of SMC 
differentiation in vitro cellular models have been identified from various sources 
including 1) embryonic stem cell and embryoid bodies 2) neural crest cells 3) 
proepicardial cells 4) mesoderm derived cells [247] and 5) smooth muscle stem cells 
and 6) smooth muscle progenitor cells based on the source of vascular progenitor 
cells (Table 1-1). 
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1.9.1. Embryonic stem cell (ESC) and embryoid bodies 
ESC based models include p19 and A404 cell types. P19,  an embryonal 
carcinoma cell line was derived from mouse teratoma formed by implanting 7.5 day 
embryos into testis [248]. P19 cells were induced to differentiate into fibroblast like 
cells expressing SM α actin on treatment with retinoic acid (RA–106 mol/L) for 48 
hours. The differentiation of p19 cells into SMC showed less than 5% efficiency and 
these cells do not express other SM markers, highlighting the requirement of 
additional techniques to improve SMC differentiation. Use of the multipotent A404, 
clonal cell line derived from p19 increased SMC differentiation efficiency, up to 90% 
on treatment with retinoic acid (RA 1 M/L) and expressed SM markers such as SM 
α actin, calponin, SM1 isoform of SMMHC, the late differentiation marker and 
myocardin, suggesting that the A404 cell line model can be used to study the early 
differentiation of SMC development [246]. Furthermore, differentiated A404 cells 
showed higher levels of histone H4 acetylation within 5’ flanking regions of SM  
actin and 5’ flanking and first intronic region of SMMHC promoters, whereas skeletal 
muscle promoters showed no acetylation in their promoter regions [246]. In addition, 
SMMHC promoter showed methylation of H3 histones specific to its 5’ flanking 
CArG element and both H3 and H4 histone modification in its translational start site, 
suggesting that chromatin modification plays a major role in selective induction of 
CArG dependent SMC specific marker genes during development and differentiation 
[246]. 
Human ESC cultured in a monolayer  with 10 mM all trans retinoic acid 
demonstrated SMC differentiation at an efficiency greater than 93% for SM α actin 
and SMMHC positive cells [249]. Several studies have demonstrated that stem cell 
surface markers can be used to isolate SMC progenitor cell subpopulations from 
ESC and enrich the SMC differentiation from embryonic stem cells [250]. Murine 
embryonic stem cell derived Sca-1+ progenitor cells were induced to differentiate into 
SMC mediated by PDGF receptors and collagen IV α1, β1 and αV integrins [251] 
whereas vascular endothelial growth factor (VEGF) treatment promoted endothelial 
differentiation [252]. This model provided early evidence for the requirement of 
extracellular matrix collagen IV in early stage of smooth muscle differentiation. 
Embryonic stem cells grown on collagen IV (5µg/ml) promote early stage SMC 
differentiation as compared to collagen type I and fibronectin [251]. Moreover, 
collagen IV synthesis was detected by western blot in collagen I and fibronectin 
treated groups and also autocrine secretion of collagen IV in some cultured 
conditions has shown to enhance the spontaneous differentiation of embryonic stem 
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cells [251]. Embryonic stem cell derived Sca-1+ cell culture on collagen IV with 
PDGF BB (10ng/ml) was reported to induce SMC differentiation in 55-66% of cells 
and long term selection in the presence of PDGF-BB and collagen IV increased the 
SMC differentiation to 95 % for SM markers such as SM α actin, calponin and 
SMMHC [251]. These results suggest that collagen IV plays a major role in SMC 
differentiation from embryonic stem cells [251]. 
Yamashita et al., [253] found that ESC derived Flk (Fetal Liver Kinase)-1 + 
(Flk1 –receptor for VEGF) cells can differentiate into endothelial and mural cells. 
Flk-1+ cells were obtained by culturing ESC on collagen IV coated dishes with 10% 
FCS for four days. Flk1+ cells treated with VEGF 165 (50ng/ml) promotes PECAM 
(Platelet endothelial cell adhesion molecule) 1+ sheets of endothelial cells whereas 
PDGF-BB (10ng/ml) has been shown to induce smooth muscle cells with expression 
of SM α actin, calponin, SMMHC and SM22α. Intracardiac injection of LacZ 
expressing Flk1+ cells into stage16-17 chick embryo showed the Lac Z signal along 
the vessels in head, yolk sac, heart and intersomitic region, and immunostaining of 
cross sections showed colocalisation of PECAM1+/nLacZ and SMA+/nLacZ, 
suggesting that Flk-1+ cells can differentiate into endothelial and mural cells in vivo 
and plays a role in to vascular development [253].  
Embryoid body (EB) cultures are three dimensional aggregates of stem 
cells grown in suspension in vitro which can form all three germ layers, recapitulate 
early embryonic development [254] and can be used to study in vitro SMC 
development [255]. Retinoic acid (all-trans-Retinoic acid- ATRA-10-8 mol/L) and 
dibutyryl –cAMP (0.5x10-3 mol/L) treatment of EBs obtained from mESCs induced 
60% of spontaneously contracting SM-like cells with expression of  SM α actin and 
SMMHC. In addition, these cells have been shown to respond to angiotensin II and 
exhibit expression of ion channels similar to VSMCs [255]. These results suggest 
that EBs may be a suitable model to study in vitro SMC differentiation. A major 
limitation of this model is the lack of selective techniques for isolating the 
differentiated SM like cells from the EB for further investigation [241, 247, 255]. 
Additional enrichment strategies were developed to eliminate the disadvantages of 
the EBs model using a stably expressing puromycin resistance gene driven by SMC 
specific promoters to enhance the enrichment of SMC from ESC-EBs [256]. These 
differentiated SMCs expressed SMC specific markers, SM α actin and SMMHC and 
showed agonist induced calcium transients whereas subcutaneous injection of these 
differentiated SMCs has been shown to develop teratoma within 3 weeks of 
administration [256]. Increasing the puromycin selection time (prior to injection for 3 
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days) eliminates the teratoma formation but fails to develop mature blood vessels in 
vivo [256]. Furthermore, enrichment for stem cell surface marker CD 34 has shown 
high efficiency for SMC differentiation [257]. Ferreira et al., [257] reported that 
hESC can be differentiated towards SMC and endothelial cells. The 
endothelial/hematopoietic marker, CD 34 was used to isolate the vascular progenitor 
cells from EBs. Treatment of CD34 + cells with VEGF -165 (50ng/ml) and PDGF 
(50ng/ml) induces endothelial like (EL) and smooth muscle like (SML) differentiation 
respectively. The smooth muscle like cells express SM markers including SM α 
actin, calponin, SMMHC and SM22α and also showed contraction in response to 
carbachol. Subcutaneous administration of EL and SML cells separately or in 3:1 
ratio results in development of vasculature in nude mice. These studies provide 
evidence that the EB model can recapitulate early embryonic development and can 
be used to study the SMC development, but presence of different cell types and low 
permeability for soluble factors to contact the inner cells makes it a less efficient 
model to study SMC differentiation mechanism [256, 258]. 
1.9.2. Neural crest cell model  
Pluripotent neural crest cells can differentiate into neurons, chondrocytes, 
glia, melanocytes and smooth muscle cells whereas the immortalized neural crest 
cell line Monc-1, has shown efficient differentiation to smooth muscle cells [224]. 
Vascular smooth muscle cells in the cardiac outflow tract arise from a neural crest 
origin and in vivo differentiation of neural crest cells to VSMC is mediated by TGF-
β1 signaling [259]. Freshly isolated rat neural crest stem cells differentiate into SMC 
with expression of SM markers( SM α actin, calponin and SMMHC) in the presence 
of TGF-β1 (20 pM) and subsequent activation of the calcineurin signalling pathway 
[259]. The p75+ murine neural crest cell line was immortalised by retroviral 
transfection of v-myc gene in their primary culture and further clonal selection 
generated multipotent mouse neural crest cell line, Monc-1 cell lines [260]. The 
Monc-1 cells differentiate to smooth muscle cells in the presence of TGF-β1 
(5ng/ml) after three days in culture [239]. The differentiated SMC showed spindle 
shaped morphology with expression of SM markers such as SM α actin, SM22α, 
calponin, SM γ actin, smoothelin and SMMHC and contracts in response to a 
muscarinic agonist carbachol. In addition, TGF-β1 downregulates E-cadherin gene 
expression and withdrawal of TGF-β1 in culture media did not result in loss of VSMC 
markers expression indicating that Monc-1 cell lines may be used to study SMC 
development [239]. In spite of the fact that Monc-1 cell line can yield a stable SMC 
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phenotype on TGF-β1 treatment, the requirement of a complicated media for 
maintenance of its undifferentiated state [261] is a major disadvantage of this model. 
Likewise, JoMa1 is an immortalised neural crest stem cell line obtained from 
transgenic mouse having conditional tamoxifen inducible expression of c-myc 
oncogene. Removal of tamoxifen and TGF-β1 (1ng/ml) for six days has reported to 
induce SMC differentiation with SM α actin, SM γ actin and calponin which suggest 
that JoMa1 line can be induced to differentiate towards SMC by TGF-β1 treatment 
and an attractive model to study SMC development whereas this model has 
limitations similar to Monc-1 neural crest stem cell line in maintaining its 
undifferentiated state [262]. 
1.9.3. Proepicardial cells 
Landerholm et al., [244] reported the requirement of functional serum 
response factor for differentiation of proepicardial cells from Hamburger-Hamilton 
stage 17 quail embryos to coronary smooth muscle cells (CoSMC).  The 
proepicardial cells attain the epithelial to mesenchymal transition with calponin, SM 
 actin and SM  actin expression within three days and by sixteen days; they 
express complete smooth muscle morphology with upregulated smooth muscle 
markers including SMMHC, SM  actin, calponin and SM  actin. The expression of 
a dominant negative SRF construct blocks the expression of smooth muscle positive 
cells whereas it has no effect on epithelial to mesenchymal transition; suggesting 
that functional SRF is necessary for the differentiation of proepicardial cells to 
CoSMC [244]. 
1.9.4. Mesoderm derived model 
The mesoderm model includes 10T1/2 cell line derived from mouse C3H 
embryo cells. The mouse C3H embryo cell line was established from 14-17 days old 
whole mouse embryos. A C3H mouse embryo cell line which exhibited high degree 
of post confluent inhibition of cell division was designated as C3H/10T1/2 otherwise 
called as 10T1/2 cell line [263]. Multipotent 10T1/2 cells can be differentiated 
towards adipocyte, osteoblast and myoblast cell lineages whereas in co-culture with 
endothelial cells, they differentiate towards smooth muscle lineage, suggesting that 
endothelial cells can induce the differentiation of undifferentiated mesenchymal cells 
towards SMC like cells during vasculogenesis and angiogenesis in vivo [240]. In 
addition, proliferating endothelial cells release various diffusible growth factors such 
as PDGF and fibroblast growth factors (FGF) in their local environment, which act as 
chemoattractants for SMC during vessel formation [264, 265]. Both the EC and 
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10T1/2 cells produce latent TGF 1 in their culture conditions. The co-culture 
environment may activate TGF 1 which directs the differentiation of 10T1/2 cells 
towards SMC lineage [240]. Of interest, multipotent 10T1/2 cells when treated with 
TGF-β1 (1ng/ml) express SM α actin, calponin, SMMHC and SM22α [240].  In 
contrast, myocardin, a transcriptional coactivator specific to SMC and a marker to 
distinguish differentiated SMC from activated fibroblast [226] was not expressed in  
TGF-β1 treated 10T1/2 cells [94], suggesting that 10T1/2 cells cannot be used as a 
definitive model to study SMC differentiation. 
Aortic endothelial cells can be induced to SM like cells on treatment with 
TGF-β1 (1ng/ml) for 10 days [266]. The differentiated SM like cells comprise a 
heterogeneous population of SMC cells such as contractile and synthetic SMCs 
indicating that during atherogenesis TGF-β1 released at the injury site can induce 
endothelial cells to differentiate into SMC. This model can be used to study the 
pathological events contributing to atherogenesis [266]. 
In summary, the heterogeneity of VSMCs is due to their diverse 
developmental origin, which contributed for establishment of different in vitro cellular 
models to investigate their role in vascular development and diseases. These 
models suggest that SMC development is regulated by different growth factors 
depending on their source of origin. Hence, the selection of model and growth 
factors for differentiation is dependent on the development origin of SMCs. 
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Table 1-1. Sources of stem cells having a differentiation potential towards SMC  
S.No. Cell model Cell type Cytokine/  
Growth factor 
or 
Extracellular 
matrix 
Result 
1 ESC and 
embryoid 
bodies 
P19 RA–10
6
 mol/L Induce 5% SMC differentiation 
[246]. 
2  A404 RA 1 M/L Induce Up to 90% SMC 
differentiation with SM α actin, 
calponin, SMMHC marker 
expression [246]. 
3  Human ESC 10 mM all 
trans retinoic 
acid 
Induce >93% SMC differentiation 
with SM α actin and SMMHC 
expression [249]. 
4  Murine ESC 
derived Sca-1
+ 
progenitor 
cells 
PDGF BB 
(10ng/ml) with 
collagen IV 
(5µg/ml) 
Induce 55-66% SMC differentiation 
[251]. 
5  hESC derived 
CD34 
+
 
PDGF 
(50ng/ml) 
Induce SMC like cells expressing 
SM α actin, calponin, SMMHC and 
SM22α [257]. 
6  Embryoid 
body (EB) 
cultures 
All-trans-
Retinoic acid- 
(ATRA)-10
-8
 
mol/L 
Induce 60% of spontaneously 
contracting SM-like cells  [255]. 
 Neural crest 
cell model 
   
7  Rat neural 
crest stem 
cells 
TGF-β1 (20 
pM) 
Differentiate into SMC with 
expression of SM markers [259]. 
8  Monc-1 cells TGF-β1 
(5ng/ml) 
Induce spindle shaped SMC like 
cells expressing SM markers [239].  
9  JoMa1 cells TGF-β1 
(1ng/ml) 
Induce SMC differentiation 
expressing SM α actin, SM γ actin 
and calponin [262]. 
38 
 
 
  
10 Proepicardial 
cells 
  Differentiate into coronary smooth 
muscle cells (CoSMC) in culture 
[244]. 
11 Mesoderm 
derived 
model 
EC and 
10T1/2 cells 
coculture 
 Induce differentiation of 10T1/2 
cells towards SMC lineage [240]. 
12  10T1/2 cells TGF-β1 
(1ng/ml) 
Induce SMC like cells [240]. 
13 Smooth 
muscle stem 
cells  
Bone marrow 
derived stem 
cells in 
circulation 
 Participate in lesion development 
[276, 279, 282]. 
14  Bone Marrow 
derived 
Mesenchymal 
Stem Cells 
(BMMSC) 
Laminin 
coated plate 
Differentiate into SMC with 
expression of SM α actin and 
calponin [285]. 
15  BMMSC TGF-β1 or in 
combination 
with ascorbic 
acid 
Induce SMC differentiation with 
expression of SM markers like SM 
α actin,  
calponin and  
SM22α [287]. 
16 Adventitial 
progenitor 
cells 
 
Sca-1 
+
 cells 
from adventitia 
PDGF-BB 
(10ng/ml)  
Differentiate into SMC [250]. 
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1.10. Smooth muscle stem cells  
VSMC are heterogeneous and retain remarkable plasticity in culture [272]. 
Part of SMC variation can be explained by their diverse embryological origin [247]. 
For example, the neural crest cells derived VSMCs are located in pharyngeal arch 
arteries including aortic arch, left and right carotid arteries, ascending aorta [273, 
274] whereas the descending aorta VSMC originate from somites [275, 276]. The 
proepicardial-derived VSMCs are present in coronary vessels and the base of the 
aorta [273, 277] and pulmonary trunk VSMCs are derived from secondary heart field 
[278, 279].  
In response to vascular injury, SMCs attain a synthetic state with a high rate 
of proliferation, migration and production of extracellular components, and contribute 
to the development of various vascular diseases [105]. Initially it was considered 
that the intimal SMCs within atherosclerotic lesions migrate from medial SMC (local 
origin) to intima during vascular injury [280]. However, recent studies, suggests that 
vascular progenitor cells were present within blood circulation [268, 281, 282], bone 
marrow [267] and from adventitial fibroblast [283], and contribute to postnatal 
neovascularisation [284]. The smooth muscle progenitor cells have the ability to 
differentiate into SMCs when cultured in the proper conditions. Therefore, the 
knowledge of a signalling mechanism controlling the SMC differentiation and origin 
of SMC during neointimal formation is important in understanding the vascular injury 
induced SMC accumulation and subsequent arterial remodelling. 
1.10.1. Bone marrow derived stem cells 
Bone marrow contains two distinct stem cell types, hematopoietic (which 
produce blood) and mesenchymal stem cell (which produce stromal and bone cells).  
Apart from blood cells, hematopoietic stem cells (HSC) have a potential to 
differentiate into many cell types including hepatocytes, epithelial cells and 
cardiomyocytes [272]. Several line of evidences confirmed the presence of bone 
marrow derived SMC progenitor cells in lesion development and tissue repair 
process [267-269]. Sata et al., [268] reported evidence of vascular smooth muscle 
regeneration from bone marrow derived cells using the experimental models 
including atherosclerosis, post angioplasty and graft vasculopathy. These models 
showed that whole bone marrow labelled cells contribute to ~25-50% of the SM α 
actin positive smooth muscle like cells within the neointimal and medial layers in 
injured artery. Studies using aortic transplants into β-galactosidase transgenic 
recipients showed stable integration of LacZ positive marrow cells expressing SM α 
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actin within the medial layers of the vessel, suggesting that smooth muscle like cells 
can originate from circulating bone marrow derived stem cells [267].  
In a chimeric mouse model, bone marrow derived from a male donor was 
transplanted into irradiated female mice, 56% of neointimal cells were shown to 
react with Y1 chromosome probe suggesting a recipient origin [269]. The circulating 
bone marrow cells were recruited only after severe vessel damage and resembled 
fetal/immature vascular smooth muscle cells, suggesting that severity of injury plays 
a role in recruitment of bone marrow cells [269].  Participation of circulating bone 
marrow in vascular repair and lesion development was also reported in non-
irradiated parabiotic mouse model. When wild type mice were conjoined 
subcutaneously with green fluorescent protein (GFP) transgenic mice, ~15% of 
neointimal and ~32% of medial cells were positive for GFP and showed SM α actin 
expression. The contribution of marrow cells in human coronary atherosclerosis was 
demonstrated using sex mismatched marrow transplantation. The coronary 
atherosclerotic plaques from gender mismatched bone marrow transplanted patients 
showed smooth muscle cells from donor origin [282]. In an effort to determine which 
cell type in heterogeneous bone marrow contributes to vascular remodelling, highly 
enriched HSC (stem cell antigen-1 (Sca-1+), c-kit+, Lin-) population was isolated from 
bone marrow of Lac Z mice and transplanted into wild type. Upon wire injury of the 
femoral artery these cells showed neointimal hyperplasia to the same extent as 
whole bone marrow [285]. The neointimal and medial region contains many LacZ 
positive cells (~33%) and expresses SM α actin. The LacZ positive cells also 
contribute to re endothelialization which suggest that bone marrow enrichment for 
Sca-1+, c-kit+, Lin- fraction homing the injured vessel have a tendency to differentiate 
into either SMC or EC which may contribute to vascular remodelling [285]. Taken 
together, these studies suggest the role of circulating bone marrow derived stem 
cells contributing to neointimal formation and lesion development after vascular 
injury.  
1.10.2. Bone Marrow derived Mesenchymal Stem Cells (BMMSC) 
Mesenchymal stem cells (MSCs) are multipotent stromal cells that have 
the ability to differentiate into osteoblasts, chondrocytes and adipocytes [286]. 
BMMSC cultured on laminin coated plates for seven days induced SMC 
differentiation and expressed SMC specific proteins such as SM α actin and 
calponin. Furthermore implanted BMMSC on laminin sheets in in vivo for two weeks 
showed an increased expression of SM α actin, calponin and SM2 isoform of 
SMMHC [270]. Several studies showed that the ERK/MAPK pathway is 
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antimyogenic in SMC and involved in activation of growth related genes mediated by 
phosphorylation of Elk-1 gene [287]. Inhibition of MEK/ERK signaling by the MEK 
inhibitor PD98059 induced myocardin, the transcriptional coactivator and SM 
markers like SM α actin, SMMHC and caldesmon in differentiated BMMSCs. 
However, MEK inhibitor induced differentiation can be reversed by PDGF-BB 
treatment which indicates that PDGF-BB is a strong activator of MEK/ERK signalling 
pathway and its inhibitory effect on SMC is mediated by activation of MEK/ERK 
signalling pathway [287]. BMMSC cultured in the presence of TGF-β1 or in 
combination with ascorbic acid induced SMC differentiation with expression of SM 
markers like SM α actin, calponin and SM22α [271].  
1.10.3. Adventitial progenitor cells 
Several studies have found evidence for the possibility of non bone marrow 
derived progenitor cells.  It has been reported that myofibroblasts migrate from the 
adventitia and participate in the neointimal formation in response to vascular injury 
[288]. Hu, et al., [250]  reported a source of smooth muscle progenitor cells in ApoE 
deficient mice that contributes to atherosclerotic lesion development.  They have 
identified Sca-1 + (21%), c-kit + (9%), CD34+ (15%) and Flk-1 + (4%) cells in the 
adventitia of aortic roots. The Sca-1 + cells were differentiated into SMC in vitro in 
the presence of PDGF-BB (10ng/ml).  Moreover, the Sca-1+ expressing LacZ gene 
transplanted into adventitia of Apo E deficient mice showed an accumulation of β-
gal positive cells in the neointima and enhanced the development of atherosclerotic 
lesion [250]. 
Other than bone marrow, circulating blood and vessel adventitia, there are 
other sources of progenitor cells in the body including skeletal muscle [289] and 
heart [290]. 
1.10.4. Risk associated with stem cell based therapy 
Stem cells have an ability to replicate indefinitely and remain undifferentiated 
in culture. One of the hall marks of stem cells is the formation of non cancerous 
tumor named as teratoma in vivo [291]. Stem cells are widely used to study the 
normal molecular mechanism associated with disease development as well as drug 
discovery for regenerative medicine. However, studies with the introduction of stem 
cell into animal models fail due to teratoma formation [292]. A recent study reported 
the malignant tumor-inducing capacity of hESCs including H1 and Human 
embryonic stem cells (HSF6) [293]. These results emphasized a need for 
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development of improved techniques to enhance the safety of stem cells in 
regenerative medicine. 
The main approach to enhance the safety of stem cell for regenerative 
medicine is to differentiate stem cell into progenitor cells, a level below in the 
hierarchy. Furthermore, these differentiated cells are subjected to sorting either for 
the progenitor specific markers or for the stem cell markers to eliminate the 
undifferentiated stem cells prior to implantation into animal [291]. These progenitor 
cells were reported to exhibit low immunogenicity in their undifferentiated state, 
which can be implanted without much immunogenic alterations as compared to ESC 
and multipotent stem cells [294]. 
1.11. Smooth muscle progenitor cells  
A number of fate mapping studies have identified several origins for smooth 
muscle progenitor cells [295, 296]. Although these progenitor cells have a different 
origin they transcribe a common set of markers such as SM α actin, calponin, 
SMMHC and SM22 α on differentiation [297]. Several findings suggest that a 
smooth muscle progenitor cell resides within the adventitial and the medial layer 
[297].  
The progenitor phenotype in these cells are maintained through 
transcriptional silencing of SRF dependent smooth muscle markers either by 
chromatin modification of CArG elements [298-300] or inhibition of SRF binding to 
CArG elements [127, 164, 167, 297, 301]. Furthermore, the silencing of SM markers 
in smooth muscle progenitor cells is enhanced through interaction of SRF-CArG 
elements with potent transcriptional repressors [297]. Passman and coworkers [302] 
have identified coexpression of repressors such as Msx1, KLF4 and Forkhead 
transcription factor 4 (Foxo 4 )with SRF and myocardin in Sca1+ smooth muscle 
progenitor cells isolated from aortic adventitia. In addition PRISM (PR domain in 
smooth muscle) (prdm6) protein is reported as a transcriptional repressor in smooth 
muscle progenitor cells. PRDM 6 recruits histone methyl transferases and class I 
HDAC to myocardin and GATA 6 and further downregulates the SMC gene 
transcription in smooth muscle progenitor cells [297, 303]. 
1.11.1. Circulating smooth muscle progenitors cells 
Several studies suggest that bone marrow derived lineage committed cells 
can differentiate into SMCs. Simper et al., [245] provide early evidence for the 
existence of circulating smooth muscle progenitor cells within human blood. They 
showed that progenitor cells within the mononuclear cell pool isolated from 
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peripheral buffy coat from human blood when grown on collagen type I matrix for 
three weeks in the presence of PDGF-BB (50ng/ml) can differentiate into smooth 
muscle outgrowth cells (SOCs). These SOCs expresses smooth muscle markers 
(SM α actin, Calponin and MHC) and CD34, Flk-1 and fms-related tyrosine kinase 1 
(Flt-1), but not Tie-2, suggesting that SOCs might have originated from bone marrow 
source distinct from Tie-2 receptor positive EOCs. These outgrowth cells are highly 
proliferative (>40 population doublings) and have markedly increased α5 and β1 
integrin subunit protein expression which is a characteristic feature of the 
proliferative SMC phenotype [245]. These results suggest that smooth muscle 
progenitor cells reside within circulating mononuclear fraction differentiate into SOCs 
and have a potential for proliferation at sites enriched in extracellular matrix 
deposition. Furthermore, the clonally expanded high proliferation potential SMC 
outgrowth cells (HPP-SOCs) are positive for the myeloid marker CD 14 and retained 
the CX3CR1 chemokine receptor. The CX3CR1 subpopulation of  bone marrow 
cells isolated from CX3CR1 recombinant gfp/+ transgenic mice differentiates into 
smooth muscle cells in the presence of smooth muscle differentiation media with 
PDGF-BB (100ng/ml) [304]. In addition, bone marrow derived CX3CR1+ progenitor 
cells have shown to differentiate into SMC mediated through fractalkine interaction 
and reported to contribute 5-10% of neointimal SMC following mild wire injury [304]. 
These studies suggest that fractalkine-CX3CR1 chemokine receptor is critical for the 
SMC recruitment and neointimal formation followed by vascular injury.  
Aortic and cardiac allograft implanted in rats results in the development of 
transplant arteriosclerosis characterised by perivascular inflammation and 
neointimal thickening, composed of SM α actin positive vascular smooth muscle 
cells. Using a MHC class I haplotype specific immunohistochemical technique and 
PCR analysis showed that neointimal SM α actin positive cells were from recipient 
origin and not of donor origin [305]. The CD14/CD105 double positive peripheral 
blood mononuclear cells (PBMNC) subpopulation but not the CD14/CD105 negative 
isolated from peripheral blood differentiated into smooth muscle like cells (SMLC) 
when cultured for long term in the presence of growth factors ( PDGF-BB 5ng/ml, b-
FGF – 5-10 ng/ml and TGF-β1 2ng/ml). Peripheral blood-derived SMLCs were 
positive for smooth muscle markers including SM α actin, calponin and SMMHC 
[306]. Furthermore, the expression of CD14/CD105 double positive cells was found 
to be elevated in atherosclerotic patients. These results suggest that CD14/CD105 
double positive PBMNCs acts as a source for human smooth muscle precursor cells 
in circulation and participate in the pathogenesis of vascular diseases [306]. 
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However, controversy exists relating to the origin of smooth muscle progenitor cells 
recruitment in neointimal formation and vascular lesion development. 
1.12. Isl1+ (LIM-homeobox transcription factor positive) progenitor cells  
Numerous studies identified a rare subset of the LIM-homeobox 
transcription factor positive (Isl1+) progenitor cells in the atria, outflow tract and right 
ventricle of mammalian heart after birth [307]. A multipotent Isl1+ cardiovascular 
progenitor cells (MCIPs) develops various cardiovascular cell types in vivo during 
embryonic development. The triple positive (Isl1+, Nkx2.5+, and Flk1+) embryonic 
derived cardiovascular multipotent precursors differentiated into cardiac muscle, 
smooth muscle and endothelial lineages in vitro. The Isl1+ cells expressing LacZ 
genes differentiated into smooth muscle cells either alone or co-cultured with human 
coronary smooth muscle cells [308]. In support of this concept, multipotent Flk1+ and 
bry+/Isl1+ isolated from embryonic stem cells differentiate into cardiomyocytes, 
endothelial and vascular smooth cells [309], Multipotent Isl1+ cardiovascular 
progenitor cells created from mouse and human iPS cells when injected directly into 
the left ventricular wall of nude mice they successfully engraft into host tissue 
without teratoma formation [310]. Furthermore, the engrafted cells differentiated into 
all three cardiac (cardiac muscle, smooth muscle and endothelial) lineages at the 
site of injection [310]. 
Isl1 null mice exhibited growth retardation and die between E 10.5 –E 11 
with severe defects in cardiac phenotype. Isl1 knockout hearts fail to undergo 
looping morphogenesis and have a single atrial and ventricular chamber [311]. 
Moreover, both right ventricle and outflow tract are absent in Isl1 homozygous mice. 
These results suggest that Isl1 is expressed in second heart field and contribute to 
venous and arterial formation in the heart [311]. In addition, lineage tracking of Isl1 
positive cells revealed the homing of these cells in the outflow tract, the right 
ventricle and in part of atria and left ventricle region which indicates that Isl1 
transcription factor marks cardiac progenitor cells of second heart field [312]. 
The colonisation of Isl1 progenitor cells in the embryonic structures such 
as outflow tract and inter-atrial septum suggest that these cells might participate in 
vascular remodelling in response to vascular injury. Thus, Isl1+ cardiovascular 
progenitor cell model is a powerful tool for studying signalling pathways responsible 
for cardiovascular disease development as well as for designing a cell based assay 
to identify new therapeutic targets and pathways for treatment of cardiovascular 
diseases.  
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1.13. Human smooth muscle stem progenitor cells  
Our group has recently isolated novel Isl1+ stem progenitor cells from 
leukocyte filters of atherosclerotic patients undergoing coronary artery bypass 
grafting (CABG) surgery and from the peripheral blood of patients with pulmonary 
hypertension.  These cells express stem cell markers such as Octamer-binding 
transcription factor 4 (Oct 4), sex determining region Y)-box 2 (Sox-2), KLF4, stage-
specific embryonic antigen 1 (SSEA-1) and c-kit. Human smooth muscle stem 
progenitor cells (hSMSPCs) are clonogenic (Fig.1.7 A), with high self renewal 
potential and exhibit high level of telomerase activity (Fig. 1.7 B) and high population 
doubling more than 140 population doublings (Fig. 1. 7 C). However, hSMSPC cells 
express smooth muscle markers SM α actin (Caplice et al., unpublished data) at a 
modest level as measured by FACS analysis. Since these cells were positive for 
stem cell and smooth muscle markers, these cells were named as human smooth 
muscle stem progenitor cells (hSMSPC). 
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Figure 1-7. Phenotypic characterisation of hSMSPC cells. 
A) To prove that hSMSPC cells were clonogenic, hSMSPC cells were transduced with 
lentiviral vector driving eGFP expression (HR-CSGW). hSMSPC cells were capable to form 
a colony from single cell. B) hSMSPC cells exhibit high level of telomerase activity and high 
population doublings (C) as compared to SMCs. D) hSMSPC cells express Isl1, stem cell 
markers SSEA-1, Oct 4,  SOX-2 and ckit  as measured by FACS analysis (Caplice et al., 
unpublished data).Data are representative of three independent experiments. **P<0.01. 
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1.14. Clinical significance of adult stem cells 
Atherosclerosis is a leading cause for coronary artery disease caused by 
narrowing of artery due to lipid accumulation [313]. Artery from patients (elsewhere) 
is grafted to the coronary artery to bypass atherosclerotic occlusions (autografts). 
The main challenge facing the treatment of disease artery is the limited availability of 
autografts from patients [314]. This led to the investigation of cell based therapeutic 
approaches to regenerate the vascular grafts. In an attempt to replace the injured 
vessel wall, cellular based therapy has been extensive investigated in the past 
decade to regenerate tissue vascular grafts [315]. More recently, several multipotent 
adult stem cells including bone marrow cells (BMC), human mononuclear cells 
(MNCs) derived from bone marrow or peripheral blood, hematopoietic stem cells 
(HSCs) endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) 
with unlimited self renewal capacity and multilineage differential potential have been 
identified within the adult animal/humans [316]. Mounting evidences have shown 
that these multipotent adult stem cells circulate within the peripheral blood and 
migrate to injured tissues and contribute to tissue repair process in vivo [317, 
318].These multipotent stem cells can be seeded on to the scaffold to generate the 
small diameter tissue engineered vascular grafts (TEVG) [315] in vivo  which can be 
used as an alternative for autografts in bypass surgery (Table 1-2). 
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Table 1-2. Potential therapeutic applications of adult multipotent stem cells for the 
generation of small diameter tissue engineered vascular grafts (TEVG) in vivo.  
 
Sno Cell source Scaffold Animal 
model 
Result 
1 Muscle-derived 
stem cells 
(MDSCs) [319], 
Poly(ester 
urethane)urea 
scaffolds 
Rat A smooth-muscle-like 
layer of cells was 
observed  
2 Endothelial 
progenitor cells 
[320] 
 
heparin- 
coated 
decellularized 
vessels (DV) 
 
Dog complete endothelium 
regeneration was seen 
3 Bone marrow 
mononuclear cells 
(BM-MNCs) [321]  
nonwoven 
polyglycolic 
acid mesh 
Mouse A luminal endothelial 
lining surrounded by 
concentric smooth 
muscle cell layer was 
found 
4 Bone marrow-
derived 
mononuclear cells 
(BMMCs) [322] 
 
nonwoven 
polyglycolic 
acid (PGA) 
mesh 
Mouse A Endothelialized 
intimal layer and 
smooth muscle medial 
layer was observed 
5 Bone marrow cell 
(BMC ) [323, 324]  
 
 
poly-l-lactic 
acid (PLLA) 
Dog A Endothelialized layer 
and smooth muscle 
medial layer was 
observed 
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1.15. Specific Aims 
The aim of this study was to identify molecular mechanisms that control 
myocardin-dependent differentiation of SMSPCs into SMCs. The specific aims of 
this work are summarised below, 
Aim 1: to characterise undifferentiated hSMSPC cells for the presence of smooth 
muscle transcription factors (SRF and myocardin), smooth muscle fate regulating 
miRNAs (miRNA 143 and miRNA145), smooth muscle markers (SM α actin, 
calponin and SMMHC) and smooth muscle repressors (KLF4, KLF5 and Elk-1) 
using qRT-PCR assay. This work also aims to identify key culture conditions and 
cytokines that can induce hSMSPC differentiation into SMCs 
Aim 2: to identify the transcriptional repressor involved in smooth muscle 
differentiation of hSMSPC.  
 This work aims to explore the putative binding sites for smooth 
muscle transcriptional repressors within the human myocardin 
promoter region.  
 More specifically aims to investigate whether knockdown of KLF4 
can induce the expression of myocardin promoter activity and to 
verify the KLF4 putative binding site on human myocardin promoter 
region using Chip assay.  
Aim 3: to determine the molecular mechanism underlying myocardin mediated 
smooth muscle differentiation in hSMSPCs.  
 Specifically, the first part aims to investigate whether TGF-β1 
stimulation can induce SMC differentiation of KLF4 knockdown 
hSMSPC cells in vitro.  
 The second part of this study aims to determine whether 
overexpression of myocardin cDNA can induce SMC differentiation 
of hSMSPCs 
Aim 4: to determine the tissue capsule formation potential of rSMSPC eGFP cells 
using a rat model. In this work the integration of rSMSPC eGFP cells within the 
peritoneal derived tissue capsule in rat model will be assessed. 
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2. General methods and materials 
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2.1. Cell Culture 
Cells were grown in an appropriate media as listed in Table 2-1 and 
maintained typically in 5% CO2 at 37°C in a cell incubator. Confluent adherent cells 
were sub cultured by monitoring the red to yellow pH indicator in media. The 
monolayer cells were washed twice with dPBS (Sigma, St.Louis, MO) in order to 
remove the serum present in the media and incubated with 0.25% trypsin (Sigma, 
St.Louis, MO) to release the adherent cells from the flask. The trypsin in detached 
cell suspension was neutralised by adding fresh serum containing media and sub 
cultured into new tissue cultured flasks. 
2.2. Cell types 
Table 2-1. List of in vitro cell types  
 
Cell type Description Media Reference 
HeK 
293T 
Human Embryonic 
Kidney 293 cell variant 
expressing SV40 Large 
T antigen. 
Dulbecco’s Modified 
Media (DMEM) with 
10% Fetal Bovine 
Serum (FBS)  
ATCC, 
University 
Manassas, 
USA. 
HUVEC Human Umbilical Vein 
Endothelial Cells 
EGM2 (Endothelial 
Cell Growth Media 2)  
Lonza, Basel, 
Switzerland. 
HASMC Human Aortic Smooth 
Muscle Cells 
SmGM2 (Smooth 
Muscle Growth 
Medium 2) 
Cascade 
Biologics, 
Eugene, USA 
rSMC Rat Smooth Muscle 
Cells 
DMEM with 10% FBS ATCC, 
University 
Manassas, 
USA 
hSMSPC Human Smooth Muscle 
Stem Progenitor Cell 
EGM2 Isolated from 
peripheral 
blood  
rSMSPC 
eGFP 
Rat Smooth Muscle 
Stem Progenitor Cell 
expressing eGFP 
EGM2 Isolated from 
rat bone 
marrow 
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2.3. Antibodies 
Table 2-2. List of antibodies used for immunofluorescence staining and western 
blotting. 
 
Antibody Clone Company Cat.log Dilution 
SM α actin mIgG 2a 1A4 Dako M0851 1 in 200 
Calponin Rbt IgG 
EP798Y 
Epitomics 1806-1 1 in 200 
SMMHC Rat IgG 2a 
KM 3669 
Kamiya 
biomedical 
company 
MC-352 1 in 200 
HA-tag Rbt IgG Sigma H6908 1 in 100 
GKLF Rbt IgG Santacruz SC-20691 1in 200 
Myocardin mIgG Abcam Ab 22621 1 in 100 
PCNA mIgG Chemicon 
Temecula, 
CA 
CBL 407 1 in 1000 
 
Rat IgG 2a  eBiosciences 13-4321-82  
Rabbit IgG  Prosci 
Incorporated 
3703  
Mouse IgG 2a  Santacruz SC-3878  
Goat anti mouse 
Alexafluor 546 
 Invitrogen A11030 1 in 500 
Goat anti rabbit 
Alexafluor 488 
 Invitrogen A11008 1 in 500 
Goat anti rat 
Alexafluor 488 
 Invitrogen A11006 1 in 500 
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2.4. Quantitative reverse transcriptase PCR (qRT-PCR) primers 
         Table 2-3. List of qRT-PCR primers. 
 
Marker Gene Symbol 
Forward/Reverse 
Sequence 5’->-3’ 
hMyocardin hMYOCD_F tcagcaatttcagaggtaacaca 
hMYOCD _R tgactccgggtcatttgc 
hSRF hSRF _L agcacagacctcacgcaga 
hSRF _R gttgtgggcacggatgac 
hCalponin hCNN1 _L ccaaccatacacaggtgcag 
hCNN1 _R tcaccttgtttcctttcgtctt 
hSM α actin hACTA2 _L ctgttccagccatccttcat 
hACTA2 _R tcatgatgctgttgtaggtggt 
hSMMHC hMYH11_L aactcgtgtccaacctggaa 
hMYH11_R ttctcctcggctaacaactga 
hKLF4 KLF4_L gccgctccattaccaaga 
KLF4_R tcttcccctctttggcttg 
hKLF5 hKLF 5_L ctgcctccagaggacctg 
hKLF 5_R tcgtctatactttttatgctctggaat 
hElk-1 Elk1_L tgcttcctacgcatacattga 
Elk1_R ggtgctccagaagtgaatgc 
hGAPDH hGAPDH_L agccacatcgctcagacac 
hGAPDH_R gcccaatacgaccaaatcc 
 
2.5. RNA isolation  
Total cellular RNA was isolated from tissue culture cell using RNeasy RNA 
isolation kit (Qiagen, Hilden, Germany) and miRNA was isolated using mirVana 
miRNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacture’s 
instructions. 
2.6. QRT-PCR 
2 μg of total RNA was reversed transcribed into cDNA using SuperScript III 
(Invitrogen, Carlsbad, CA). Real-time RT-PCR (qRT-PCR) was carried out with 100 
ng of cDNA specific primer for each qRT-PCR reaction with primer specific probe 
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and SYBR green (Roche Applied Sciences, West Sussex, UK). The quantification 
was done relative to GAPDH expression in each sample. PCR amplification with no 
RNA, no RT and water only served as negative controls. Probe specific qRT-PCR 
primers and SYBR green qRT-PCR primers were designed using the Roche – 
universal probe library (www.roche-applied-science.com) and Primer 3 software 
respectively. 
2.7. Immunofluorescence microscopy 
The cells were washed with phosphate buffered saline (PBS) (Sigma, 
St.Louis, MO), fixed with chilled methanol (Sigma, St.Louis, MO) for 10 minutes at -
20OC and washed twice with PBS for 5 minutes each at room temperature (RT). The 
non specific binding sites were blocked by incubating the cells in blocking buffer 
(10% goat serum in 0.1% Triton X-100/ PBS (Sigma, St.Louis, MO)) for 20 minutes 
in humidified chamber at RT. The cells were labelled with primary monoclonal 
antibodies for 2 hours at RT and washed thrice with PBS to remove the excess 
primary antibody. The cells were stained with alexafluor conjugated secondary 
antibody as listed in table 2-2 for 45 minutes at RT and washed three times with 
PBS followed by 10 minutes staining of the nuclei with 10µg/ml 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen, Carlsbad, CA) in sterile water. The slides were 
washed with PBS, dried and mounted with immu-Mount (Thermo Shandon Inc, 
Pittsburgh, PA). The slides were analysed using TE 2000 Nikon confocal 
microscope using EZ-C1 version 3.90 software. 
2.8. Fluorescence-activated cell sorting (FACS) analysis 
The media was removed from the cells, washed once with PBS and 
incubated in 0.25% trypsin for five minutes. The tissue culture flask was tapped 
gently and flushed with media to collect the cells and centrifuged at 600g for 5 
minutes. The pellet was washed once with FACS buffer (0.5% BSA, 1 mM 
Ethylenediaminetetraacetic acid (EDTA) (Sigma, St.Louis, MO) in PBS) and 
resuspended in FACS buffer. The FACS analysis was carried out in BD FACS 
calibur (BD Biosciences, San Jose, USA) cytometer. The live cells were gated on 
forward and side scatter and eGFP signal was collected in the FL1 channel. The 
FACS data was analysed for percentage eGFP expression by 2D dot plot using 
WinMDI (Windows Multiple Document Interface for flow cytometry) 9.2 software. 
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2.9. Lentiviral production 
Lentivirus was generated in HeK 293T cells. A day before transfection, 16 x 
106 cells were seeded onto 15 cm tissue culture dish in DMEM supplemented with 
10% FBS. The media was changed four hours before transfection to induce the 
growth of the cells. The HeK 293T cells were transfected with three plasmids (30 g 
transfer construct, 24 g packaging construct pCMV- R8.91 encoding packaging 
protein Gag-Pol, Rev, Tat and 16 g envelope pMD.G – encoding G protein of the 
vesicular stomatitis virus (VSV)) using standard calcium phosphate precipitation 
method as described below. The three plasmids were mixed together and the 
volume was made to 1.8 ml with sterile water and added 200 μl of CaCl2. 2 ml of N, 
N-bis [2-hydroxyethyl]-2-aminoethanesulfonic acid (BES) (Calbiochem, Middlesex, 
UK), pH 7.0 was added to the DNA/CaCl2 complex in a drop wise manner while 
vortexing and incubated at room temperature for 5 minutes. The transfection mix 
was added to the cells in a drop wise manner and incubated in 3% CO2 at 37
OC.  
The media was replaced 16 hours post transfection with DMEM supplemented with 
2% FBS and incubated in 5% CO2 at 37
OC. Lentivirus was harvested 48 hours after 
withdrawal of transfection media. The viral supernatant was collected and 
centrifuged at 600 g for 5 minutes at 4OC and filtered through 0.45 μm filter. The 
lentivirus was concentrated by ultrafiltration using centricon-70 (Millipore, Billerica, 
MA) which remove residual VSV-G and pelleted by ultracentrifugation in a Sorval 
WX ultra series centrifuge (Thermo electro corporation, Waltham, Massachusetts) 
with swing rotor at 72,000 g for 90 min at 4OC and resuspended in fresh media. 
Using these protocols, titers of ~5 x 107 to 3 x 108 TU/mL were achieved. The virus 
titre was estimated based on the transduction of HeK 293 T cells. A day before 
transduction HeK 293T cells were seeded at plating density 5 x 104 cells per well in 
a 24 well plate with DMEM media. Next day the media was removed and the cells 
were transduced with serial dilution of the concentrated vector that corresponds to 
the final amount of 1, 10-1, 10-2, 10-3, 10-4 µl of vector.  After 72 hours of 
transduction, the cells were analysed for eGFP expression or the cells were stained 
with HA-tag antibody and percentage of HA-tag positive cells were determined using 
FACS analysis. The lentivirus titre was calculated using the following formula 
         
               
Titre ( Transducing units/ml) =
Number of target cells x (Percentage of eGFP+ cells/100)
Volume of vector (ml)
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2.10. ShKLF 4 Lentivirus production protocol 
A day before the transfection HeK 293T cells were seeded at 50,000 cells 
per cm2 plating density in 6 well plate in DMEM 10% media. Next day the cells were 
transfected using 3:1 ratio of X-tremeGENE HP DNA transfection reagent (μl) 
(Roche Applied Sciences, West Sussex, UK) and plasmid DNA (μg). First the 
plasmid DNA mix comprised of three plasmids, 0.5μg of transfer construct shKLF4 
Nature B, 0.25μg packaging construct pCMV- R8.91 and 0.25μg envelope pMD.G 
was diluted in diluent Opti-MEM I (Invitrogen, Carlsbad, CA) and than 3μl of X-
tremeGENE HP DNA transfection reagent was added to the diluted plasmid DNA to 
form transfection complex. The transfection reagent: DNA complex was mixed and 
incubated for 20 minutes in the dark at room temperature. The transfection complex 
was added to the cells in a drop wise manner without removing the media. After 16 
hours of transfection, the media was changed to DMEM supplemented with 2% 
FBS. Lentivirus was harvested 48 hours after removal of transfection media. The 
viral supernatant was collected and centrifuged at 600 g for 5 minutes at 4OC and 
filtered through 0.45 μm filter and stored at -70OC. Since the culture vessel size is 
larger 15 cm (176 cm2) for the production of lentiviral constructs the amount of DNA 
used was higher (70 µg) as compared to shRNA lentivirus production in 6 well plate 
(9.6 cm2) with 5 µg of DNA. 
2.11. Transduction Protocol 
Cells were maintained in media outlined in table 2-1. One day before 
transduction, the cells were seeded at 50,000 cells per cm2 plating density in 100 µl 
EGM2 media in 8 well chamber slides. Next day, the cells were transduced with 5 
MOI of lentivirus in 100 µl EGM2 media. After 24 hours of transduction, the growth 
media was changed to 200 µl either differentiation media (SmGM2 1%FBS with TGF 
β1 5ng/ml) or SmGM2 1%FBS. Fresh media (SmGm2 1% FBS) of volume 100µl 
was added every 3 days without removing the conditioned media.  
2.12. Transient transfection  
The hSMSPC cells were co-transfected by using lipofectamine (Invitrogen, 
Carlsbad, CA) with reporter plasmids encoding firefly (Photinus pyralis) luciferase  
pGL3 Enhancer-hMyocd driven by human myocardin promoter  and renilla (Renilla 
reniformis) luciferase construct pRL-TK driven by thymidylate kinase- a 
housekeeping gene promoter in 25:1 ratio.  The reporter plasmids were mixed 
gently in Opti-MEM I reduced serum media (Invitrogen, Carlsbad, CA) and 
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lipofectamine was diluted in Opti-MEM I. The diluted reporter plasmids was 
combined with diluted lipofectamine and incubated at room temperature for 45 
minutes. After incubation, the volume was made up to 50 μl with Opti-MEM I and 
mixed gently. The growth media from cells were removed and replaced with 150 μl 
of EGM2. 50 μl of transfection complex were added to the each well in drop wise 
manner. The cells were incubated in 5% CO2 at 37
OC.   
2.13. Dual Luciferase Assay 
 In a dual luciferase assay the firefly and renilla luciferase activity were 
measured sequentially from a single sample. The glomax 20/20 luminometer 
(Promega, Wisconsin, USA) was programmed for Dual injection with a 10 second 
integration time. 100 µl of Firefly assay buffer (25mM Glycylglycine, 15mM K2PO4 
pH8, 4mM ethylene glycol tetraacetic acid (EGTA), 15mM MgSO4, 0.1mM 
Coenzyme A, 75μM Luciferin , 2mM ATP (Sigma, St. Louis, MO) and 1mM 
Dithiothreitol (DTT) (Invitrogen, Carlsbad, CA)) was added to 20µl of cell lysate. The 
tube was placed in the luminometer and initiated the luminescence activity. The 
luminescence activity was measured for 10 seconds and referred as relative 
luminescence units (RLU) RLUs1. After 10 seconds, 100) µl of renilla luciferase 
buffer (1.1M NaCl, 2.2mM EDTA, 220 mM K2PO4 pH5.1, 0.44 mg/ml BSA, 1.3mM 
NaN3, and 1.43 μM Coelenterazine h (Sigma, St. Louis, MO)) was added and 
luminescence activity was measured for 10 sec and referred as RLUs2. The 
RLUs1/RLUs2 ratio was calculated for each sample. 
2.14. Western Blot analysis  
The cells were washed and scraped in ice cold PBS, centrifuged for 12000 
rpm at 4OC for 10 minutes. The pellet was resuspended in 60 μ1 of crack lysis buffer 
(50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS and 10% glycerol supplemented 
with Complete protease inhibitor (Roche Applied Sciences, West Sussex, UK) and 
phosphatase inhibitor (Sigma, St. Louis, MO). The lysate was sheared by passing 
five times through 23-gauge needle and boiled (99OC) for 10 minutes, centrifuged 
for 14,000g at 4OC for 10 minutes. The supernatant was collected and stored at -
70OC. The protein concentration was determined using the Pierce BCA protein 
assay kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s 
instructions.  
The BCA assay reagent A and B was mixed at 50:1 ratio to obtain a bright 
green colour solution and added 200µl to each well in 96 well plate. 10 µl of cell 
lysate or known concentrations of reference protein (BSA) standards were added to 
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BCA assay mixture.The plate was incubated for 30 minutes at 37oC and the colour 
change from green to purple color was measured at 540 nm using a plate reader. A 
standard curve was plotted using absorbance and known concentration of reference 
protein (BSA). The concentration of unknown sample was calculated using standard 
curve and used 50µg of protein sample for western blot analysis. 
Protein was denatured and loaded onto an SDS-polyacrylamide gel with 
4% stacking and 12% separating gels (1.5mm thick) and run at 80-120 V and 
constant current. 50 μg of protein from each sample were mixed with an appropriate 
volume of loading buffer to give a final volume of 30 μl for loading. The samples 
were boiled for 5 min and then loaded on the stacking gel  along with a prestained 
protein marker (broad range 6-175 kDa, New England Biolabs, Lpswich, MA) to 
determine the molecular mass of proteins. Protein was transferred onto 
nitrocellulose membrane (GE Healthcare, Littlechalfont, UK). Prior to protein 
transfer, the membrane was soaked in dH2O and pre-chilled blot buffer. Transfer 
was carried out at 85V constant voltage for 1 hour. Transfer of protein was routinely 
checked by Ponceau S staining (Thermo Fisher Scientific, Waltham, MA). After 
transfer of proteins, the membrane was blocked (shaking) in blocking buffer (5% 
milk in TBST (50mM Tris HCl pH 8.0, 0.15M NaCl, 0.05% Tween) buffer for 30 min 
at room temperature. The membrane was incubated with the primary antibody 
diluted in 5% milk in TBST buffer. To remove excess of primary antibody, the 
membrane was washed with TBST, three times for 10 min. Next, the membrane was 
incubated for one hour at RT with the horseradish peroxidase (HRP) labeled 
secondary antibody in TBST 5% milk solution. Blots were then washed with TBST 
three times for 10 min and finally with enhanced chemiluminescence (ECL) solution 
(Millipore, Massachusetts, USA) for 1 minute. The signal was recorded with 
MultiSpectral Imaging System (BioSpectrum®) camera. Bands quantified using 
Image J (NIH software).  
2.15. Chromatin immunoprecipitation (ChIP) Assay  
hSMSPCs (8 x 106) were cultured in EGM2 media on 10 cm tissue culture 
flask were scraped in ice cold PBS with 100 mM phenylmethanesulfonylfluoride or 
phenylmethylsulfonyl fluoride (PMSF), centrifuged (600g, 5 min) and resuspended in 
10 ml of EGM2 media. The harvested cells were chromatin immunoprecipitated as 
described by the manufacturer Active Motif (Active motif, Carlsbad, CA). The cells 
were fixed with 270 μl of 37% formaldehyde and then incubated at 37OC for 10 
minutes on a rocker and quenched with glycine for 5 minutes, centrifuged and 
resuspended in lysis buffer with protease inhibitor. The cells were sheared by 
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sonication, centrifuged and supernatant was collected. The size of the sonicated 
DNA showed a smear between 0.5 to 1 Kb as determined by 1% agarose gel 
electrophoresis. The immunoprecipitation was performed in total volume of 200 μl 
contained 25 μl of Protein G beads, 20 μl of ChIP buffer I, 100 μl of sheared 
chromatin, 1 μl of PIC, 2 μg of anti-KLF4  or 2 μg normal IgG and volume made to 
200 μl with sterile water.  The components were resuspended thoroughly and 
immunoprecipitation was performed over night at 4OC on end to end rotator. The 
Protein G beads only and rabbit IgG were used as negative controls. The beads 
were washed three times with wash buffer and the chromatin was eluted, reversed 
the cross links at room temperature. The protein- chromatin complexes along with 
the INPUT sample taken before sonication was heated and subjected to proteinase 
K treatment. The INPUT DNA was diluted 10 times before PCR amplification. 
Purified DNA from chip assay or input DNA were used as template for PCR 
amplification with 10 μM forward and reverse primer and 2X LightCycler 480 SYBR 
green I master mix in 10μl reaction and subjected to 35 cycles using Roche 
LightCycler 480 system. Water and without template were used as PCR negative 
controls. 
2.16. Hematoxylin and Eosin (H&E) Staining Protocol 
  The frozen sections were allowed to thaw briefly at room temperature 
and fixed with 4% paraformaldehyde for 10 minutes at room temperature. The slides 
were washed once with PBS for 5 minutes. The slides were immersed in 
hematoxylin solution for 5 minutes and dipped in 1% acid alcohol for 10 seconds 
than sections were stained with eosin for one minute, dried and mounted under a 
cover slip with DPX mounting media. 
2.17. Tissue Engineering 
Irradiated 10 mm lengths of 3 mm diameter silastic tubing are coated with 
fibronectin (5μg/cm2) for 45 minutes at room temperature in a rocker. The silastic 
tubes along with 50 million rSMSPC eGFP cells in 3 ml of saline were injected into 
peritoneal cavity of hPAP fisher rats. The uncoated and fibronectin coated tubes 
were used as negative controls. The implants were removed after two weeks and 
examined for tube capsule formation. The capsule was removed from the tubes, 
OCT embedded, sectioned and subjected to H&E staining, eGFP detection and 
immunohistochemical analysis of smooth muscle marker protein expression. 
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2.18. Statistical analysis 
Statistical analyses were performed using graphpad prism software. 
Statistical significance was tested by unpaired students t test and p<0.05 was 
considered statistically significant. 
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3. Specific Aim 1 - Characterisation of 
undifferentiated hSMSPC cells for the 
presence of smooth muscle associated 
transcription factors 
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3.1. Introduction to progenitor cells differentiation into SMC 
Smooth muscle differentiation plays an important role in the pathogenesis 
of vascular diseases, which underlies the importance of understanding the 
molecular mechanism of smooth muscle differentiation. Stem cells have the ability to 
differentiate into many cell types including smooth muscle cells at the site of 
vascular injury in the tissue repair process [325]. Many investigators have identified 
several sources of the committed smooth muscle progenitor cells in bone marrow, 
peripheral blood, brain and liver [294]. Mounting evidence suggests that cytokines 
such as TGF- β1, PDGF-BB and hormone like growth factor retinoic acid influence 
progenitor cell differentiation into smooth muscle cells. Cytokines and growth factor 
involved in progenitor cell differentiation into SMCs are listed in the table below. 
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Table 3-1. List of progenitor cell source growth factor and cytokines involved in 
differentiation into SMC 
 
Cell type Cytokine 
/Growth 
factor 
Dosage  Phenotype change 
Embryonal 
carcinoma cell 
line (p19) 
Retinoic 
acid 
106 mol/L Differentiated into fibroblast 
like cells expressing SM α 
actin [246]. 
A404  1 mM/L  Up to 90% cells differentiated 
in to SMC like cells expressing 
SM α actin, calponin, SM1 
isoform of SMMHC [246]. 
ESC  10 mM > 93% cells differentiated into 
SMC cells expressing SM α 
actin and SMMHC [249]. 
ESC Sca1+ PDGF-BB 10 ng/ml Differentiated into SMC cells 
expressing SM α actin, 
calponin and SMMHC [251]. 
Adventitial 
progenitor cells 
 10 ng/ml Differentiated into SMC [250]. 
Neural crest cell 
line (Monc-1 ) 
TGF-β1 5 ng/ml Differentiated into SMC 
expressing SM α actin, SM 
22α, calponin, SMγ actin, 
smoothelin and SMMHC and 
showed contraction muscarinic 
agonist carbachol [260]. 
Multipotent adult 
progenitor cells 
(MAPC) 
 2.5 ng/ml Differentiated into SMC 
phenotype [326]. 
hESC – CD 34+ 
subpopulation 
PDGF-BB 
and TGF-β1  
5 ng/ml and 
2.5 ng/ml 
Differentiated into SMC 
expressing SM α actin, SM 
22α, calponin [327]. 
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Extracellular matrix (ECM) plays a vital role in control of SMC 
differentiation. ECM contains agrin, fibulins and fibronectin which interacts with 
integrins and activate multiple signalling pathways [328]. Glycosylation of basement 
membrane enhances its binding of growth factors [329] and changes in ECM 
composition determine the phenotype of smooth muscle cell [327]. In the normal 
vessel media, dense ECM surrounding SMC helps to maintain a non proliferative 
SMC state [330]. Multipotent human Isl1+ heart progenitor cells, when seeded on 
fibronectin coated culture plates differentiate into SMC [331]. Lu et al., [332] 
demonstrated that hemangioblasts from ESC can be induced to differentiate into 
SMC expressing SM α actin, SM 22α and calponin when cultured on fibronectin 
coated slides in SMC media. In addition, CD 34+ subpopulations of hESCs were 
induced to SMC expressing smooth muscle markers such as SM α actin, SM 22 α 
and calponin. The cells were maintained on fibronectin coated culture surface in 
DMEM 5% FBS with PDGF-BB (5 ng/ml) and 2.5 ng/ml of TGF-β1 [327].  Taken 
together, these results suggest that the cytokine along with fibronectin can induce 
differentiation of progenitor cells into SMC.  
In our lab, a novel Isl-1+ stem progenitor cells was isolated from the 
peripheral circulation of human subjects. Interestingly, in vitro characterisation of 
hSMSPC cells has provided first time evidence that these cells express higher levels 
of KLF4 as measured by FACS analysis, a possible candidate for regulating SMC 
differentiation in hSMSPC cells. It has been shown that the progenitor phenotype is 
maintained by expression of one or more repressors [302] and it is interesting to 
note that smooth muscle associated miR-143 and miR-145 are involved in 
downregulation of smooth muscle repressors, KLF4 and Elk-1 [208]. However, 
smooth muscle specific markers and miRNAs have not been identified yet in 
hSMSPC cells.  
Therefore, the current hypothesis that hSMSPC express low levels of 
smooth muscle associated transcription factor and higher levels of repressor. 
The present study aims to characterise undifferentiated hSMSPC cells for 
the presence of smooth muscle transcription factors (SRF and myocardin), smooth 
muscle fate regulating miRNAs (miRNA 143 and miRNA145), smooth muscle 
markers (SM α actin, calponin and SMMHC) and smooth muscle repressors (KLF4, 
KLF5 and Elk-1) using qRT-PCR assay. 
The second part of this study aims to identify key culture conditions and 
smooth muscle associated cytokines that can induce hSMSPC differentiation into 
SMCs. Additional aims determine the role of growth media such as EGM2, EGM2 
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with 1% FBS, SmGM2, SmGM2 with 1% FBS and cytokines such as TGF-β1 (2.5 
ng and 5 ng/ml), PDGF-BB (5 and 10 ng/ml) and retinoic acid (10 and 20 µM) to 
induce SMC differentiation in hSMSPC cells.  
3.2. Methods 
3.2.1. Cell culture 
hSMSPC Isl1+ progenitor cells were isolated from bypass filter of 
atherosclerosis patients undergoing CABG surgery.  The total cells from filters were 
collected by flushing the filters with PBS and RPMI medium. The passaged cells 
were maintained in EGM2 medium. HASMCs were obtained from Cascade 
Biologics, Eugene, USA and maintained in SmGM2 medium. The cells were 
maintained at 37OC in a humidified atmosphere containing 5% CO2. The cells were 
passaged in to 75 cm2 culture dish for RNA isolation and onto nunc wells for 
immunohistochemical analysis. HASMC from early passage was used for RNA 
isolation and immunohistochemical analysis. 
3.2.2. RNA isolation 
hSMSPC and HASMC cell were washed twice with dPBS and washed with 
0.25% trypsin to lift the attached cells. The cells were pelleted by centrifugation at 
600g for 5 minutes. Total cellular RNA from hSMSPC and HASMC was isolated 
using RNeasy RNA isolation kit according to the manufacture’s instruction. 
3.2.3. QRT-PCR 
QRT-PCR analysis was carried out as outlined in general method section 
2.5 with specific primers. The primers used were outline in general methods table 2-
3. 
3.2.4. hSMSPC differentiation protocol 
3.2.4.1. Coating of Nunc wells with fibronectin 
Fibronectin was diluted in sterile PBS and the 8 well nunc slides were 
coated with fibronectin at 5 μg/cm2 concentration in minimal volume. The coated 
slides were allowed to air dry for 45 minutes at room temperature under the laminar 
air flow chamber. 
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3.2.4.2. Treatment of hSMSPC cells with different culture media to induce 
SMC differentiation.  
The aim of this experiment was to characterise SMC differentiation from 
hSMSPC under various culture conditions. Confluent hSMSPC was detached from 
the culture dish and seeded at 10,000 cells per cm2 onto fibronectin coated 8 well- 
nunc slides in the presence of four different media such as EGM2, EGM2 1% FBS, 
SmGM2, SmGM2 1%FBS. The hSMSPC were maintained in above mentioned 
growth media for 7 days. Later on, the cells were washed with PBS and 
immunostained for smooth muscle marker proteins as outlined in general methods 
section 2.7 with smooth muscle marker antibodies such as SM α actin (1 in 200), 
calponin (1 in 200) and SMMHC (1 in 200). The images were obtained with 60X oil 
immersion lens using confocal microscopy. The percentage of smooth muscle 
markers positive cells were counted in 10 randomly chosen 60X fields from three 
separate experiments. 
3.2.4.3. Comparison of various cytokines and growth factor for their role 
in hSMSPC differentiation into SMC  
The purpose of this experiment was to investigate the role of cytokines in 
hSMSPC differentiation into SMC. hSMSPCs were seeded at 10,000 per cm2 onto 
fibronectin coated 8 well nunc slides in basal EGM2 medium. Next day, the medium 
was replaced with SmGM2 1% FBS alone with cytokines such as TGF-β1 (2.5 and 5 
ng/ml), PDGF-BB (5 and 10 ng/ml) and retinoic acid (10 and 20 μM) respectively. 
After 3 days, fresh media was added to each treatment with appropriate cytokines 
without removing the conditioned media. At Day 7, the growth media was removed 
and washed with PBS and cells were immunostained for smooth muscle marker 
proteins as outlined in general methods section 2.7 with antibodies such as SM α 
actin (1 in 200), Calponin (1 in 200) and SMMHC (1 in 200). The images were 
obtained with 60X oil immersion lens using confocal microscopy. The percentage of 
smooth muscle positive cells relative to total number of cells were counted in 10 
randomly selected high power fields (n=3). 
3.3. Results 
3.3.1. Characterisation of hSMSPC using qRT-PCR analysis 
The expression levels of smooth muscle marker genes such as SM α actin, 
calponin and SMSMHC and smooth muscle transcription factors SRF, myocardin, 
miR-143 and miR-145 was analysed by qRT-PCR assay. In addition, the expression 
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of smooth muscle repressors including KLF4, KLF5 and Elk-1 was also analysed in 
undifferentiated hSMSPC cells. The expression levels of these markers in hSMSPC 
cells were compared with HASMCs (Fig. 3.1). 
The results demonstrate that the undifferentiated hSMSPC cells express 
low levels of myocardin (Fig.3.1B), miR-143 and miR-145 (Fig.3.1C&D). It was also 
found that these cells express modest levels of SM α actin (Fig.3.1E), low levels of 
calponin (Fig.3.1F) and nearly equivalent levels of SMMHC (Fig.3.1G) when 
compared to HASMCs. However, they contain SRF mRNA levels equal to HASMC 
cells. Notably, hSMSPCs also express higher levels of repressors of myocardin–
SRF dependent transcription including KLF4, KLF5 and Elk-1 (Fig. 3.1H-J). These 
repressors can inhibit myocardin induced SMC transcription [138, 167, 287], 
suggesting that the progenitor phenotype of hSMSPC cells may be maintained in an 
undifferentiated state by repression of myocardin gene expression by repressors. 
3.3.2. Serum reduced smooth muscle medium (SmGM2 1%FBS) enhances 
differentiation of hSMSPC to Smooth muscle like cells. 
hSMSPCs were maintained in EGM2, endothelial medium after isolation 
from the filters. To identify suitable media for hSMSPC differentiation these cells 
were grown in different growth media such as EGM2, serum reduced EGM2 (EGM2 
1% FBS), SmGM2 and serum reduced SmGM2 (SmGM2 1%FBS) for 7 days 
(Fig.3.2.). Expression of smooth muscle marker proteins was detected by 
immunofluorescence analysis.  
Undifferentiated hSMSPCs grown in basal EGM2 media showed a 
punctate staining pattern within the nucleus for SM α actin (Fig.3.2A). The reason 
for SM α actin punctuate is unclear. However, these cells did not express calponin 
(Fig.3.3A) and SMMHC at the protein level (Fig.3.4A).  This result for SM α actin and 
calponin is consistent with the qRT-PCR analysis (Fig. 3.1E&F). Although, SMMHC 
(Fig.3.1 G) mRNA signal was detected by qRT-PCR, the SMMHC protein 
expression was not detectable by immunofluorescence analysis, suggesting that 
SMMHC gene expression levels are not high enough for translated protein 
expression or may be related to the presence of non-functional SMMHC protein in 
hSMSPC cells In order to optimise the growth media for hSMSPC differentiation, 
these cells were grown in various growth media. The cells maintained in smooth 
muscle growth media (SmGM2) and serum reduced SmGM2 1%FBS express SM α 
actin, to a greater extent (Fig.3.2 C&D). In these two treatments, the SM α actin 
expression is evenly distribution throughout the cells with 3.5 and 4 fold increase in 
SmGM2 and SmGM2 1% FBS (Fig. 3.2E), respectively. Furthermore, the 
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expression of calponin was increased to a similar extent in all treatments (Fig.3.3) 
as compared to basal medium (EGM2). However, there was no difference in 
SMMHC expression observed between different growth media (Fig.3.4). These 
results indicate that hSMSPC showed a potential to differentiate towards SM like 
cells when cultured in SmGM2 or SmGM2 supplemented with 1% FBS.  Since the 
SmGM2 1% FBS showed more SM α actin positive cells, it was selected for further 
differentiation study. 
3.3.3. TGF β1 induces differentiation of hSMSPC to SM like cells 
Having shown that hSMSPC have the potential to differentiate into SMC in 
SmGM2 1%FBS, this study sought to test whether commonly associated smooth 
muscle cytokines can further enhance SMC differentiation of hSMSPC cells. Several 
studies of progenitor cells reported the role of TGF-β1, PDGF-BB and retinoic acid 
in SMC differentiation, survival and growth. In order to investigate the role of TGF-
β1, PDGF-BB and retinoic acid in the hSMSPC differentiation process, two different 
concentrations of TGF-β1 (2.5 and 5 ng/ml), PDGF-BB (5 and 10 ng/ml) and retinoic 
acid (10 and 20 µM) were used in this study. hSMSPCs were suspended in EGM2 
media and seeded at 10,000 cells/cm2 density in the 8 well chamber slides. At day 
1, the media was changed with SmGM2 1% FBS with 2.5, 5 ng/ml TGF-β1 or 5, 10 
ng/ml PDGF-BB and 10, 20 µM retinoic acid respectively. At day 7, 
immunohistochemistry for SM markers was performed on all treatments along with 
untreated hSMSPCs.  
Stimulation with PDGF-BB (5, 10 ng/ml) and retinoic acid (10, 20 µM) did 
not show any significant increase in the expression of SM α actin (Fig. 3.5), calponin 
(Fig. 3.6) and SMMHC (Fig. 3.7) at the protein level. However, TGF-β1 5 ng/ml 
showed a 5.7 fold increase in expression of SM α actin (Fig. 3.5) and only a slight 
increase in calponin expression was observed in hSMSPCs (Fig. 3.6). However, no 
difference in expression of SMMHC was induced by TGF-β1 treatment (Fig. 3.7). 
Taken together, these results suggest that TGF-β1 5 ng/ml signaling may be 
inducing SMC differentiation but expression of repressors in hSMSPCs may 
contribute to the inhibition of TGF-β1 induced SMC differentiation. 
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Figure 3-1. Characterisation of hSMSPC derived from human blood using qRT-PCR.  
Total RNA was isolated from the undifferentiated hSMSPC grown in EGM2 media and hSMC 
grown in SmGM2 media. White bars indicate hSMC and black bars indicate hSMSPC.  
Comparative qRT-PCR analysis of  smooth muscle transcription factors, SRF (A) and 
myocardin (B), smooth muscle cell fate regulating miRNAs, miR-143 (C) and miR-145 (D), 
smooth muscle markers SM α actin (E), calponin (F), SMMHC (G), and smooth muscle 
repressors KLF5 (H), KLF4 (I) and Elk-1 (J) between hSMSPC and hSMC. GAPDH was 
used to normalise the relative expression levels. ** P<0.01, *P<0.05, ns – not significant 
P>0.05 
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Figure 3-2. Growth media (SmGM2 1% FBS) induced differentiation in hSMSPC in 
vitro.  
To optimise the media for hSMSPC differentiation, cells were plated at 2.5 x10
4
 /cm
2
 in 
EGM2, EGM2 1% FBS, SmGM2, and SmGM2 1% FBS growth media respectively on 
chamber slides for 7 days. The differentiated cells were immunostained with SM α actin 
antibody.  The expression of SM α actin (red) in hSMSPC grown in EGM2 (A), EGM2 
1%FBS (B), SmGM2 (C), and SmGM2 1% FBS (D) were shown Fig. 3.2. The white boxed 
area is enlarged and presented on right side of the each panel.The graph (E) represents the 
quantification of SM α actin positive cells in different growth media from n=3 independent 
experiments. 
** P<0.01, *P<0.05 
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Figure 3-3. Growth media (SmGM2 1% FBS) induced differentiation in hSMSPC in 
vitro.  
Cells were plated at 2.5 x10
4 
/cm
2
 in EGM2, EGM2 1% FBS, SmGM2, and SmGM2 1% FBS 
growth media respectively on chamber slides for 7 days. The differentiated cells were 
immunostained with calponin antibody. The differentiated hSMSPC cells were stained for 
calponin (green) and nucleus (blue) in EGM2 (A), EGM2 1%FBS (B), SmGM2 (C), and 
SmGM2 1% FBS (D) media and the small white rectangular boxed area shows the magnified 
field image in respective treatments. The graph (E) Represents the quantification of calponin 
positive cells in different growth media from n=3 independent experiments. 
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Figure 3-4. Growth media (SmGM2 1% FBS) induced differentiation in hSMSPC in 
vitro.  
Cells were plated at 2.5 x10
4 
/cm
2
 in EGM2, EGM2 1% FBS, SmGM2, and SmGM2 1% FBS 
growth media respectively on nunc chamber slides for 7 days. The differentiated cells were 
immunostained with SMMHC antibody. The differentiated hSMSPC cells were stained for 
SMMHC (red) and nucleus (blue) in EGM2 (A), EGM2 1%FBS (B), SmGM2 (C), and 
SmGM2 1% FBS (D) media. A small portion marked as white small rectangular region was 
magnified and presented on to the left in each treatment. The graph (E) Represents the 
quantification of SMMHC positive cells in different growth media from n=3 independent 
experiments. 
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Figure 3-5. Cytokine-induced SMC differentiation (SM α actin) in hSMSPC.  
 hSMSPC cells were plated in EGM2 for 24 hours to facilitate attachment and the cells were 
differentiated in culture using various cytokines (TGF-β1 (2.5 and 5 ng/ml), PDGF-BB (5 and 
10 ng/ml) and retinoic acid (RA) (10 and 20 μM)) in SmGM2 with 1% FBS media for 7 days. 
The differentiated cells were stained with SM α actin antibody for immunofluorescence 
analysis. Right panel shows differentiated hSMSPC cells stained for SM α actin (red) and 
nucleus (blue) in different cytokines and left panel shows the magnified field image in 
respective treatment. The graph (B) Represents the quantification of SM α actin positive cells 
in different cytokines from three different experiments. n=3,  *P<0.05. 
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Figure 3-6. Cytokine-induced SMC differentiation (calponin) in hSMSPC.  
 hSMSPC cells were differentiated in culture using various cytokines (TGF-β1 (2.5 and 5 
ng/ml), PDGF-BB (5 and 10 ng/ml) and retinoic acid (10 and 20 μM)) in SmGM2 with 1% 
FBS media for 7 days. The differentiated cells were stained with calponin antibody for 
immunofluorescence analysis. Right panel shows differentiated hSMSPC cells stained for 
calponin (green) and nucleus (blue) in different cytokines and left panel shows the magnified 
image in respective treatment inside the white rectangular region. The graph (B) represents 
the quantification of calponin positive cells in different cytokines from three different 
experiments. n=3. 
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Figure 3-7. Cytokine-induced SMC differentiation (SMMHC) in hSMSPC. 
 hSMSPC cells were differentiated in culture using various cytokines (TGF-β1 (2.5 and 5 
ng/ml), PDGF-BB (5 and 10 ng/ml) and retinoic acid (10 and 20 μM)) in SmGM2 with 1% 
FBS media for 7 days. The differentiated cells were stained with SMMHC antibody for 
immunofluorescence analysis. Right panel shows differentiated hSMSPC cells stained for 
SMMHC (red) and nucleus (blue) in different cytokines and left panel shows the magnified 
field image in respective treatment inside the white rectangular region. The graph (B) 
represents the quantification of SMMHC positive cells in different cytokines from three 
different experiments. n=3.  
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3.4.  Discussion 
The goal of these experiments was to identify the key transcription factors, 
growth media and cytokines that may regulate SMC differentiation in hSMSPCs. 
Results show that 1) hSMSPC cells do not express myocardin, smooth muscle 
markers, miR 143 and miR145 but they do express SRF, the basic SMC 
transcription factor. However, hSMSPCs express potent repressors for myocardin 
including KLF4 and Elk-1. 2) Serum reduced smooth muscle growth medium 
(SmGM2 1% FBS) facilitates smooth muscle differentiation in hSMSPCs 3) TGF-β1 
stimulation in serum reduced SmGM2 (SmGM2 1% FBS) media induces hSMSPC 
differentiation towards smooth muscle like cells.  
The major finding of this study comes from the qRT-PCR assay, which 
reveals that hSMSPC express smooth muscle transcription activators including 
myocardin and smooth muscle marker calponin at low level. In contrast, hSMSPC 
express smooth muscle repressors including KLF4, KLF5 and Elk-1 at higher levels. 
Recently, miR143/ 145 were shown to regulate smooth muscle cell fate in progenitor 
cells during development [208]. Notably, this study has identified low expression 
levels of miR 143/145 and higher expression levels of their target genes such as 
KLF4 and Elk-1 transcription. These results suggest that expression of these 
repressors may be responsible for suppression of myocardin induced SMC 
differentiation in hSMSPC cells. 
Expression levels of smooth muscle markers including SM α actin and 
SMMHC were detectable by qRT-PCR assay. However, SM α actin was detected 
only as punctate staining within the nucleus using immunofluorescence analysis 
(Fig. 3.2A), suggesting the presence of non-functional splice variants in hSMSPC 
cells. SM α actin has in total seven transcripts, of which, four transcripts codes for 
functional proteins and three processed transcripts with no functional protein 
(Ensembl Gene ID: ACTA2 ENSG00000107796).  
The SMMHC mRNA signal was detectable by qRT-PCR analysis but its 
protein level was not detected by immunofluorescence analysis, indicating the 
presence of non functional variants or that the mRNA levels are not sufficient to be 
converted into detectable protein in hSMSPC cells. SMMHC has 12 transcripts with 
six functional isoforms and six transcript variants (Ensembl Gene ID: MYH11 
ENSG00000133392). However, the qRT-PCR primers for both SM α actin and 
SMMHC were designed in such a way to detect the full length functional isoforms 
along with their transcripts variants. These results indicate the presence of non-
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functional SM α actin and SMMHC transcript variants in undifferentiated hSMSPC 
cells. 
PDGF-BB [244, 245] and retinoic acid [246, 249] were known to induce 
smooth muscle differentiation of variety of cells. PDGF-BB acts as chemoattractant 
during embryonic development and mediates the recruitment of SMC precursor cells 
and pericytes towards endothelial cells [333]. However, after birth, PDGF-BB is 
associated with vascular injury induced SMC proliferation [105] and suppression of 
SMC differentiation proteins [334]. Expression levels of retinoic acid is involved in 
SMC development and maturation [335], inhibition of SMC proliferation [336] and 
enhancement of the contractile SM proteins [337]. In addition, retinoic acid induces 
differentiation of p19 and ESC into SMC [246, 249]. 
When cultures of hSMSPC cells were treated with PDGF-BB and retinoic 
acid, they do not show any drastic changes in the smooth muscle marker 
expression. Moreover, retinoic acid treatment in hSMSPC cells resulted in 
detachment of cells from the surface of the culture plate. Notably, TGF-β1 treated 
hSMSPC cells were differentiated towards smooth like phenotype with increased 
expression of SM α actin and to a lesser extent calponin. TGF β1 is a potent 
cytokine involved in vascular smooth muscle cell differentiation [241]. However, 
TGF-β1 treatment in hSMSPC cells was unable to induce calponin and SMMHC to a 
greater extent, suggesting that TGF-β1-myocardin induced signaling may be 
controlled by expression of repressor KLF4 in hSMSPC cells. 
Notably, KLF4 has been shown to bind the TCE regions of smooth muscle 
promoters and negatively regulate TGF-β1 induced smooth muscle gene 
transcription [139]. Furthermore, knockdown of smooth muscle repressor KLF4 
enhanced the differentiation of ESC [338]. It would be interesting to test whether 
knockdown of KLF4 might enhance the TGF-β1 induced smooth muscle gene 
transcription in hSMSPC cells. KLF4 was also reported to ablate myocardin induced 
activation of CArG dependent smooth muscle genes through hypoacetylation of 
CArG elements [138, 167]. The presence of KLF4 may be a major contributing 
factor for downregulation of myocardin gene expression. Therefore, it will be 
important to evaluate the transcriptional regulation of myocardin gene expression by 
KLF4 in hSMSPC cells. 
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4. Specific Aim 2 – Identification of 
transcriptional repressor involved in 
smooth muscle differentiation in hSMSPC 
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4.1. Introduction 
Smooth muscle gene expression varies between different stages of 
development and involves various regulatory elements and signaling pathways [75, 
105]. Several cis regulatory elements (TCE element [139, 140], G/C repressors [99, 
339] and E boxes [340]) have been identified within smooth muscle gene promoters 
and have been reported to be involved in the regulation of smooth muscle gene 
expression. The complexity in smooth muscle gene regulation is achieved by a 
unique combination of transcription factors binding to cis regulatory elements in 
smooth muscle promoter specific manner. 
Myocardin is a transcription cofactor that physically interacts with SRF 
activating smooth muscle gene transactivation [142, 151]. Several repressor 
proteins including Elk-1 [127], Forkhead transcription factors 4 (Foxo 4) [301], KLF4 
[138, 167], HES-related repressor protein 1 (HERP1) [341], High mobility group 2 
like 1 protein (HMG2L1) [342], Thymine DNA glycosylate (TDG) [343], Runt related 
transcription factor 2 (Runx 2) [344], Carboxyl terminus of hsp70-interacting protein) 
ligase (CHIP) [166], Msx1 and Msx1 [165] have been reported to inhibit myocardin-
induced SMC genes. Repressor proteins inhibit myocardin-induced SMC 
transcription through their interaction with myocardin basic and SAP domain [301], 
blocking the formation of SRF/myocardin complex [344], formation of a ternary 
complex with SRF and myocardin [165], decreasing myocardin stability via 
proteasome mediated degradation [166], competing for a common SRF docking site 
[127] and/or recruiting of corepressors such as HDAC histone deacetylase to the 
promoter region and prevents the chromatin activation for SMC transcription [138, 
167], collectively these studies suggest that transcriptional repressors may play an 
essential role in the regulation of myocardin gene expression. Embryonic stem cells 
(ESC) are characterised by their ability to self renew indefinitely and maintain 
pluripotency, defined as potential to differentiate into cells of three germ layers. The 
ESC pluripotent state is maintained by network of transcription factors including Oct 
4 (Octamer binding transcription factor 4), Sox2 (SRY (sex determining region) Box-
2) and Nanog (Nanog Homeobox). Nanog is a major regulator of pluripotency in 
ESC. Nanog maintains the pluripotent state by suppressing the transcription of 
downstream genes for differentiation and activation of genes necessary for self 
renewal of ESC. LIF/Stat3 signaling rapidly upregulates KLF4 activating the direct 
downstream target KLF4 but not Oct4/Sox-2, which then forms a complex with Oct4 
and Sox-2 and induces Nanog expression in embryonic stem cells. Withdrawal of 
LIF, resulted in drastic downregulation of KLF4 and both Oct4 and Sox2 was unable 
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to induce Nanog promoter, suggest that KLF4 binding on Nanog promoter region 
enhances the Oct4/Sox2 binding and activation of Nanog expression. KLF4 found to 
regulate Nanog expression by directly binding on its promoter region.  
 KLF4 is a key transcription factor for maintenance of self renewal and 
pluripotency in progenitor cells [345]. The shRNA mediated knockdown of KLF4 
leads to differentiation of ESC [338] providing evidence of KLF4 –mediated control 
of pluripotent transcription factors and differentiation in progenitor cells. However, 
the mechanism of KLF4 mediated suppression of progenitor cells differentiation is 
unclear.  
KLF4 is one of the most reported repressors associated with 
downregulation of SMC genes [138, 167]. KLF4 abrogates myocardin induced 
smooth muscle transactivation by physically interacting with SRF and inhibiting 
myocardin/SRF complex formation and attenuates smooth muscle gene expression 
[167]. However, to date there is no direct evidence for transcriptional regulation of 
myocardin gene expression by KLF4 
Therefore, this study hypothesis that KLF4 acts as a negative regulator 
for the myocardin promoter activity in hSMSPC cells.  
4.2. Methods and materials 
4.2.1.  PCR (Polymerase chain reaction) amplification and cloning of 
myocardial promoter region: 
To amplify and clone a 3.9 Kb human myocardin promoter region from 
human genomic DNA, DNA was isolated by using the genomic DNA isolation kit 
(Promega, Wisconsin, USA) following the manufacture’s instruction. Using Primer 
output 3 software (http://primer3.wi.mit.edu/), the PCR primers (forward 5’-
AAAGACCTGAATTCTATCAATAACC-3’ and the reverse 5’-
ACAACCCAGGATCCATCCAACTCTCCGTGA-3’) were designed to amplify 3.925 
Kb of the human myocardin promoter. To clarify the region of PCR amplification, an 
in silico PCR using UCSC browser http://genome.ucsc.edu/cgi-bin/hgPcr) was 
carried out with the designed PCR primers, which amplified a 3.925 Kb 
(chr17:12565490+12569414) region on chromosome 17. A 3.925 Kb fragment of the 
human myocardin promoter was amplified by PCR using 50 ng of human genomic 
DNA and PCR mixture containing 1X high fidelity PCR buffer, 2.0 mM MgSO4, 0.2 
mM each dNTPs (Invitrogen, Carlsbad, CA), 0.4 µM human myocardin promoter 
primers (forward and reverse), 2.5 units of platinum taq DNA polymerase high 
fidelity (Invitrogen, Carlsbad, CA), 2.0 µl of DMSO (Sigma, St.Louis, MO) in 50 µl 
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reaction. The reaction was performed for 35 cycles of 30 seconds at 95°C, 30 
seconds at 55°C, 4.5 minutes at 68°C in a thermocycler (Montreal Biotech Inc, 
Canada) PCR machine. The 3.9 kb PCR amplified fragment was eluted from 1% 
agarose gel by using the gel extraction kit (Qiagen, Hilden, Germany) and cloned 
into pGlow TOPO cloning vector (Invitrogen, Carlsbad, CA). The ligation reaction 
was carried out by following 1:3 vector/ insert ratio in 1X ligation buffer and 40U of 
ligase enzyme (New England Biolabs, Ipswich, MA) in 20 μl reaction volume at room 
temperature for 10 minutes and then transformed into One Shot TOP10 (Invitrogen, 
Carlsbad, CA) chemically competent cells by heat shock method. Positive clone was 
identified through colony PCR with the human myocardin forward and reverse 
primers. Restriction digestion of the positive clone with EcoRI and BamHI restriction 
enzymes confirmed the presence of PCR amplified 3.9 kb human myocardin 
promoter region and further sequencing confirmed the correct sequence and 
orientation of the human myocardin promoter region in a cloning vector. 
4.2.2. Construction of reporter plasmids for screening human myocardin 
promoter activity in vitro 
4.2.2.1. Construction of lentiviral plasmid vector containing human 
myocardin promoter driving eGFP expression. 
The human myocardin promoter driving eGFP reporter lentiviral plasmid 
pHRSIN-ChMYOCDGW-dINotI referred in short as HR-ChMYOCDGW was based 
on pHRSIN-CSGW-dINotI referred as HR-CSGW vector which has spleen focus-
forming virus (SFFV) promoter driving eGFP expression. The myocardin promoter 
replaces the SFFV promoter region in the HR-CSGW plasmid to generate HR-
ChMYOCDGW. The HR-CSGW vector was cut with EcoRI /BamHI (New England 
Biolabs, Ipswich, MA) restriction enzymes to remove the SFFV promoter, then 
excised the vector backbone. For the insert, pGlow TOPO containing 3.925 Kb 
human myocardin promoter was cut with EcoRI /BamHI restriction enzymes, then 
the human myocardin promoter was excised as a 3.9 Kb EcoRI–BamHI fragment 
and ligated into the EcoRI–BamHI  sites of HR-CSGW vector backbone to generate 
HR-ChMYOCDGW plasmid. 
4.2.2.2. Construction of human myocardin promoter-luciferase reporter 
plasmid 
The pGlow TOPO vector containing human myocardin promoter was cut 
with BamHI,  to  release the human myocardin promoter region (3.925 Kb), then 
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excised and ligated into BglII (BamHI cohesive termini compatible) linearised pGL3 
Enhancer plasmid (Promega, Wisconsin, USA) to generate pGL3 E-hMyocdP 
plasmid. Eleven putative recombinant colonies were screened to detect the positive 
colony carrying human myocardin promoter (Fig 10.1). The correct sequence and 
orientation was confirmed using restriction enzymes and sequencing using the RV3 
5’ binding primer.The resulting sequence obtained from sequencing was named as 
seq1 and seq2 respectively. Further primers were designed within the sequenced 
regions seq1 and seq2 to sequence the remaining unsequenced human myocardin 
promoter within the pGL3 E vector. The sequences obtained from sequencing using 
primers within seq1 and seq2 was named as seq3 and seq4. The sequence for 
seq1, seq2, seq3 and seq4 were shown in (Fig 10.5). These sequences were 
aligned against the human genome using multialign software 
http://multalin.toulouse.inra.fr/multalin/cgi-bin/multalin.pl). The results showed one 
mismatch within the entire 3.925kb sequence. The mismatch was highlighted as (*) 
mark within the aligned sequence in (Fig 10.6). 
4.2.3. Comparative sequence analysis of myocardin promoter 
To identify the evolutionary conserved regions (ECRs) region conserved 
between species, ECR base program (http://ecrbrowser.dcode.org/) was used to 
compare mouse, rat and human myocardin promoter sequences.  The putative 
transcriptional factors that bind to the 3.9 kb upstream region (-4007 to -100bp) of 
the human myocardin promoter was predicted using matInspector 
(www.genomatix.de) software with 0.75 cut-off core and matrix similarity. 
4.2.4. Cell culture and transduction 
4.2.5. Determination of optimal media and cell density for high transduction 
efficiency 
To optimize media for hSMSPC transduction, hSMSPC were seeded at 
5x104 per cm2 in 24 well plate in EGM2 media. The cells were allowed to settle for 
16 hours and then transduced with 5 MOI of HR-CSGW lentivirus in different growth 
media such as EGM2, EGM2 0.5%FBS, EGM2 serum free (SF), SmGM2, SmGM2 
SF, DMEM 10% FBS, DMEM SF and X-vivo media. After 24 hours, the growth 
media was removed and FACS analysis was performed as outlined in general 
methods section 2.8. 
To optimize hSMSPC cell density for high transduction efficiency, hSMSPC 
cells were plated at range from 10,000 – 80,000 cells per cm2 in 24 well plate in 
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EGM2 media. The cells were allowed to settle for 24 hours and then transduced with 
5 MOI of HR-CSGW lentiviral particles. At day 1, the growth media was removed 
and FACS analysis was performed as outlined in general methods section 2.8. 
4.2.5.1. Human myocardin promoter driven expression in cell types 
To check the cell type specificity of activation of the human myocardin 
promoter driving eGFP (HR-hMYOCDGW), HASMC, hSMSPC and HUVEC cells 
were transduced with 5 MOI of HR-ChMYOCDGW or HR-CSGW lentivirus at a cell 
density of 50,000 cells per cm2 in 24 well plate. At, day 4, growth media was 
removed and FACS analysis was performed as described in general methods 
section 2.8.  
4.2.6. Optimisation of puromycin selection in hSMSPC (Puromycin kill curve 
analysis) 
Puromycin drug resistance marker was used for generation of stable cells 
expressing the shRNA construct. Puromycin is a protein synthesis inhibitor used as 
a selective agent in cell culture to eliminate untransduced cells but it is toxic to cells. 
Therefore, kill curve analysis was performed to determine the minimal dose of 
puromycin needed to cause 100% cell death in untransduced hSMSPC cells. The 
cells were plated at 4x104 cells per cm2 cell density in EGM2 medium. The next day 
the growth media was changed with media supplemented with 0-15 μg/ml 
concentration range of puromycin. The cells were monitored daily and a phase 
contrast image was taken 24 hours after puromycin selection. The cells were 
washed with PBS, collected using 0.25% trypsin and suspended in EGM2 medium. 
The dead cells were stained with trypan blue and the percentages of viable cells 
were counted using a haemocytometer. 
4.2.7. Puromycin at 1 μg/ml concentration causes massive cell death in non 
transduced hSMSPC cells 
In order to evaluate the optimal dose of puromycin required to kill 100 % of 
untransduced hSMSPC cells, hSMSPC cells were incubated in range of puromycin 
(0-15 μg/ml) concentrations for two days. The result showed that hSMSPC cells 
were very sensitive for puromycin and started to lift within 24 hours of incubation 
(Fig. 4.1.A).  The percentage of viable cells remained in puromycin containing media 
was counted after two days of puromycin incubation and plotted against 
corresponding puromycin concentration (Fig. 4.1.B). The result demonstrated that 
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puromycin at 1 μg/ml concentration caused 100% lethality in non transduced 
hSMSPC cells.  
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Figure 4-1. Optimisation of puromycin selection conditions for hSMSPC cells. 
To determine the minimum dose of puromycin to cause 100% lethality in untransduced 
hSMSPCs, cells were plated at 7x10
4 
cells per well in 24 well plate in EGM2 media. The next 
day the cells were treated with various concentrations (0-10 µg/ml) of puromycin in EGM2 
media. A)  Puromycin at 1µg/ml caused massive cell death within 24 hours of treatment. B) 
Puromycin kill curve showing cell death in relation to increasing doses of puromycin over 48 
hours in hSMSPC cells. 
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4.2.8. Construction of shRNA KLF4 lentiviral vectors  
To screen potential LV_shKLF4 target sequences for efficient KLF4 
knockdown, five different LV_shKLF4 sequences targeting different regions of 
human KLF4 mRNA as listed in (Fig.4.5A (i)), were used to generate shRNA 
expressing pKLO.1.puro-1 based lentiviral vectors. The two complementary oligos 
containing sense and anti sense strand connected by a spacer region capable of 
forming a short hairpin loop were synthesized using each LV_shKLF4 target 
sequence. In addition, the poly T termination signals sequence and EcoRI site was 
added to the shRNA sequence. The oligos were annealed to form dsDNA with a 5’ 
sticky end (suitable for AgeI digested site) and a 3’ end compatible for ligation with 
an EcoRI cut site, cloned into AgeI/EcoRI linearised pKLO.1-puro lentiviral vector. 
Lentivirus for each LV_shKLF4 plasmid was generated by following the protocol as 
outlined in general methods 2.9. 
4.2.9. ShRNA-mediated KLF4 knockdown 
To test the efficiency of designed LV_shKLF4 lentiviral vectors for KLF4 
knockdown in hSMSPC cells, these cells were seeded at 5x104 cells/cm2 plating 
density a day before transduction in EGM2 medium. The next day, growth media 
was replaced and the cells were infected with each LV_shKLF4 lentiviral 
supernatant along with the empty vector with no shRNA (pKLO.1.puro-1) 24 hours 
after transduction puromycin (1μg/ml) was added to the cells. KLF4 expression was 
assessed three days post puromycin selection by qRT-PCR and western blot as 
described in general methods section 2.6 and 2.14. 
4.2.10. TGF-β1 stimulation on shRNA-mediated KLF4 knockdown and human 
myocardin promoter activity in hSMSPC 
To evaluate the LV_shKLF4 B mediated knockdown effect on human 
myocardin promoter activity; hSMSPC cells were seeded at 50,000 cells per cm2 
plating density 16 hours before transduction in EGM2 media and transduced with 5 
MOI of HR-ChMYOCDGW lentiviral particles alone or cotransduced with 
LV_shKLF4 B lentiviral supernatant. In addition, hSMSPC cells were stimulated with 
or without differentiation media. At, day 4, growth media was removed and FACS 
analysis was performed as described in general methods section 2.8. 
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4.2.11. Transient Transfection and dual luciferase reporter assay 
 To measure human myocardin promoter activity over time, 24 hours prior 
to transfection, hSMSPC cells were seeded at 7x104 cells per cm2 plating density in 
EGM2 media. hSMSPC cells were cotransfected with pGL3 E–hMyocd promoter 
and renilla luciferase plasmid (outlined in general methods section 2.12) alone or 
coinfected with LV_shKLF4 B supernatant. The transfection media was changed 16 
post transfection to differentiation media. Luciferase activity was measured at 24, 48 
and 72 hours post TGF-β1 stimulation. The growth media was removed and 
replaced with 20 μl of 1X passive lysis buffer (PLB) made in sterile water (Promega, 
Wisconsin, USA) and kept in the orbital shaker (Microtitre plate Shaker SSM5; 
Stuart) for 15 minutes at 300 rpm. The cell lysate was transferred to 1.5 µl 
eppendorf tubes for measuring luciferase activity in luminometer (Promega, 
Wisconsin, USA). Dual luciferase reporter assay was performed as outlined in 
general methods section 2.13. 
4.2.12. Primer designing and in silico PCR 
To design unique PCR primers to amplify the predicted putative KLF4 
binding sites in hSMSPC, the human myocardin promoter sequence flanking 
predicted KLF4 binding sites was used for designing ChIP PCR primers using 
primer 3 software. The PCR primers were subjected to in silico PCR (UCGC 
genome browser http://genome.ucsc.edu) against human genome and ensured 
uniqueness for each designed primer sets. The primer specificity was also checked 
by PCR amplification of hSMSPC genomic DNA for 30 cycles (94OC for 45 sec, 
62OC for 30sec, and 72OC for 20 sec). The PCR product was resolved on 1% 
agarose gel and visualised with ethidium bromide. No template DNA and water only 
were used as PCR negative controls.  
4.2.13. Sonication and shearing analysis 
To ensure optimal shearing of chromatin lengths between 200 to 1500 bp 
for ChIP assay in hSMSPC, hSMSPC cells were fixed with formaldehyde and 
homogenised using dounce homogenizer. Then, the cross linked DNA was sheared 
with the sonicator by following the optimal conditions (6 pulses, 50% duty cycle and 
30% output) on ice. A portion of lysate was used to check the DNA shearing 
efficiency. The lysate was heated at 65OC overnight to reverse the cross links and 
subjected to RNase treatments for 15 min at 37OC followed by proteinase K for 15 
min at 67OC, and DNA was recovered by using QIA quick purification kit (Qiagen). 
88 
 
The efficiency of chromatin shearing was assessed by loading 1 μg and 2 μg of 
sheared hSMSPC DNA on agarose gel and visualised with ethidium bromide. 
4.2.14. ChIP assay 
The chromatin immunoprecipitation (ChIP) assay was carried out in 
hSMSPC cells with antibodies against KLF4 (SC- 20691, Santa Cruz) or normal IgG 
(rabbit IgG, 3703, Prosci incorporated) following protocol mentioned in general 
methods section 2.15.   
4.2.15. Real time PCR 
To check whether co immunoprecipitation of KLF4 bind to myocardin 
promoter region, ChIP-PCR was performed using lightcycler 480 with SYGR green I 
with the primer pairs flanking putative binding sites S1 to S5 as listed in Fig 5.1.B. 
The input DNA was diluted to 1:10 ratio prior to PCR amplification and the reaction 
(20μl) mixture contained 2X PCR light cycler 480 SYGR Green I mastermix, 10μM 
of each forward and reverse primer, chromatin immunoprecipitated DNA as template 
was subjected to 40 cycles (94OC for 20 sec, 59OC for 30 sec, 72OC for 30 sec) of 
PCR amplification. The fold enrichment was normalised to IgG (no antibody) control 
signal. 
4.3. Results 
4.3.1. Plating density at 5x104 cells per cm2 enhances hSMSPC transduction 
efficiency 
To evaluate the optimal cell density for hSMSPC transduction, varying cell 
densities ranging from 1x104 to 8x104 cells per cm2 were plated in EGM2 medium. 
hSMSPC cells were transduced with 5 MOI of HR-CSGW lentivirus vector and 24 
hours of post transduction, FACS analysis for eGFP was carried out to determine 
optimal cell density for hSMSPC transduction. The results showed that transduction 
efficiency of hSMSPC increased with increasing cell density and reached a 
maximum transduction efficiency of approximately 39% at 5x104 cells per cm2 
(Fig.4.2A). However, further increases in cell density showed a decline in hSMSPC 
transduction potential; suggesting that, hSMSPC cell density at 5x104 cells per cm2 
was the optimal plating density for efficient hSMSPC transduction. 
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4.3.2. Serum containing EGM2 medium enhances hSMSPC transduction 
efficiency 
In order to optimize the best growth media condition that facilitates high 
hSMSPC transduction efficiencies, different growth media such EGM2, EGM2 0.5% 
FBS, EGM2 SF, SmGM2, SmGM2 SF, DMEM 10% FBS, DMEM SF or X-VIVO 
media for hSMSPC cell transduction was compared.  The hSMSPC cells were 
transduced at 5MOI of HR-ChMYOCDGW in the different growth media and it was 
found that basal EGM2 medium (with 2% serum) showed the higher transduction 
rates (42% Fig.4.2B) at 24 hours post transduction compared to serum free media 
with 31% of transduction. In addition, EGM2 0.5% FBS showed 37% transduction 
efficiency as compared to serum free EGM2 suggesting that small variations in FBS 
levels affect the hSMSPC transduction potential. The transduction efficiency of 
SmGM2 (27%), SmGM2 SF (11%), DMEM 10% FBS (18.6%), DMEM SF (20%) or 
X-VIVO (20%) conditions yielded much lower transduction rates (Fig.4.2B). These 
findings indicate that serum containing EGM2 medium enhances efficient lentivirus 
transduction into hSMSPC cells. 
4.3.3. Human myocardin promoter driven eGFP reporter gene expression is 
restricted to HASMC and hSMSPC 
The present study aims to determine the selective transcriptional activation 
of human myocardin promoter driving eGFP reporter expression in different cell 
types. The schematic representations of self replicating vectors were shown in Fig. 
4.3A. To evaluate the ability of selective activation of the human myocardin 
promoter in HASMC, hSMSPC and HUVEC, cells were infected with to 5 MOI of 
HR-ChMYOCDGW or HR-CSGW for 4 days.  The HR-CSGW was used to assess 
the transduction efficiency and permissivity of lentivirus vector in HASMC, hSMSPC 
and HUVEC cells. Expression of eGFP was detected by confocal microscopy and 
further verified using flow cytometry.  Flow cytometry analyses of eGFP expression 
showed ubiquitous expression of eGFP in HR-CSGW transduced hSMSPC, HUVEC 
and HASMC cells (Fig.4.3B) with 69.8%, 52.8% and 46.6% of transduction 
efficiencies (Fig.4.3D) respectively; suggesting that hSMSPC, HASMC and HUVEC 
have no restriction for entry or interaction of lentivirus expression. However, human 
myocardin promoter from HR-ChMYOCDGW transduced lentivirus selectively 
activated eGFP expression in HASMC and hSMSPC but not in HUVEC 
(Fig.4.3C&D). These results suggest that human myocardin promoter directed eGFP 
expression was specific to smooth muscle cells, and not endothelial cells. 
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4.3.4. Identification of three Evolutionary Conserved Regions (ECRs) within 
the myocardin promoter of human, mouse and rat 
The goal of this study was to identify any ECRs from alignments of the 
mouse and rat promoter sequences with the 3.9 kb human myocardin promoter 
sequence using web based ECR browser outline in 4.2.3 of methods. Using ECR 
browser parameters of at least 70% homology over 100 bps and the human genome 
as the base genome, three highly conserved ECRs within the human myocardin 
promoter (highlighted in brown box Fig. 4.4.A) were identified The sequence 
alignment was colour coded to indicate intergenic (red), UTRs (yellow) and 
transposons and simple repeats (green). The distal ECR sequence with transposons 
and simple repeats was referred as R1, the middle intergenic region was labelled as 
R2 and the ECR sequence near to the translational start site (+1) comprising of 
UTRs and intergenic sequence was labelled as R3 (Fig.4.4A.).  Examination of 
ECRs conserved between human and rat showed the alignment of rat sequence to -
461/-101, -1526/-1409 and -2089/-1821 position on human myocardin promoter. 
The summary of the three ECR regions of the human myocardin promoter with rat 
and mouse was depicted in table 4.1. The ECR sequence was submitted to rVista 
2.0 to identify potential conserved transcription factor binding sites (TFBS) and 
compared against matrices of TRANSFAC professional V10.2 library optimized for 
0.85 matrix similarity. The results showed four TFBS conserved in R1 sequence and 
62 TFBS in R3 sequence that are conserved between human and rat whereas the 
R2 sequence showed no conserved TFBS in the analysis. The dynamic overlay of 
potential TFBS for R1 and R3 is shown in Fig.4.4. (B & C). 
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Table 4-1. ECR conserved region between rat, mouse and 3.9 kb upstream of human 
myocardin promoter. 
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4.3.5. Prediction of putative transcription factors involved in the 
transcriptional regulation of human myocardin promoter 
The goal of the promoter analysis was to identify the key regulatory 
elements involved in the transcriptional regulation of myocardin gene expression. 
Using genomatrix software [346] the human myocardin promoter sequence (cloned 
3.925 Kb) was screened for putative transcription factor elements. The complete list 
of predicted transcription factors is given in an appendix. This analysis revealed 
putative bindings sites for cardiac transcription factors (GATA1, GATA3, NFAT, 
Nkx2.5, TBX), skeletal muscle transcription factors (MyoD, Myf5, Myogenin) and 
smooth muscle regulatory elements (SRF, GKLF, Elk1, HES1, twist, AML3 (Runx2), 
RBPJκ, YY1). Notably, the myocardin promoter has stem cell pluripotency 
associated transcription factors Nanog, OCT4, Sox2 and cMyc putative binding sites 
within its promoter with high core similarity scores. In addition, the results showed 
Isl1, NFkappaB and p53 putative binding sites within the human myocardin 
promoter. 
While exploring the putative transcription factors for possible transcriptional 
repressors of myocardin gene expression, putative binding sites for GKLF, Elk1, 
HES1, twist, AML3 (Runx2) and YY1, (listed in table 4.2) were found, suggesting a 
possible mechanism for myocardin repression in hSMSPCs. Out of these 
repressors, KLF4 is a well known transcriptional repressor reported to suppress 
myocardin induced smooth muscle gene activation in SMCs [167]. The qRT-PCR 
results showed that hSMSPCs express low levels of myocardin and higher levels of 
KLF4. Thus, it is possible that the excess KLF4 may act as a transcriptional 
repressor regulating myocardin gene expression in hSMSPCs. 
Therefore, the present study investigated the possibility of KLF4 repressing 
myocardin gene expression in hSMSPC cells. KLF4 has five different putative 
binding sites within the human myocardin promoter with high core similarity scores. 
The graphical representation of the five putative binding sites within the human 
myocardin promoter is shown in Fig. 4.5.A. The predicted KLF4 binding site 1 (-569) 
on (-) stand, site 3 (-3702) on (+) stand and site 5 (-3792) have a high core similarity 
1 and 0.975, 0.88 and 0.966 matrix similarity respectively. The KLF4 putative 
binding site 2 located at (-1093) on (-) strand and site 4 (-3774) on (+) strand have 
0.83 core similarity and 0.87 matrix similarity respectively (Fig. 4.5.B). The exact 
location of predicted KLF4 binding sites sequences within the human myocardin 
promoter sequence is shown in Fig. 4.5.B. 
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4.3.6. LV_shKLF4 B target sequence efficiently silence KLF4 expression in 
hSMSPC 
To evaluate the functional relationship between the human myocardin 
promoter and transcription factor, KLF4, five different short hairpin lentiviral 
constructs were generated targeting different 18-23bp sequences of KLF4 mRNA as 
shown in Fig. 4.6. A (i&ii).  The schematic representation of the physical location of 
five LV_shKLF4 sequences in human KLF4 mRNA was shown in Fig. 4.6. A(i). The 
actual shRNA target site and target sequences were depicted in Fig. 4.6. A(ii).  The 
schematic diagram of the lentiviral vector (pKLO.puro.1) containing short hairpin 
RNA for KLF4 is shown in Fig. 4.6B.  Out of the five sequences, LV_shKLF4 B 
construct showed 65% and < 90% silencing of KLF4 as analysed by qRT-PCR and 
western blotting respectively, in hSMSPC cells (Fig. 4.7 A-C) and therefore, it was 
selected for subsequent KLF4 knockdown experiments. 
 
Table 4-2. List of putative binding sites for smooth muscle repressor transcription 
factors on human myocardin promoter 
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4.3.7. Regulation of myocardin gene expression by KLF4 protein.  
Previous studies showed that the myocardin promoter can drive eGFP 
expression in hSMSPC and in HASMC, but not in HUVEC cells (Fig. 4.3), and 
moreover results from cytokine stimulation studies reported that TGFβ1 stimulates 
SMC differentiation of hSMSPCs (Fig. 3.5.).  To test whether KLF4 directly regulates 
myocardin gene expression, hSMSPC cells were infected with HR-ChMYOCDGW 
alone or cotransduced with LV_shKLF4 B supernatant and stimulated with or 
without TGF-β1 (5ng/ml) in 1% SmGM2 media for 4 days. Expression of eGFP was 
detected on day 4 using confocal microscopy Fig. 4.8A. Flow cytometry analysis 
showed no obvious increase in human myocardin promoter directed eGFP 
expression with TGF-β1 stimulation as compared to basal myocardin promoter 
activity. However, KLF4 knockdown resulted in a two fold increase in myocardin 
promoter directed eGFP expression (Fig 4.8 i&ii), indicating that myocardin 
transcriptional machinery exists and is repressed by the presence of KLF4 
expression in hSMSPC. Notably, TGF-β1 stimulation resulted in increased induction 
of human myocardin promoter activity when compared to human myocardin 
promoter activity in KLF4 knockdown hSMSPC cells. However, this increase was 
not statistically significant, suggesting that myocardin promoter-driven gene 
expression is repressed by KLF4 in hSMSPC cells. 
4.3.8. KLF4 silencing and time course of human myocardin promoter 
activation in hSMSPC 
Previous results showed that knockdown of KLF4 in hSMSPC significantly 
increased myocardin promoter directed eGFP expression by day 4 post 
transduction. To further investigate the pattern of myocardin promoter activation 
upon TGF-β1 stimulation over time, a time course analysis using human myocardin 
promoter luciferase reporter construct was performed. hSMSPC cells were first 
transduced +/- LV_shKLF4 B lentiviral construct. The next day the cells were co 
transfected with human myocardin promoter luciferase reporter construct and pRL-
TK renilla luciferase construct, then stimulated with TGF-β1 (+/-) for 24, 48 and 72 h 
respectively. 
The human myocardin promoter directed luciferase activity was slightly 
increased at 48 h post transfection, but then significantly decreased below basal 
levels at 72 h post transfection in hSMSPC cells. However, human myocardin 
promoter activity showed a drastic increase in promoter activity (nearly doubled) at 
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48 h post transfection and reached baseline promoter activity at 72 h post 
transfection in KLF4 knockdown hSMSPC cells (Fig 4.9. B-D). 
TGF-β1 stimulation, slightly increased human myocardin promoter activity 
as compared to baseline promoter activity 24 h post stimulation but then a sustained 
repression was observed 48, 72 h post stimulation. Although, human myocardin 
promoter activity was decreased 48 h post stimulation, a significant increase in 
promoter activity was observed 72 h post stimulation in KLF4 knockdown hSMSPC 
cells. However, there was no significant difference in human myocardin promoter 
activity observed between unstimulated and TGF-β1 stimulated hSMSPC as well as 
KLF4 knockdown hSMSPC cells. These results again support KLF4 as a 
transcriptional repressor for myocardin gene expression in hSMSPC cells (Fig 4.9. 
B-D). 
4.3.9. QRT-PCR primer designing for chip-PCR assay 
To analyse KLF4-bound DNA sequence in immunoprecipitated samples by 
qRT-PCR, primers were designed to amplify approximately 200 bp of human 
myocardin promoter that contained putative KLF4 binding sites. The schematic 
representation of putative KLF4 binding sites (grey elongated circles) within the 
human myocardin promoter along with the direction and location of designed PCR 
primer (shown by arrows) and its amplicon size (brown bars) were shown in Fig. 
4.11.A. As a first step, the designed PCR primers were subjected to in silico PCR 
(UCSC browser) against human genome and found that the designed primers for 
ChIP assay were unique to myocardin promoter sequence. Further, the specificity of 
designed ChIP-PCR primers was also tested by PCR amplification with primers 
listed in Fig.4.11.B on genomic DNA isolated from hSMSPC cells.  The hSMSPC 
genomic DNA was amplified as single amplicon for each primer pairs of expected 
sizes as shown in (Fig.4.12.A); suggest that the designed PCR primer is unique to 
each putative KLF4 binding site on human myocardin promoter. 
4.3.10. Sonication of hSMSPC genomic DNA for six pulses yielded optimal 
sheared chromatin for ChIP assay 
 To optimize chromatin shearing for ChIP assay using sonicator, hSMSPC 
(8x 106) cells were scrapped in ice cold PBS and fixed with 1% formaldehyde in 
EGM2 media. The cross-linked chromatin was homogenized and the pellet was 
collected after centrifugation. The pellet was suspended in shearing buffer and 
subjected to six pulses of sonication using sonicator. Each cycle consisted of 30 sec 
of sonication with 50% duty cycle and 30% output followed by one minute incubation 
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on ice. The sheared DNA was subjected to reversal of cross links and subsequent 
proteinase K and RNase A treatments. Then, DNA was recovered using QIA quick 
spin column kit. The efficiency of sonicated DNA was tested by electrophoresis 
through a 1% TAE agarose gel. The resolved sheared chromatin Fig. 4.12.B 
showed a smear of DNA fragments ranging between 200 to 1500 bp optimal for 
ChIP assay indicates that hSMSPC chromatin sonicated for six pulses generated 
chromatin fragments optimal for ChIP assay. 
4.3.11. KLF4 binds to human myocardin promoter in cultured hSMSPC cells 
To further test how KLF4 regulates human myocardin gene expression in 
hSMSPC cells, ChIP assay was performed to confirm the KLF4 binding within the 
human myocardin promoter in hSMSPC cells. For ChIP assay, hSMSPC cells were 
fixed with formaldehyde to cross link the protein-DNA complexes within the cells. 
Then, DNA was sheared to smaller fragments ranging between 200 to 1500bp by 
sonication (Fig.4.12B.). An aliquot of sheared DNA was taken before 
immunoprecipitation and used as reference sample (INPUT sample). The sheared 
chromatin was immunoprecipitated with antibody against KLF4 or normal IgG. The 
immunoprecipitated DNA along with the INPUT sample was then reversed cross 
links and purified using proteinase K treatment. The purified immunoprecipitated 
DNA and INPUT samples were analysed by 40 cycles of PCR amplification using 
SYBR green I with specific primers pairs corresponding to five putative KLF4 binding 
regions of the human myocardin promoter as listed in Fig.4.11B. It is clear that the 
region corresponding to the putative KLF4 binding site 3 (-3702) was significantly 
enriched in the immunoprecipitated chromatin as compared with other predicted 
KLF4 binding sites (site-1, 2, 4 & 5) on myocardin promoter from the hSMSPC cells 
(Fig. 4.13). In support of this, primer set designed to amplify the clustered potential 
KLF4 binding site (site 3, 4 & 5) also showed significant levels of enrichment as 
measured by RT-PCR analysis. Taken together, these studies indicate KLF4 can 
directly binds to the human myocardin promoter at position -3702 to -3686 on (+) 
stand upstream of translation start site (TSS) and inhibits human myocardin gene 
expression in hSMSPC cells. Apart from KLF4, we also found putative binding sites 
for other transcription factor involved in the regulation of myocardin gene expression 
within the human myocardin promoter (Fig 4.10). 
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Figure 4-2. Effect of cell density and growth media on the transduction efficiency in 
hSMSPC cells.  
A) To evaluate the effect of cell density on hSMSPC transduction, cells were grown at 
different cell densities in EGM2. The next day the cells were transduced with 5MOI of 
lentivirus expressing eGFP (HR-CSGW) vector. After 24 hours FACS analysis shows high 
percentage of eGFP expression in cells plated at 5x10
4
 cells per cm
2
 cell density. B) To 
evaluate whether growth media has effects on hSMSPC transduction potential, cells were 
plated at 5x10
4
 cells per cm
2 
in 24 well plate in EGM2 media. The next day transduction was 
done with 5MOI of HR-CSGW vector in different growth media including EGM2, EGM2 0.5% 
FBS, EGM2 SF, SmGM2, SmGM2 SF, DMEM 10%, DMEM SF or X-Vivo medium. After 24 
hours of transduction, FACS analysis was performed for eGFP expression. EGM2 media 
shows high percentage of eGFP positive cells. Data are representative of three independent 
experiments. n=3,  SF- Serum Free. ** P<0.01, *P<0.05. 
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Figure 4-3. Construction and characterisation of human myocardin promoter 
construct.  
A) Schematic representation of self replicating (SIN) second generation lentiviral vector. (i) 
pHRSIN-CSGW-dINotI (HR-CSGW) vector with SFFV promoter (ii) pHRSIN-ChMYOCDGW-
dINotI (HR–ChMYOCDGW) vector with human myocardin promoter. LTR, Long terminal 
repeat; SFFV, spleen focus-forming virus (promoter);  , packaging signal; RRE, Rev 
response element; cPPT, central polypurine tract; WPRE, Woodchuck hepatitis virus post-
transcription regulatory element. To evaluate the selective activation human myocardin 
promoter directed eGFP expression in different cell types, HASMC, hSMSPC and HUVECs 
were plated at 5x10
4
 cells/cm
2 
seeding density in EGM2 media. At 24 h post seeding, cell 
types were transduced with 5 MOI lentiviral vector encoding SFFV (HR-CSGW) promoter 
expressing eGFP (act as a positive control for vector integration) and 5MOI lentiviral vector 
encoding human myocardin promoter expressing eGFP (HR-ChMYOCDGW) vector. B) 
Ubiquitous expression of HR–CSGW vector in all three, HASMC, hSMSPC and HUVEC cell 
types. C) Selective expression of HR–ChMYOCDGW vector only in HASMC and hSMSPC 
but not in HUVEC. D) Day 4 FACS analysis of cell types transduced with lentiviral vector 
encoding SFFV and hMyocardin promoter with eGFP expression. Values are the means ± 
SD of three independent experiments. n=3, *** P<0.001, **P<0.01, *P<0.05 
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Figure 4-4. ECRs in the myocardin promoter. 
 A) Comparative genome analysis of myocardin promoter sequences between human rat, 
and mouse revealed three highly conserved ECR which was highlighted in brown box and 
labelled as R1, R2 and R3 respectively. Red peak corresponds to intergenic conserved 
region, green peak corresponds to transposable elements and simple repeats and yellow 
corresponds to UTRs. B) Prediction of conserved transcription factors within region R1 
between human and rat. C) Prediction of conserved transcription factors within region R3 
between human and rat. 
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Figure 4-5. The human myocardin promoter has five putative KLF4 binding sites that 
potentially regulating human myocardin gene expression. 
 A) The schematic representation of human myocardin promoter (-100bp to -4kb relative to 
translational start site) containing five putative KLF4 binding sites (the position of putative 
KLF4 binding sites are represented by semicircles). The consensus KLF4 binding sequences 
are also shown. B) A schematic representation of upstream nucleotide sequence of human 
myocardin promoter with the position of putative binding sites for KLF4. The putative binding 
sites are underlined and labelled as site KLF4 #1 – 5 relative to TSS.  The translation start 
site is indicated by black bent arrow. 
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Figure 4-6. Screening and construction of a shRNA lentiviral vector targeting human 
KLF4 expression. 
A) Selection of target sites within the KLF4 gene. i) Graphical representation of physical 
position of five selected target shKLF4s on KLF4 mRNA sequence. The shKLF4s 5316, B, C 
and 8284 were localised in same location on coding region expect shKLF4 1080 located in 
3’UTR region. ii) The table shows the exact location of five selected shKLF4 target sites and 
their sequence on mRNA of KLF4.  B) A Schematic diagram of the lentiviral vector 
(pKLO.puro-1) containing short hairpin RNA for KLF4. The shKLF4 was driven by U6 
promoter and the vector encodes puromycin resistance gene (Puro
R
) driven by human 
phosphoglycerate kinase eukaryotic (hPGK) promoter. The vector harbours LTR, Long 
terminal repeat,  - packaging signal; RRE, Rev Response element; cPPT, central 
polypurine tract. Schematic depiction of the complementary forward and reverse oligos 
designed for shKLF4 B sequence with poly T termination sequence and EcoRI site as shown 
in the below panel. The sense and antisense shKLF4 B sequences were  shown as bold 
characters has spacer capable of forming loop and cloned into Agel/EcoRI site of the vector.  
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Figure 4-7. Knockdown of KLF4 expression using shKLF4 B lentiviral construct in 
hSMSPC cells.  
To investigate the effect of designed target shKLF4 lentiviral constructs, hSMSPC cells were 
infected with five different shKLF4 lentiviral supernatant or with empty viral construct as 
negative control. Next day, the transduced cells were subjected to puromycin selection (1 
μg/ml) for 3 days. Total RNA was isolated and the mRNA expression of KLF4 was measured 
by RTPCR (A) normalised to GAPDH expression, the protein level of KLF4 was estimated by 
western blot (B&C) and normalised relative to PCNA protein expression. Error bars 
represent the mean ± SD of three independent experiments. n=3,  *P<0.05 
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Figure 4-8. Suppression of KLF4 is required for human myocardin promoter 
expression in hSMSPC.  
To evaluate the effect of KLF4 knockdown on human myocardin expression upon TGF β1 
stimulation, hSMSPC cells were infected with human myocardin promoter expressing eGFP 
lentiviral constructs alone (HR-ChMYOCDGW) or with LV_shKLF4 B lentiviral supernatant 
and stimulated with or without TGF-β1 (5ng/ml) in EGM2 media for 4 days. Confocal 
microscopy (A) and FACS analysis (B) was used to detect the eGFP expression.  The boxed 
area within the image (A) was shown in higher magnification in bottom panel (A) .i) 
Representative eGFP FACS analysis showing untransduced and transduced hSMSPC cells. 
The boxed area within the top panel image (A) was shown in higher magnification in bottom 
panel. ii) FACS analysis was used to estimate the percentage of eGFP expressing hSMSPC 
cells. Data are representative of three independent experiments. n=3, *P<0.05. 
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Figure 4-9. Knockdown of KLF4 induced human myocardin promoter activity in time 
dependent manner detected by luciferase reporter assay.  
A) Schematic representation of luciferase reporter plasmid. i) Schematic representation of 
pGL3 E plasmid containing human myocardin promoter driving firefly luciferase reporter 
gene. ii) Schematic representation of pRL-TK plasmid B) to measure the time course effect 
of TGF-β1 on human myocardin promoter activity in hSMSPC and KLF4 knockdown 
hSMSPC cells, the cells were infected with LV_shKLF4 B or empty vector lentiviral 
supernatant. At 24 h post transduction, cells were cotransfected with pGL3 E containing the 
human myocardin promoter driving the expression of firefly luciferase reporter construct and 
pRL-TK Renilla luciferase reporter construct. At 16 h post transfection the cell were 
stimulated with or without TGF-β1 (5ng/ml). Dual luciferase activity were measured at 24 (B), 
48 (C) and 72 (D) hours post stimulation and human myocardin promoter activity was 
defined as ratio of firefly luciferase activity/Renilla luciferase activity. The black bar 
represents human myocardin promoter directed luciferase activity in hSMSPC cells and the 
white bar represents human myocardin promoter directed luciferase activity in KLF4 
knockdown hSMSPC cells. Results are expressed as means ± SD of three independent 
experiments n=3, *P<0.05 
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Figure 4-10. Schematic showing putative binding sites for myocardin regulating 
transcription factors within the 3.925 Kb cloned human myocardin promoter.  
GKLF indicates GKLF4 - gut-enriched Krüppel-like factor , Elk1- ETS domain-containing 
protein, Runx2 - Runt related transcription factor 2, Twist1 - Twist-related protein 1, HES - 
Hairy and enhancer of split-1,YY1 - Yin Yang 1, SP1- specificity protein 1, RBPjk - 
Recombining binding protein suppressor of hairless, Sox2 - SRY (sex determining region Y)-
box 2, MYF5 - Myogenic factor 5, Phox2 - Paired mesoderm homeobox protein 2, MEF2 - 
myocyte enhancer factor-2, PTEN - Phosphatase and tensin homolog, Isl-1 - Insulin gene 
enhancer protein, PRDM5 - PR domain containing 5, SRF - serum response factor. 
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Figure 4-11. Schematic representation showing ChIP-PCR amplification of KLF4 
binding region within the myocardin promoter. 
 A) Graphical representation of upstream region of human myocardin promoter displaying 
location of putative KLF4 binding site, S1 to S5 (grey elongated circles) and their 
corresponding ChIP-RT-PCR amplicon. The ChIP-PCR amplicon were shown by the brown 
bars below the KLF4 putative binding sites, labeled P1 to P5. The forward and reverse arrow 
indicates position of forward and reverse primers used in ChIP assay. B) The primer 
sequence used in RT- PCR amplification and their relative position on human myocardin 
promoter was shown as table. 
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Figure 4-12. Checking qRT-PCR designed primers for amplification of predicted KLF4 
binding sites and optimization of sonication in hSMSPC cells.  
A) PCR amplification of ChIP assay primers in hSMSPC. To check the specificity of 
designed PCR primers sets ( listed on table Fig.4.11B ) flanking potential KLF4 binding sites, 
PCR amplification was performed for 30 cycles using the genomic DNA from hSMSPC to 
ensure that the designed primers produce single amplicon from myocardin promoter region 
and analysed on a 1% TAE agarose gel stained with ethidium bromide. M – 100 bp DNA 
ladder, P1, P2, P3, P4 are primer set flanking site 1, 2, 3 and 4 respectively. P5 – primer set 
flanking site 3 & 4. B) Agarose gel analysis of sheared DNA from hSMSPC after sonication, 
showing the optimal size of fragmentation (200 to 1500 bp) visualized by ethidium bromide. 
Following the method outlined in section 4.2.13, sonicated chromatin was prepared from 
formaldehyde cross linked hSMSPC cells and, the degree of chromatin shearing was 
analysed by loading 1 μg and 2 μg of sheared DNA on 1% TAE agarose gel, visualized with 
ethidium bromide. Lane #1 - 1 Kb DNA ladder, Lane #2 and #3 are 1 μg and 2 μg of 
hSMSPC sonicated and purified DNA. The sonicated chromatin for 6 pulses yielded optimal 
sheared chromatin ranging between 200 bp to 1500 bp suitable for ChIP assay. 
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Figure 4-13. Binding of KLF4 to a human myocardin promoter at site 3 (-3702) in 
hSMSPC cells.  
To examine whether KLF4 binds to myocardin promoter region, qRT- PCR was performed 
on KLF4 immunoprecipitated DNA in hSMSPC cells. The cells (8x10
6
) were fixed with 1% 
formaldehyde and the DNA was sheared by sonication. ChIP assay was performed on 
sheared chromatin from hSMSPC using antibody against KLF4 or normal IgG. The 
chromatin immunoprecipitated DNA was extracted by reversal of cross links followed by 
proteinase K and RNase A treatments. The recovered chromatin through ChIP assay was 
analysed by 40 cycles of qRT-PCR using the primers flanking the KLF4 binding sites (KLF4-
Site#1 to KLF4-Site#5) listed in table Fig.4.11.B. The results were presented as fold 
enrichment over IgG control (A-E). The results showed that ChIP assay performed with KLF4 
antibody and PCR with primer flanking site 3 (C) greatly enriched for human myocardin 
promoter DNA in hSMSPC cells. Values are the means ± SD of three independent 
experiments. n=3,  *P<0.05. 
113 
 
4.4. Discussion 
These experiments aimed to identify the major transcription factors 
involved in the regulation of human myocardin gene expression. The current study 
hypothesized that the presence of the transcriptional repressor KLF4 may regulate 
human myocardin promoter activity and block hSMSPC differentiation into mature 
contractile SMCs. The results from the present study demonstrate that 1) Myocardin 
promoter activity is restricted to HASMC and hSMSPC. 2) Human myocardin 
promoter has three ECR between human, rat and mouse and has putative binding 
sites for many transcriptional repressors including KLF4. 3) KLF4 has five 
evolutionary conserved putative binding sites within the human myocardin promoter. 
4) KLF4 silencing resulted in increased human myocardin promoter activity in 
hSMSPC. 5) KLF4 binds within the human myocardin promoter predominantly at 
site 3 (-3702) position upstream of TSS in cultured hSMSPC cells. 
Molecular mechanisms involved in transcriptional regulation of SMC are 
complex involving unique combinations of transcription factors and cytokine 
stimulation.  Myocardin is a strong transcriptional coactivator of smooth muscle gene 
expression and regulated by many transcriptional modulators and signaling 
pathways [105, 164]. However, the transcriptional regulation of myocardin 
expression itself during smooth muscle differentiation is not fully elucidated. The 
current study specifically identifies a critical role for KLF4 in the transcriptional 
regulation of the myocardin promoter. Furthermore, a significant advance in this 
study is the identification of five putative KLF4 binding sites within the human 
myocardin promoter. KLF4 has been widely reported to be rapidly upregulated in 
proliferative SMCs upon vascular injury. KLF4 abrogates myocardin induced 
activation of SMC markers via hypoacetylation of H4 histones [138]. Therefore, 
KLF4 appears to play a major role in regulation of myocardin induced transactivation 
of smooth muscle marker gene expression. In this study, following knockdown of 
KLF4 myocardin promoter driven gene expression was significantly increased, 
suggesting that presence of abundant KLF4 might act as repressor for human 
myocardin promoter activity in hSMSPC cells. The current study provides first line 
evidence that KLF4 represses human myocardin promoter activity through binding 
on its promoter at -3702 upstream of TSS in hSMSPC cells. Taken together, these 
experiments indicates for the first time a novel repression mechanism of KLF4, 
through binding within the myocardin promoter and regulating myocardin gene 
expression in hSMSPC cells. 
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TGF-β1 has been shown to regulate the expression of KLF4. TGF-β1 is 
demonstrated to induce myocardin expression in SMC differentiation of progenitor 
cells such as multipotent SMC progenitor’s 10T1/2 cells [240] and neural crest cells 
[223].  Davis-Dusenberry et al [211]., demonstrate that TGF-β1 downregulates KLF4 
expression through induction of myocardin and miR 143/145 in SMCs. They further 
showed that silencing of KLF4 using siRNA induced myocardin mRNA expression in 
SMCs, suggesting that repression of KLF4 by TGF-β1 is critical for the induction of 
SM contractile phenotype in SMCs. Consistent with this findings, the current study 
demonstrated that silencing of KLF4 followed by TGF-β1 stimulation induced the 
human myocardin promoter activity in hSMSPC cells. However, a small delay in 
TGF-β1 induced myocardin promoter activation was observed in hSMSPC cells. 
This delay might be due to suppression of myocardin by Smad 3 in the initial stages 
TGF-β1 induced progenitors’ cells differentiation into SMC [347].  
Recently, three closely related KLF transcription factors, KLF2, KLF4 and 
KLF5 have been identified as key regulators in controlling SMC development and 
phenotypic modulation [139, 348]. It has been reported that KLF4 and KLF5 bind to 
TCE elements within the SM α actin and SM 22α promoters. KLF4 repress TGF-β1 
induced SM 22α promoter whereas KLF5 activates TGF-β1 dependent activation of 
the same promoter, indicating that KLF4 and KLF5 can exhibit opposing effect on 
the promoter [139]. Thus, it would be interesting to expand the current study to 
explore the possibility of other KLF transcription factors like KLF2 and KLF5 binding 
to the putative KLF4 binding sites within the human myocardin promoter in hSMSPC 
cells.  
The ChIP analysis in hSMSPCs showed increase in enrichment of KLF4 at 
all five putative binding sites within the human myocardin promoter. However, more 
significant enrichment was observed within the site 3 (-3702 bp) of the human 
myocardin promoter. These initial studies indicate the critical role of KLF4 in 
regulation of myocardin gene expression in hSMSPCs. However, further analysis 
using site directed mutation analysis and EMSAs are warranted to fully establish the 
possible functionality of each site.  
Following vascular injury in vivo and PDGF-BB in cultured cells has been 
reported to induce KLF4 expression with downregulation of SM markers in SMCs 
[349]. The ChIP analysis in the current experiment was carried out in unstimulated 
hSMSPC cells.  Hence, it would also be interesting to study the effect of PDGF-BB 
stimulation on hSMSPC for the gain of KLF4 function and knockdown KLF4 for loss 
of function to examine the occupancy of these putative KLF4 binding sites within the 
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human myocardin promoter in hSMSPC cells. Such findings would not only shed 
light on the mechanism of SMC differentiation but also identify KLF4 as a 
therapeutic target for controlling SMC dedifferentiation. 
In summary, the present study for the first time identified putative binding 
sites for KLF4 and demonstrated direct binding of KLF4 within the human myocardin 
promoter predominantly at position -3702 bp using ChIP assay in hSMSPC cells. 
The following study will explore whether shRNA mediated silencing of endogenous 
KLF4 or overexpression of myocardin in differentiation media can induce SMC 
differentiation in hSMSPC cells. 
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5. Specific Aim 3 - Determination of 
molecular mechanism underlying 
myocardin mediated smooth muscle 
differentiation in hSMSPCs  
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5.1. Introduction 
Myocardin is a strong coactivator for SRF-CArG dependent transactivation 
of smooth muscle gene transcription in smooth muscle cells and cardiomyocytes 
[94, 142, 143, 145]. Myocardin physically interacts with SRF and activates a set of 
contractile smooth muscle genes in SMC [350].  Overexpression of myocardin alone 
is sufficient to induce SMC differentiation markers such as calponin and SMMHC in 
10T1/2, NIH 3T3 and 3T3 L1 cells [350]. Ectopic expression of myocardin in 
xenopus embryo activates the expression of cardiac specific and smooth muscle 
genes detected by in situ hybridization [351]. In stem cells, forced expression of 
myocardin in ESC induced SMC differentiation with upregulation of SMC markers 
such as SM α actin, calponin and SM22α [145]. In contrast, gene transfer of a 
dominant negative form of myocardin and siRNA mediated knockdown decreased 
the expression of SMC marker genes in SMC [145]. In addition, downregulation of 
myocardin expression in xenopus embryo using antisense morpholino technique 
results in repression of cardiac marker expression [351]. 
Significantly, the expression of myocardin gets downregulated in parallel 
with SMC differentiation marker genes in response to vascular injury [98] as well as 
in cultured SMCs [143]. Myocardin null mutant mice survive only to embryonic day 
E10.5 and show abnormalities in vascular development specific to SMC 
differentiation [158]. Genetic analysis of mice harboring a selective ablated 
myocardin gene in neural crest cell derived SMC died prior to postnatal day P3 with 
patent ductus arteriosus (PDA) and exhibit cell autonomous defect in SMC 
contractile proteins [352]. Taken together, these studies suggest that myocardin is 
sufficient and necessary to induce SMC differentiation and contractile SMC 
phenotype in muscle and non muscle cells. 
TGF-β1 signaling plays a crucial role in SMC development and 
differentiation [241, 353]. Gene targeting approaches to TGF-β1 function in mice 
have shown that loss of TGF-β1 signaling results in dysregulated SMC 
differentiation and disruption of vessel wall integrity [354]. Furthermore, deletion of 
one allele of TGF-β1 in young mice resulted in downregulation of SMC 
differentiation markers [355]. These studies show a tight relationship between TGF-
β1 signaling and SMC differentiation during embryonic development. 
Several in vitro models have been employed to study the molecular 
mechanism underlying the TGF-β1 induced SMC differentiation in progenitor cells 
[239, 259]. TGF-β1 has been reported to induce SMC differentiation in various cell 
types including neural crest stem cells [239], mesenchymal progenitor cells [240] 
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and endothelial cells [266]. TGF-β1 also induces the SM differentiation markers in 
cultured SMCs [237]; these studies demonstrate the important role of TGF-β1 in 
progenitor cell differentiation into SMC. Transforming growth factor control element 
(TCE), cis element located within SM promoter regions was found to be highly 
evolutionally conserved across species and reported to be essential for TGF-β1 
inducibility of SMC differentiation markers in SMC and fibroblast [237, 356]. Of note, 
mutation of the SM α actin promoter TCE element completely attenuated TGF-β1 
induced SM marker activation in SMCs [139, 140].  
Multiple signaling pathways involved in TGF-β1 induced transactivation of 
SM differentiation marker gene transcription [357]. The molecular mechanism of 
TGF-β1 mediated activation of SMC marker proteins transcription reveals three 
TGF-β1 responsive elements within SM promoters such as the CArG box, SBE and 
TCE element [213].  
In TGF-β1 induced SMC differentiation, Smad3, the major TGF-β1 
mediator, has been reported to bind to one of three TGF-β1 responsive elements 
within SM promoters depending on cell type. Smad 3 binds to SRF and regulates 
CArG-SRF dependent SM22α transcription during myoblast differentiation of 10T1/2 
cells [358] whereas Smad3 binds to SBE element and activates SM22α gene 
transcription in monc-1 [239] . Smad3 has also been shown to interact with 
myocardin to synergistically activate SM22α activity in 10T1/2 cells [213]. These 
studies suggest that myocardin and TGF-β1 signaling are essential for SMC 
differentiation.  
KLF4, a zinc finger transcription factor, has been identified as a binding 
factor that can bind to TCE regions located upstream within smooth muscle 
promoters and downregulates expression of smooth muscle marker genes [140]. Of 
interest, overexpression of KLF4 protein repressed TGF-β1 induced SMC marker 
activation in 101/2 cells [140] and also KLF4 attenuates myocardin induced 
activation of SMC markers [167]. However, inhibition of endogenous KLF4 using 
antisense morpholino restores SM α actin and SMMHC expression [140]. KLF4 
mediates PDGF-BB induced transcriptional suppression of smooth muscle 
differentiation marker genes [167]. Furthermore, siRNA mediated knockdown of 
KLF4 expression partially abrogates PDGF-BB induced downregulation of SM 
markers in cultured SMCs [167]. These studies strongly suggest that KLF4 acts as a 
potent transcriptional repressor for smooth muscle differentiation markers.  
Retroviral expression of KLF4 along with Oct4, Sox2 c-myc have the ability 
to induce reprogramming of human adult fibroblasts to become embryonic stem cell-
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like cells termed as iPS induced pluripotent stem cells. Thus, KLF4 is a key 
transcription factor involved in the self renewal and pluripotency maintenance of the 
stem cells.  
 Results from previous studies demonstrate that the hSMSPC cells have 
low levels of myocardin and higher levels of KLF4 expression as measured by qRT-
PCR. Of significance, genomatrix analysis of 3.9 Kb (-4007 to -100 bp) of the human 
myocardin promoter region for putative transcription binding sites reported five 
putative binding sites for KLF4 within the human myocardin promoter and results 
from ChIP assay further verified binding of KLF4 within the myocardin promoter 
region. Moreover, previous findings demonstrated that TGF-β1 can induce the 
human myocardin promoter directed luciferase activity in KLF4 knockdown cells.  
Therefore, this study hypothesis that TGF-β1 can induce SMC 
differentiation in KLF4 knockdown or myocardin overexpressed hSMSPC cells 
(Fig.5-1). 
5.2. Methods 
5.2.1. Cell culture and KLF 4 detection by Western blotting 
To compare KLF4 expression levels between HASMC and hSMSPC cells, 
HASMC and hSMSPC were grown to confluence in  and EGM2 respectively was 
harvested in ice cold PBS. Then, western blot was performed on harvested cells 
following the protocol outlined in general methods 2.14 with anti-KLF4 antibody and 
rabbit HRP-labelled secondary antibody 
5.2.2. KLF4 immunofluorescence analysis 
For KLF4 immunofluorescence, hSMSPC and HASMC cells were seeded 
on nunc wells at 20,000 cells per cm2 and allowed to grown for 24 hours. The cells 
were harvested, fixed and immunostained with anti-KLF4 antibody (1:200) as 
described in general methods 2.7. 
5.2.3. LV_shKLF4 mediated knockdown of KLF4 protein and hSMSPC 
differentiation 
To differentiate hSMSPC into SMC, hSMSPC cells were seeded at 50,000 
cells per cm2 plating density on nunc wells coated with 5µg/cm2 fibronectin (Sigma, 
St.Louis, MO) in EGM 2 media a day before the transduction. The cells were 
allowed to settle down and LV_shKLF4 B or empty vector lentivirus supernatant 
diluted in differentiation media was added to the cells. Twenty four hours of 
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transduction, the cells were cultured in differentiation media containing 1µg/ml 
puromycin in order to remove the non transduced cells.  The differentiation of 
hSMSPC into SMC was assessed at day 7 post stimulation by immunofluorescence 
as outlined in general methods 2.7 with smooth muscle markers antibodies such as 
SM α actin (1 in 200), Calponin (1 in 200) and SMMHC (1 in 200). 
5.2.4. Cell culture and in vitro hSMSPC differentiation assay 
hSMSPC and HeK 293T (negative control) cells were maintained in EGM2 
and DMEM 10% media respectively. To examine whether lentivirus mediated 
myocardin gene expression can induce SMC differentiation of hSMSPC cells, both 
hSMSPC and HeK 293T cells (used as negative control) were plated at 50,000 cells 
per cm2 on nunc wells. The cells were allowed to settle down and transduced with 
myocardin lentivirus (LV_myocardin) at 5 MOI in EGM2 media. The myocardin 
lentiviral vector plasmid (pLV-CMV-myocL-HA) [359] encoding full – length human 
myocardin cDNA was the generous gift of Antoine A.F. de Vries from Leiden 
University Medical Center, the Netherlands. The lentiviral particles were produced 
using the protocol outline in general methods 2.9. Then, media was changed to 
SmGM2 with 1% FBS or differentiation media after 24 hours post transduction. To 
measure the time dependent SMC differentiation over 14 days, the lentiviral 
transduced cells were assessed for SMC differentiation at different time points day 
0, day 3, day 7 and day 14 of TGF-β1 stimulation using immunofluorescence 
protocol outline in general methods section 2.7. Smooth muscle marker antibody 
such as SM α actin (1 in 200), Calponin (1 in 200) and SMMHC (1 in 200) and HA-
tag (1 in 200) were used to measure the SMC differentiation in hSMSPC and HeK 
293T cells.  
To quantify the SMC marker expression, numbers of SMC marker 
expressing cells were counted in 10 random fields from three separate experiments. 
The percentage of SMC positive cells and myofilamentous cells were determined by 
dividing the SMC positive cells by the total number of DAPI positive cells.  
5.2.5. Smooth muscle marker detection by Western blotting 
To quantify the smooth muscle protein expression in differentiated 
hSMSPC cells, the hSMSPC cells were plated at 50,000 cells per cm2 in 6 well plate 
and transduced with myocardin lentivirus at 5 MOI in EGM2 media. The media was 
changed to SmGM2 with 1 % FBS after 24 hours post transduction and maintained 
in SmGM2 1% FBS media for 7 days. To measure the SMC proteins overtime the 
protein was extracted from transduced hSMSPC cells day 0, day 1, day 2, day 3, 
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day 7 and day 14 and analysed by western blot by following protocol outlined in 
section 2.14, for smooth muscle protein antibodies such as SM α actin (1 in 500), 
Calponin (1 in 500). β lamin (1 in 500) was used as loading control and the bands 
were quantified relative to PCNA using Image J software.  
 
5.3. Results 
5.3.1. hSMSPC has high KLF4 expression level as compared to HASMC 
 To quantify KLF4 protein expression levels, hSMSPC and HASMC cells 
were grown in chamber slides and immunostained using anti-KLF4 antibody. The 
results showed that hSMSPC displayed high levels of KLF4 expression when 
compared to HASMC (Fig.5.2.A). A strong KLF4 expression, mostly accumulated in 
the corner of the nucleus was noted in hSMSPCs whereas a diffused nuclear 
staining was observed in hSMC. Western blot analysis was also performed with 
hSMSPC and hSMC and detected the presence of KLF4 protein as doublet band 
around 55 K Da in both cell types. The reason for KLF4 doublet band is unknown. 
KLF4 expression was normalised to β-actin. Consistent with immunofluorescence 
analysis results, hSMSPC showed elevated KLF4 expression as compared to hSMC 
as shown in Fig.5.2.B&C. 
5.3.2. Silencing of KLF4 results in increased SMC differentiation of 
hSMSPCs 
To address the role of KLF4 in hSMSPC differentiation, we examined the 
effect of KLF4 knockdown on hSMSPC differentiation using shRNA lentivirus 
vectors.  hSMSPC cells were transduced with LV_shKLF4 B or empty vector and 
stimulated with TGF-β1 for 7 days.  By four days after TGF-β1 stimulation, KLF4 
knockdown hSMSPC cells revealed a marked increase in cell size (Fig.5.3) 
compared to those transduced with an empty vector measured by phase contrast 
microscopy. Immunostaining for smooth muscle markers such as SM α actin and 
calponin revealed that KLF4 knockdown accelerated SMC differentiation in 
hSMSPC (Fig.5.4.A&B).  
In KLF4 knockdown hSMSPC cells, both the expression of SM α actin and 
calponin was significantly increased by TGF-β1 stimulation during SMC 
differentiation to 9 fold and 23 fold with 17% and 8% of myofilament, respectively, 
after 7 days of stimulation as compared with empty vector shown in Fig. 5.4.A&B. 
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These results indicate that TGF-β1 stimulation induced SMC differentiation in KLF4 
knockdown hSMSPC cells. 
5.3.3. Overexpression of myocardin induced smooth muscle differentiation 
in hSMSPC cells 
To examine whether overexpression of myocardin can induce SMC 
differentiation specifically in hSMSPC cells, undifferentiated hSMSPC cells or HeK 
293T (negative control) cells were infected with a lentiviral vector encoding 
myocardin cDNA driving a HA-tag in EGM2 media. At 24 hours post transduction, 
the media was replaced by SmGM2 1% FBS or differentiation media and maintained 
for a period of 14 days. The cells were collected at day 0, 1, 2, 3, 7 and 14 time 
points and analysed by SDS PAGE as described in methods for SMC markers such 
as SM α actin and calponin. Protein levels were normalised to β lamin and to the 
control (day 0 untransduced cells). By Western blotting, SM α actin, calponin and β 
lamin proteins were detected at position 42 kDa, 34 kDa and 55 kDa respectively in 
lysate of both hSMSPC and HeK 293T cells.  Significantly, in hSMSPC cells over 
expression of myocardin resulted in upregulation of smooth muscle marker 
expression such as SM α actin and calponin in time dependent manner (Fig. 5.5 (A) 
& (B)). The expression of SM α actin (Fig 5.5 (C)) was increased 25 fold as 
compared to HeK 293T cells with 15 fold increases after 14 days of transduction 
(Fig. 5.5 (D)) The expression of calponin in hSMSPC was significantly increased to 
18 fold at day 2 (Fig. 5.5 (E)) and reached a maximum of 62 fold at day 14 of 
transduction whereas calponin was less efficiently induced only 7.4 fold at day 14 in 
HeK 293T cells (Fig. 5.5 (F). These results demonstrate that over expression of 
myocardin induced SMC differentiation in hSMSPC but not in HeK 293T cells. 
The levels of myofilament organisation were compared between 
differentiated hSMSPC and HeK 293T cells post TGF-β1 stimulation using 
immunofluorescence analysis. At day 0, the early smooth muscle marker protein, 
SM α actin showed a punctate staining pattern within the nucleus detected by 
immunostaining in both hSMSPC and HeK 293T cells (Fig.5.6 (A)). However, the 
late SMC lineage genes such as calponin and SMMHC marker expression were 
undetectable in both undifferentiated hSMSPC (Fig.5.6 (A)) and HeK 293T cells 
(Fig.5.8 (A)).  
The expression of SM α actin began to increase from day 3 onwards and 
gradually spreads throughout the cells with myofilament organisation in both 
myocardin transduced hSMSPC alone or in combination with TGF-β1 as compared 
to undifferentiated hSMSPC cells (Fig.5.6 (B & C). The results were shown in table 
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5-2. These results suggest that TGF-β1 has similar effect on SM α actin expression 
but TGF-β1 significantly increased the myofilamentous SM α actin positive cells to 
23% and 52% as compared to LV_myocardin alone with 14% and 27% 
(Fig.5.6.(B&C).) after day 7 and day 14 respectively. Similarly, LV_myocardin 
transduction alone or in combination with TGF-β1 treatment of HeK 293T cells 
induced SM α actin expression in time dependent manner to a lesser extent. The 
expression of SM α actin in LV_myocardin treatment alone and with TGF-β1 was 
shown in table 5-1. However, both LV_myocardin alone and with TGF-β1 failed to 
induce myofilament organisation in HeK 293T cells (Fig.5.8 A-C). 
The expression of both calponin and SMMHC was increased to a similar 
extent in both LV_myocardin transduced alone or in combination with TGFβ1 
stimulated hSMSPC cells (Fig.5.7 A-C). However, TGF-β1 stimulation increased 
both calponin and SMMHC myofilament positive cells to a lesser extent as 
compared to LV_myocardin transduced hSMSPC cells (Fig.5.7 A-C). The results 
were shown in table 5-1. 
In contrast, myocardin induced both calponin and SMMHC less efficiently 
in LV_myocardin transduced alone or LV_myocardin with TGF-β1 stimulated HeK 
293T cells. However, both LV_myocardin alone and with TGF-β1 failed to induce 
neither calponin and SMMHC myofilament organisation in HeK 293T cells (Fig.5.9 
A-C). The results were shown in table 5-2. 
Taken together, these data demonstrates that overexpression of 
myocardin activates SMC differentiation with expression of SMC lineage genes such 
as SM α actin, calponin and SMMHC more efficiently in hSMSPC cells than in HeK 
293T cells. 
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Table 5-1.The results of the smooth muscle marker expression and myofilament 
organisation in differentiated hSMSPC cells stimulated with or without TGF- β1. 
 
 hSMSPC hSMSPC cells with  
TGF-β1 
Day 3 Day 7 Day 14 Day 3 Day 7 Day 14 
SM α actin 16% 46% 81% 16% 39% 79% 
SM α actin myofilament 
organisation 
- 14% 27% - 23%  52% 
Calponin 87%  90% 92% 87%  91% 88% 
Calponin myofilament 
organisation 
21% 66% 69% 32% 78% 71% 
SMMHC 49%,  68%, 91%  50%,  60%, 90% 
SMMHC myofilament 
organisation 
7% 22% 58% 17% 27% 62% 
 
 
Table 5-2. The results of the smooth muscle markers expression and myofilament 
organisation in differentiated HeK 293T cells stimulated with or without TGF- β1. 
 
 HeK 293T HeK 293T cells with  
TGF-β1 
Day 3 Day 7 Day 14 Day 3 Day 7 Day 14 
SM α actin 8.3% 13.2% 16% 5.6% 12% 22% 
SM α actin myofilament 
organisation 
- - - - - - 
Calponin 3.4%  20% 20% 3.9%  21% 20% 
Calponin myofilament 
organisation 
- - - - - - 
SMMHC 0.5%  11% 12% 2.2%  13% 20% 
SMMHC myofilament 
organisation 
- - - - - - 
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Figure 5-1. Schematic representation showing hypothetical molecular mechanism by 
which KLF4 inhibits human myocardin gene expression in hSMSPC A) In 
undifferentiated hSMSPC, KLF4 bind to myocardin promoter and represses myocardin gene 
transcription which in turn unable to activate SRF-CArG smooth muscle transcription. B) In 
differentiated hSMSPC, knockdown of KLF4 increases the myocardin expression which 
transactivates the smooth muscle gene transcription. 
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Figure 5-2. Comparison of KLF4 protein expression levels from hSMSPC with HASMC 
by immunofluorescence and western blot analysis. A) To check the KLF4 expression 
level, hSMSPC and hSMC were grown on nunc chamber slides and immunostained with 
KLF4 antibody. KLF4 expression was predominantly nuclear localised in hSMC whereas 
KLF4 expression was mixed both nuclear and perinuclear in hSMSPC. B & C) Western blot 
analysis of protein isolated from confluent hSMC (lane 1) and hSMSPC (lane 2) using KLF4 
antibody. β actin (42 kDa) was used as loading control. Increased expression of KLF4 as 
doublet band around 55-KDa was detected in hSMSPC as compared with hSMC cells. Data 
are representative of three independent experiments. n=3,  *P<0.05.  
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Figure 5-3. Effect of shRNA mediated KLF4 knockdown on cell morphology in 
hSMSPC. A) hSMSPC cells were infected with LV_shKLF4 B or an empty vector 
(pKLO.1.puro) in differentiation media and subjected to puromycin after 24 hours post 
transduction. shRNA mediated knockdown of KLF4 induced morphological changes in 
hSMSPC after 5 days of puromycin selection as compared to empty vector measured using 
phase contrast light microscope. The lower panel represents an enlarged view of black 
boxed area from respective top panel. 
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Figure 5-4. Differentiation of hSMSPC into smooth muscle cells through lentiviral 
mediated knock down of KLF4 upon TGF β1 stimulation. A) to determine whether 
knockdown of KLF4 induce SMC differentiation in hSMSPC cells, hSMSPC cells were 
infected with LV_shKLF4 B vector or an empty vector in differentiation media(SmGM2 
1%FBS with TGF β1 5ng/ml). Puromycin was added after 24 hours post transduction and 
immunostained at day 7 for SM α actin (A) and calponin (B). The white boxed areas within 
the merged image are magnified in the lower panel.The confocal images showed the 
differentiation of hSMSPC into SMC in shKLF4 B transduced hSMSPC cells. Values are the 
means ± SD of three independent experiments. n=3, *P<0.05. 
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Figure 5-5. Overexpression of LV_myocardin induced smooth muscle marker proteins 
(SM α actin and calponin) over time, measured by western blot analysis in hSMSPC 
and HeK 293T cells.  To determine whether forced expression of LV_myocardin can induce 
smooth muscle markers in hSMSPC and HeK 293T cells, the cells were infected with 
LV_myocardin and the transduced cells were harvested over time (do, d1, d2, d3, d7 and 
d14) and western blot analysis carried out which showed time dependent increase in the 
expression of SM α actin and calponin in both LV_myocardin transduced hSMSPC and HeK 
293T cell (A&B). Graphical representation of densitometry quantification for the expression 
of SM α actin and calponin over time in LV_myocardin transduced hSMSPC cells and HeK 
293T cells respectively (C, D, E and F). Protein levels were normalised to β lamin and to the 
control (day 0 untransduced cells). Data are representative of three independent 
experiments. n=3,  *P<0.05.  
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Figure 5-6. Forced expression of myocardin induced SMC differentiation with time 
dependent increase in SMA marker expression in hSMSPC cells. To examine whether 
forced expression of myocardin and TGF-β1 treatment can induce SM α actin expression in 
hSMSPC, the cells were transduced with 5 MOI of lentiviral particles encoding complete 
myocardin cDNA with or without TGF-β1 (5ng/ml). The transduced cells were fixed at various 
time points (3, 7, and 14 days post transduction) for immunofluorescence analysis with anti 
HA-tag and anti SM α actin antibody. A)  Representative confocal images of in vitro SMC 
differentiation taken at different time points showing time dependent increase in SM α-actin 
expression in LV_myocardin transduced in both with or without TGF-β1 (5ng/ml) treatment in 
hSMSPC cells. The white boxed areas within the merged image are magnified in the lower 
panel B & C) Plotted are the percentage of HA-tag, SM α actin and myofilament relative to 
total DAPI positive cells in LV_myocardin with or without TGF-β1 (5ng/ml) treatment at 
indicated time points calculated from three separate experiments. n=3, ** P<0.01, *P<0.05. 
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Figure 5-7. Forced expression of myocardin induced SMC differentiation with time 
dependent increase in calponin and SMMHC marker expression in hSMSPC cells. To 
examine whether forced expression of myocardin and TGF-β1 treatment can induce calponin 
and SMMHC expression in hSMSPC, the cells were transduced with 5 MOI of lentiviral 
particles encoding complete myocardin cDNA with or without TGF-β1 (5ng/ml). The 
transduced cells were fixed at various time points for immunofluorescence analysis with anti-
calponin and anti SMMHC antibodies. A) Representative confocal images of in vitro SMC 
differentiation showing time dependent increase in calponin and SMMHC expression in 
LV_myocardin transduced in both with or without TGF-β1 (5ng/ml) treatment in hSMSPC 
cells. The boxed areas within the merged image are magnified in the lower panel B&C). 
Plotted are the percentage of calponin and SMMHC and their corresponding myofilament 
expression level relative to total DAPI positive cells in LV_myocardin with or without TGF-β1 
(5ng/ml) treatment at indicated time points calculated from three separate experiments. n=3,  
** P<0.01, *P<0.05. 
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Figure 5-8. Forced expression of myocardin induced SMC differentiation to a lesser 
extent in HeK 293T cells. To examine whether forced expression of myocardin and TGF-β1 
treatment can induce SM α actin expression in HeK 293T, the cells were transduced with 5 
MOI of lentiviral particles encoding complete myocardin cDNA with or without TGF-β1 
(5ng/ml). The transduced cells were fixed at various time points for immunofluorescence 
analysis with anti-HA-tag and anti SM α actin antibodies. A)  Representative confocal images 
of in vitro SMC differentiation taken at different time points showing time dependent increase 
in SM α actin expression in LV_myocardin transduced in both with or without TGF-β1 
(5ng/ml) treatment in HeK 293T cells. The white boxed areas within the merged image are 
magnified in the lower panel. B & C). Plotted are the percentage of HA-tag, SM α actin and 
myofilament relative to total DAPI positive cells in LV_myocardin with or without TGF-β1 
(5ng/ml) treatment at indicated time points calculated from three separate experiments. n=3, 
** P<0.01, *P<0.05. 
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Figure 5-9. Forced expression of myocardin induced SMC differentiation to a lesser 
extent in HeK 293T cells. To examine whether forced expression of myocardin and TGF-β1 
treatment can induce calponin and SMMHC expression in HeK 293T, the cells were 
transduced with myocardin lentiviral particles with or without TGF-β1 (5ng/ml). The 
transduced cells were fixed at various time points for immunofluorescence analysis with anti-
calponin and anti SMMHC antibodies. A)  Representative confocal images of in vitro SMC 
differentiation showing time dependent increase in SM α actin expression in LV_myocardin 
transduced with or without TGF-β1 treatment in HeK 293T cells. The white boxed areas 
within the merged image are magnified in the lower panel. B & C are plotted percentage of 
calponin and SMMHC and myofilament relative to total DAPI positive cells in LV_myocardin 
with or without TGF-β1 treatment at indicated time points calculated from three separate 
experiments. n=3, ** P<0.01, *P<0.05. 
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5.4. Discussion 
The purpose of the current study was to investigate the effect of TGF-β1 
mediated SMC differentiation in KLF4 knockdown and myocardin overexpressed 
hSMSPC cells. We hypothesized that the presence of KLF4 in hSMSPC results in 
blockade of SMC differentiation through repressing myocardin. Thus, either 
knockdown of endogenous KLF4 or overexpression of myocardin can induce SMC 
differentiation in hSMSPC cells. To test this hypothesis, initially the expression level 
of KLF4 was compared to that in SMC by both immunostaining and western blot 
analysis. Then, the expression of KLF4 was downregulated using shRNA targeting 
KLF4 or myocardin was overexpressed using lentiviral vector and stimulated with 
differentiation medium for seven days. The results revealed that hSMSPC has 
higher levels of KLF4 as compared to SMC and that silencing of KLF4 increased the 
SMC differentiation of hSMSPC in response to TGF-β1 stimulation as measured by 
immunostaining of smooth muscle specific markers SM α-actin and calponin. 
Furthermore, overexpression of myocardin induced complete SMC differentiation of 
hSMSPCs with upregulation of myofilamentous smooth muscle markers such as SM 
α actin, calponin and SMMHC, effects moderately augmented by TGF- 1 stimulation 
at late stage time points. 
Epigenetic modification of histones H3 & H4 lysine’s within the CArG boxes 
controls the cell specific activation of SMC genes [98]. Histone modification of CArG 
element enables the accessibility to SRF which in turn recruits its cofactor 
myocardin and transactivates smooth muscle specific SMC gene expression [98]. 
KLF4 is a known transcriptional repressor for SMC genes and has been shown to 
reduce SRF binding ability to CArG element within the SM α actin promoter [167]. 
KLF4 also represses myocardin-induced smooth muscle differentiation marker gene 
expression in SMC [138, 140, 360]. KLF4 binds to TCE element adjacent to CArG 
elements, directly recruit histone deacetylase to SMC promoters and renders 
chromatin inaccessible to SRF [138]. Furthermore, the results outlined in previous 
work showed that KLF4 can directly bind to the myocardin promoter and repress 
transcription of myocardin gene expression in hSMSPC cells.  Collectively, these 
data suggest that presence of abundant KLF4 in hSMSPC might block SRF access 
to the SMC promoters causing a reduction myocardin-induced SMC differentiation in 
hSMSPC cells.  
The presence of two CArG elements, in combination with a TCE element, 
has been shown to be necessary for TGF-β1 inducibility of smooth muscle marker 
gene transcription [237]. In addition, TGF-β1 was also shown to increase SRF 
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expression and binding to CArG elements within SMC gene specific promoters 
[361]. Interestingly in our own studies, knockdown of KLF4 in differentiation media 
induced myocardin expression in hSMSPCs (Chien ling Huang, 2013, personal 
communication) suggesting that silencing of KLF4 followed by TGF-β1 stimulation 
induced SRF /myocardin SM gene transcription in hSMSPCs.  It is conceivable that 
reduction in KLF4 binding to TCE elements might have allowed SRF access to 
CArG elements and led to the further activation of myocardin/SRF/CArG-dependent 
SMC genes in hSMSPCs 
Several studies have demonstrated that siRNA mediated knockdown of 
KLF4 resulted in ablation of both oxidised phospholipids and PDGF-BB induced 
downregulation of smooth muscle differentiation marker transcription in SMCs [167, 
362]. In transgenic mice, conditional KLF4 knockout delayed the repression of SM 
marker genes following vascular injury [360]. Recent studies have demonstrated 
that knockdown of KLF4 can also induce differentiation of ES cell differentiation 
[338]. Similarly, in this study, KLF4 downregulation in hSMSPC through shRNA 
lentiviral vector increased SMC differentiation. Moreover, silencing of KLF4 alone 
promoted hSMSPC differentiation into SMCs, suggesting that hSMSPC contain the 
basic transcription machinery and cofactors required for SMC differentiation but are 
kept in an undifferentiated state by the transcriptional repressor KLF4. 
KLF4 acts as a master regulator for pluripotency core transcription factors 
including Oct 4, Sox 2 and Nanog [338]. In addition, overexpression of KLF4 
maintains the undifferentiated state of embryonic stem cells. Of interest, human 
myocardin promoter also has putative binding sites for other stem cell transcription 
factors such as Oct 4, Sox 2 and Nanog within the -4007 bp upstream to 5’ of the 
TSS. Thus, knockdown of KLF4 along with other stem cell factors that may bind the 
human myocardin promoter could further enhance the commitment of hSMSPC to 
differentiated SMCs.  
A basic structural hallmark of contractile SMC is the presence of 
myofilament and growth cessation [27]. Myofilament bundles are essential for the 
contractile phenotype of differentiated SMC and represent an important step along 
the SMC phenotype switching pathway. Myocardin, a SAP domain transcription 
factor, acts as a SRF cofactor and is expressed in cardiomyocytes and in vascular 
and visceral SMCs from embryonic to postnatal development [145]. Overexpression 
of myocardin induces growth arrest and enhances spindle shape morphology unique 
to SMCs with enriched myofilament expression in BC3H1 cells [363].  Similarly, the 
SMC progenitor cell line 10T1/2 also displays low levels of myocardin expression 
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and undergoes differentiation to a contractile SMC phenotype by forced expression 
of myocardin [94].  Furthermore, myocardin is activated by TGF-β1 in 10T1/2 cells 
[240].   Since, myocardin and TGF-β1 have both been shown previously to induce 
SMC differentiation, the combined effect of myocardin and TGF-β1 was examined 
on SMC differentiation of hSMSPC cells. Interestingly, overexpression of myocardin 
showed growth arrest and increased spindle morphology in hSMSPCs, but not in 
HeK 293 T cells, suggesting that smooth muscle specific molecular cofactors and 
transcriptional machinery needs to be present for phenotype modulation to occur. 
While the expression profiles of baseline smooth muscle markers were 
similar between undifferentiated hSMSPC and HeK 293T cells, following 
LV_myocardin transduction, the expression of smooth muscle lineage markers was 
significantly increase in hSMSPC in comparison to in HeK 293T cells.  More 
specifically, expression of the widely recognised SMC differentiation specific 
markers calponin and SMMHC were efficiently induced by forced myocardin 
expression in hSMSPCs indicating that the molecular machinery responsible for the 
SMC differentiation program are likely to be present in hSMSPCs and not  in HeK 
293 T cells.  Furthermore, the relative percentage levels of Myocardin-HA-tagged 
cells in hSMSPCs and HeK 293 T cells (Fig. 7.2 & Fig. 7.4) was confirmed showing 
that both cell types to be equally expressing myocardin reaffirming that although 
expressing myocardin at high levels, without the necessary molecular machinery for 
SMC differentiation as must be present in hSMSPCs, phenotypic modulation does 
not occur efficiently.   
Calponin was the first SMC marker detected at day 1 following 
LV_myocardin transduction, followed by increases in SM α actin and SMMHC at day 
3 in hSMSPC cells.  In contrast, SM α actin was the first SMC marker detected at 
day 3 post-LV_myocardin transduction whereas calponin and SMMHC were only 
evident at day 7 in HeK 293T cells, suggesting that the low levels of myocardin gene 
expression contributes to the undifferentiated state of hSMSPC cells. The findings of 
the current study were consistent with those of Chen et al., [143] who found that 
myocardin activates the highly specific smooth muscle markers, SM-calponin and 
SMMHC to a greater extent in SMC than in non SMC. In contrast, myocardin 
transactivation of the less specific markers SM α actin and SM22α is higher in non 
SMC compared to SMC [143] further demonstrating that enhanced calponin and 
SMMHC expression is the bench mark for SMC differentiation. 
The presence of an unique epigenetic modification (H3K4dMe) has been 
detected at SMC gene promoters in SMCs but not in non SMCs [138]. While 
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myocardin does not bind directly to CArG elements to induce SMC transcription, it 
does stabilize SRF binding to CArG elements in an H3K4dMe-dependent manner 
[98, 138].  Therefore, indicating that the presence of SMC promoter specific histone 
methylation along with smooth muscle restricted expression of myocardin enables 
transactivation of myocardin/SRF/CArG-dependent SM specific gene transcription in 
SMC but not in non-SMCs. Herein it was demonstrated that overexpression of 
myocardin induced SMC differentiation in a SMC specific manner. Thus it would be 
interesting to determine if the myocardin-mediated SMC differentiation of hSMSPCs 
was H3K4dMe-dependent providing a compelling epigenetic basis for the SMC 
differentiation capacity of hSMSPCs or indeed other SMC progenitor cells. 
The smooth muscle specific phenotypic changes following lentiviral 
mediated overexpression of myocardin was routinely quantified at protein levels 
using Western blot as is standard throughout the literature.  However, superseding 
these findings, we also measured myofilament levels using immunofluorescence in 
hSMSPC and HeK 293T cells. Myofilament is the structural and functional hallmark 
specific to contractile SMC phenotype and therefore a better indicator of SMC-like 
phenotype.  Interestingly, overexpression of myocardin resulted in a significant 
increase in the stellate cells with spindle morphology in hSMSPC cells and induced 
SMC differentiation to a far greater extent than in HeK 293T cells, with expression of 
myofilamentous SM markers including SM α actin, calponin and SMMHC 
indistinguishable from that of SMCs. These findings demonstrate that hSMSPCs can 
be differentiated into SMC-like cells.  However, to determine if fully differentiated 
hSMSPCs have similar functionality to that of adult SMCs, contraction assays and 
calcium signalling as described by Simper et al.,[245] would need to be performed.   
In summary, these results suggest that KLF4 acts as transcriptional 
repressor blocking smooth muscle differentiation of hSMSPCs and that silencing of 
KLF4 augments TGF-β1-induced SMC differentiation of hSMSPCs. Furthermore, 
lentiviral-mediated forced expression of myocardin alone or in combination with 
TGF-β1 induces smooth muscle lineage specific differentiation of hSMSPCs to 
SMC-like cells that display myofilament levels indistinguishable from adult SMCs. 
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6. Specific Aim 4 - Determination of tissue 
capsule forming potential of rSMSPC eGFP 
cells using a rat model  
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6.1. Introduction 
Atherosclerosis is a major cause of coronary artery disease leading to 
myocardial ischemia, stroke and aortic aneurysm. Atherosclerotic lesions develop 
due to a chronic inflammatory reaction to excessive lipid deposition in the arterial 
wall which leads to arterial damage [364]. A major therapy for diseased coronary 
artery involves replacement of damaged arteries with small diameter vascular grafts. 
The saphenous vein, radial artery and mammary artery from the patients are 
commonly used autografts for vessel replacement [314]. Although, autografts may 
be non thrombogenic and highly flexible, repeat bypass procedures, size or length 
availability are always limitations associated with their use. Synthetic grafts such as 
those made from dacron fabric grafts and expanded polytetrafluoroethylene 
(ePTFE) have been invented to overcome the limited availability of autografts [365]. 
However, synthetic grafts initiate a foreign body reaction in small diameter vessels, 
cause neointimal hyperplasia and their usage is limited [366, 367].  
Implantation of sterile materials such as boiled liver, egg white, filter 
membrane or boiled blood clot into the peritoneal cavity of animals like dogs, rats or 
rabbit results in their encapsulation with multiple layers of granulated tissue [368-
370]. Insertion of a foreign object initiates an inflammatory reaction which involves 
cytokines, chemokines and matrix metalloproteinases. These soluble mediators 
further mediate a cascade of cellular processes such as cellular activation, 
angiogenesis, migration and recruitment of inflammatory cells to the site [371] and 
over a period of time, these reaction results in formation of multi-layered tissue 
encapsulation of foreign bodies which is mainly composed of myofibroblasts and 
lined by endothelial like cells [367, 372]. Use of tissue granulation in response to 
implantation of sterile silastic tubes (10mm length with 3mm diameter) in the 
peritoneal cavity of animal [367] provides a new scope for tissue engineering of 
vascular grafts. 
Insertion of free floating silastic tubes into the peritoneal cavity of rat, rabbit 
or dog induces the tissue granulation covering the entire tube within 2 weeks. The 
tissue capsule resembles hollow tubes with inner mesothelial lining and a media 
with multiple layers of myofibroblast like cells [367, 373]. These tissue capsules 
harvested from the animals own peritoneal cavity has been successfully grafted in 
the carotid, femoral or abdominal artery [367, 373]. Since, tissue granulation is 
autologous problems associated with tissue rejection are overcome [374]. In due 
course, the cells located in the grafted tissue capsule respond to the local 
environmental cues and remodel into structures similar to the native blood vessel 
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[374]. In 3-4 months, grafted tissue capsule increases in thickness with formation of 
adventitia and lamellae and the myofibroblasts present in the media of tissue 
capsule further differentiate into smooth muscle cells similar to the nearby artery 
[367] . These results suggest that tissue capsules harvested from peritoneal cavity 
can be used as artificial arteries in arterial reconstruction surgery for replacing the 
damaged arteries. 
Previous research findings demonstrated that knockdown of KLF4 and 
overexpression of myocardin induced SMC differentiation of hSMSPC cells in vitro. 
Therefore, this study hypothesis that rSMSPC expressing eGFP can integrate 
into tissue capsule structures in vivo and contribute to their cell wall content.  
The present study aims to establish a rat model to study the possibility of 
rSMSPC eGFP cell integration within the peritoneal derived tissue capsule. 
6.2.  Methods 
6.2.1. Silastic tube implantation and harvest of tube capsule 
Fisher hPAP rats were anesthetized using urethane (1.25 g/kg of body 
weight) and a small (2 inch) abdominal incision was made in cleanly shaved rat 
abdomen. Irradiated 10 mm lengths of 3 mm diameter silastic tubes were placed 
inside a 50 ml sterile falcon and coated with fibronectin at 5 μg/cm2 concentration for 
45 minutes at room temperature on a rocker. Then, four 10 mm length uncoated 
silastic tubes or coated with fibronectin or fibronectin plus 50 million rSMSPC eGFP 
cells were implanted inside the peritoneal cavity of each animal. Sterile saline (3 ml) 
was injected to allow the tubes to float freely inside the peritoneal cavity. Two weeks 
after implantation, the rats were anesthetized using urethane and examined for tube 
capsule formation. The tissue capsules were removed from the tubes and 
processed for eGFP detection, H&E staining and immunohistochemical analysis of 
smooth muscle marker protein expression. 
6.2.2. Tissue digestion and FACS analysis 
Total cell suspension of harvested tissue capsules were obtained by 
collagenase enzymatic digestion. The tissue capsules were dissociated by cutting 
into small pieces and dispersed in RPMI-1640 medium supplemented with freshly 
made collagenase (2mg/ml). The enzymatic digestion was initiated by incubating the 
lysate for 30 minutes at 37OC on an orbital shaker with 1200 rpm.  The enzymatic 
reaction was stopped by addition of RPMI-1640 with serum and cells were pelleted 
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by centrifugation at 600g for 5 minutes at 4OC. The cells were suspended in FACS 
buffer and filtered through cell strainer for eGFP FACS analysis. 
6.2.3. Hematoxylin and Eosin (H&E) staining protocol 
The tissue capsule was tied at one end with silk suture and optimal cutting 
temperature (OCT) medium was slowly injected through the other end filling the 
whole tube (Fig.8.1C). The pre-frozen tissue capsules were placed into moulds with 
OCT, liquid embedding material and frozen into hardened blocks for sectioning. The 
embedded frozen capsules were sliced to 5 μm thickness sections using cryostat for 
histological analysis. The OCT sections were allowed to thaw briefly at room 
temperature and fixed with 4% paraformaldehyde for 10 minutes at 4oC. The slides 
were washed once with PBS for 5 minutes. The slides were immersed in Mayer’s 
hematoxylin Z solution for 5 minutes and dipped in 1% acid alcohol for 10 seconds 
then washed in running tap water for 5 minutes. The sections were stained with 
eosin for one minute and then sequentially dehydrated with 90% and 100% alcohol 
concentrations for five minutes. The sections were cleared in xylene for a minute, 
dried and mounted under a cover slip with DPX mounting media. 
6.3. Results 
To demonstrate that SMSPC can integrate into neovascular structures in 
vivo and contribute to their myofibroblasts like content, silicon tubes were implanted 
as uncoated or coated with fibronectin or fibronectin coating plus 50 million rSMSPC 
eGFP cells (mixed in 3ml saline ) into rats peritoneal cavity and tissue capsules 
were harvested 14 days post implantation (Fig. 6.1 A(i-iii)). 
The uncoated silastic tubes showed an inflammatory response with 32% 
tissue encapsulation. However, fibronectin coated silastic tubes injected with or 
without 50 million rSMSPC eGFP cells induced tissue granulation over the entire 
length of tube with 66% and 73% (Fig. 6.1B) tissue encapsulation, respectively. The 
tissue capsules harvested from fibronectin coated with 50 million rSMSPC eGFP 
cells showed a thick tissue granulation when compared to fibronectin only coated 
tubes. However, there was no significant difference in tissue capsule formation 
between fibronectin coated silastic tubes injected with or without 50 million rSMSPC 
eGFP cells (Fig. 6.1B).  The tissue capsules were separated carefully from the tubes 
and used for subsequent analysis. Of interest, when the whole tissue capsule was 
checked for eGFP cells, patches of eGFP cells were detected on the tissue capsule 
from fibronectin coated tubes injected with 50 million rSMSPC eGFP cells using 
confocal microscopy (Fig.6.1 E).  
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To examine the integration of rSMSPC eGFP cells within the tissue 
capsule, the capsule harvested from fibronectin coated tubes injected with or without 
50 million rSMSPC eGFP rats were subjected to tissue digestion with collagenase 
enzyme. The tissue capsule harvested from fibronectin coated tubes was used as 
control.  
A small number of eGFP positive cells (~1%) were detected by FACS 
analysis in fibronectin coated tube capsules injected with 50 million rSMSPC eGFP 
cells (Fig. 6.1E). Subsequent confocal microscopic analysis of frozen sections from 
uncoated, fibronectin coated tubes injected with or without rSMSPC eGFP cells 
showed localisation of few eGFP cells within tissue capsules from fibronectin coated 
tubes injected with rSMSPC eGFP (Fig. 6.2), which is consistent with the results 
from the tissue digestion. 
In order to study the structure of tissue capsules developed in the 
peritoneal cavity, frozen sections of 5 µm thickness from uncoated or fibronectin 
coated tubes injected with or without 50 million rSMSPC eGFP were stained with 
hematoxylin and eosin stain (Fig. 6.3). The tissue capsule section from uncoated 
tubes (Fig. 6.3A), showed a very thin layer of tissue encapsulation with scattered 
cells throughout the capsule. However, tissue capsule section from fibronectin 
coated tubes with or without 50 million rSMSPC eGFP cells injected rats showed a 
homogenous thick layer of tightly packed cells covering the length of the tube (Fig. 
6.3B&C). 
To investigate the SMC content of the harvested tissue capsules, frozen 
sections from uncoated or fibronectin coated tubes injected with or without 50 million 
rSMSPC eGFP were assessed by immunofluorescence staining for anti- SM α actin 
and anti-calponin. As shown in Fig. 6.4 A (i), tissue capsule from uncoated tube 
stained positively for SM α actin but negatively for calponin (Fig. 6.4B (i)), The 
capsules from both fibronectin coated tubes with or without 50 million rSMSPC 
eGFP cells from the injected rats were stained positive for both SM- α actin and 
calponin (Fig. 6.4 A (i&ii) and Fig. 6.4 B (i&ii). However, expression of calponin was 
higher in capsules from fibronectin coated with 50 million cells injected rats 
compared to fibronectin coated tube capsules. 
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Figure 6-1. Tubular tissue capsule formation in rat’s peritoneal cavity. To investigate 
the role of rSMSPC eGFP cells integration during neovessel formation in vivo in rats 
peritoneal cavity, silastic tubes uncoated or fibronectin coated tubes injected with or without  
50 x 10
6
 rSMSPC eGFP cells was implanted into rats peritoneal cavity. A) Tissue capsule 
harvested from  A-i) uncoated silastic tubes ii) fibronectin coated silastic tubes and iii) 
fibronectin coated silastic tubes with 50 x 10
6
 rSMSPC eGFP cells after 2 weeks of 
implantation. B) Percentage of tubes formation in different treatments. C) Pre frozen tissue 
capsule placed into a mold with OCT, liquid embedding material. D) Percentage of rSMSPC 
eGFP cells detected by FACS analysis in tissue capsule harvested from fibronectin coated 
silastic tubes injected with 50 x 10
6
 rSMSPC eGFP cells. E) Capsule from fibronectin coated 
tubes injected with 50 x 10
6
 rSMSPC eGFP cells showing a patch of rSMSPC eGFP cells 
integrated within tissue capsule harvested after 2 weeks of implantation. (Right – whole 
tissue capsule; middle panel-patches of eGFP cells and left panel- merge). Data are 
representative of three independent experiments. n=3,  *P<0.05. 
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Figure 6-2. Detection of rSMSPC GFP integration within the tissue capsule.  
To determine the number of rSMSPC eGFP cells integration directly in tissue capsule 
formation, fibronectin coated (top panel) or fibronectin coated with rSMSPC eGFP 50x10
6
 
cells injected (bottom panel) frozen sections were analysed for the presence of eGFP cells 
by confocal microscopy. A small number of rSMSPC eGFP cells were found localised within 
the tissue capsule obtained from rSMSPC eGFP injected rats. Data are representative of 
three independent experiments. n=3. 
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Figure 6-3. H & E staining of tube capsule histology of tissue capsule harvested from 
rat peritoneal cavity after 2 weeks. 
 In order to study the detailed structures of tissue capsule, the harvested tissue capsule 
(uncoated (A), fibronectin coated (B), fibronectin coated along with 50 million rSMSPC eGFP 
cells (C)) from rat’s peritoneal cavity was sectioned and stained with haematoxylin to stain 
the nuclei, followed by eosin staining to stain other structures. The stained sections were 
examined by bright field microscope. Top panels show the complete structure of the tissue 
capsule with 2X magnification. Middle panels are magnified (20X) view of the area in top 
panel highlighted by black rectangle. The framed region in middle panel is further magnified 
to 40X from respective tissue capsule in the bottom panel. Data are representative of three 
independent experiments. n=3. 
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6.4. Discussion 
The current experiments aimed to investigate the contribution of rSMSPC 
expressing eGFP cells to SMC content of tissue capsule formed in rat’s peritoneal 
cavity. The results of this present study demonstrate that 1) presence of fibronectin 
alone or in combination with rSMSPC eGFP cells induced multiple layers of tissue 
encapsulation covering the entire length of tube. 2) Histological analysis confirmed 
the presence of tightly packed cells in fibronectin coated tubes injected with 
rSMSPC expressing eGFP cells. 3) Integration of rSMSPC eGFP cells within the 
tissue capsule was detected by both confocal and FACS analysis in fibronectin 
coated tube capsules injected with rSMSPC eGFP cells. Finally, expression of 
smooth muscle markers such as SM α actin and calponin were found to be relatively 
high in fibronectin coated tissue capsules injected with rSMSPC expressing eGFP 
cells. However, insufficient rSMSPC eGFP cell integration into neovessels in vivo 
was observed, suggesting that rSMSPC expressing eGFP cells contribute only a 
small extent to the SMC content of the tissue capsule. A possible explanation for 
this might be that these cells require more time to integrate into the capsule or 
require other cues such as cytokines, chemokines, cytoprotective factors or growth 
stimulators for more effective engraftment and expansion. Therefore, additional 
experiments will be required using varying cell number for injection and increasing 
the length of silastic tube inside the cavity might enhance SMSPC integration into 
capsule. Moreover, a number of additional growth promoters, cytokines such as 
TGF-β, IGF-1, and PDGF-BB would need to be tested with SMSPC cells and 
capsule formation in vivo.  
Interestingly, tissue capsules isolated from the fibronectin coated tubes 
injected with rSMSPC eGFP cells did not collapse while suturing for OCT 
processing, suggesting that integration of small number of rSMSPC eGFP into 
capsule may enhance capsule structural integrity. It is also conceivable that SMSPC 
have exhibited ECM effects within the capsule as shown in other in vitro studies of 
smooth muscle progenitor cells [375]. Further gene or chromosome tagging studies 
would be required to examine whether implanted cells differentiated into SMC in 
vivo but remained undetected by our analysis as it is known that GFP can be down 
regulated following stem cell differentiation. It is also interesting to note that calponin 
staining was higher in SMSPC treated capsules suggesting possible augmentation 
SMC differentiation within capsule.  This latter effect could conceivably have been 
mediated through paracrine factors secreted from implanted SMSPC. However, 
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further research will need to be carried out to investigate the specific role of 
rSMSPC eGFP cells in neovessel formation in the rat peritoneal cavity. 
In addition, a wide variation in tissue capsule formation was observed 
between animals. This is most likely because of the small number of animals studied 
(n=3) per group. Thus, data reported in this study represent a preliminary step to 
investigate the rSMSPC differentiation into SMC in vitro. More experiments are 
required to verify the effect of rSMSPC eGFP cells on reducing the inflammatory 
responses in rat peritoneal cavity and augmenting more myofibroblasts 
differentiation to SMC phenotype.  In addition, a further study is undertaken to 
investigate the role of rSMSPC eGFP in three dimensional (3D) tissue formation on 
biodegradable porous poly (L-lactic acid) (PLLA) scaffold in vivo in rats. 
In summary, this study investigated the role of rSMSPC eGFP in tissue 
capsule formation and found that rSMSPC eGFP can integrate into tissue capsule 
structure in vivo and contribute to their smooth muscle cell content. It is conceivable 
that small number seeded SMSPCs may also have paracrine effects on modulating 
myofibroblasts within the capsule augmenting SMC differentiation through bystander 
effect. Thus, better understanding of rSMSPC differentiation into SMC may provide 
important developments in tissue engineering and may lead to autologous vascular 
grafts in using a patient’s own cells as a source which mainly overcomes any 
immune response. 
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7. General Discussion and Future 
directions 
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General Discussion and Future directions 
The goals of the present work were to investigate myocardin gene 
regulation involved in differentiation of hSMSPC into SMC. This study selected 
hSMSPC cells, a novel circulating Isl-1+ stem progenitor cell isolated from bypass 
filters as a cell model to evaluate SMC differentiation. SMSPC are clonogenic, self 
renewing with high population doubling and express classic stem cell markers such 
as Oct 4, Sox-2, Nanog, KLF4, SSEA-1 and c-kit. 
The work has been divided into four parts. The first part characterised 
undifferentiated hSMSPC cells for the presence of smooth muscle transcription 
factors and their repressors, the second part identified putative binding sites for 
smooth muscle transcriptional repressors on the myocardin promoter region, the 
third part determined the molecular mechanism for smooth muscle differentiation in 
hSMSPC cells in vitro and finally, the fourth part investigated the integration of 
rSMSPC expressing eGFP into tissue capsule formation and their contribution to 
their smooth muscle content in a rat’s peritoneal cavity in vivo. 
In specific aim 1, hSMSPCs were characterised using qRT-PCR and found 
that the transcript levels of smooth muscle transcription factors, smooth muscle 
markers and smooth muscle repressors. hSMSPC cells express SRF, a major 
transcription factor required for SMC marker gene transcription, suggesting that 
hSMSPC cells may be already in a permissive state enabling differentiation towards 
smooth muscle cells. Notably, SRF alone is a weak transcriptional activator and it 
depends on a complex formation in a 2:1 stoichiometric ratio with its powerful 
coactivator, myocardin [94, 142, 143, 145] for initiation of SMC gene transcription 
[111, 112].  
Myocardin is the major SRF cofactor that controls differentiation of smooth 
muscle cells [94, 142, 143, 145]. Furthermore, overexpression of myocardin alone is 
sufficient to induce CArG-SRF dependent SMC differentiation markers in a variety of 
cell types such as 10T1/2 cells, NIH 3T3 cells and 3T3-L1 cells [350]. Of note, 
myocardin homologous mutant mice die by embryonic day (E) 10.5 exhibiting no 
evidence for VSMC differentiation [158], indicating that myocardin is necessary for 
VSMC differentiation [143].  However, hSMSPC cells express low levels of 
myocardin gene expression. Therefore, it is important to test whether myocardin 
expression is critical for SMC differentiation in hSMSPC cells.   
Furthermore, hSMSPCs express myocardin repressors including KLF4 and 
Elk-1, raising the possibility that presence of these repressors may be responsible 
for maintenance of stem progenitor phenotype by suppression of myocardin gene 
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expression in hSMSPC cells. Thus, hSMSPC cells are a useful model to study the 
regulation of myocardin signaling pathway involved in differentiation of progenitor 
cells into SMCs. 
Examination of different growth conditions for induction of SMC 
differentiation indicated that SmGM2 with 1% FBS can induce SMC differentiation 
with an increase in SM α actin expression. However, SmGM2 1%FBS media is not 
sufficient to induce full repertoire of SMC marker genes. TGF β1 signalling controls 
SMC differentiation in embryonic stem cells and neural crest [239, 240]. TGF-β1 
induces SMC differentiation by binding to three TCE elements (CArG box, SBE and 
TCE elements) located within the promoters of smooth muscle markers [239]. 
Investigation of smooth muscle associated cytokines to induce SMC differentiation 
in hSMSPC cells showed that TGF-β1 can induce the expression of SM α actin and 
calponin to a lesser extent in hSMSPC cells, suggesting that the effect of TGF- β1 
may be inhibited by transcriptional repressors in hSMSPC cells. 
Multiple repressors are involved in the downregulation of myocardin 
induced SMC transcription [164]. Passmann et al., [302] demonstrated that 
downregulation of SRF and myocardin by KLF4 is responsible for progenitor 
phenotype maintenance in Sca1+ vascular SMC progenitor cells isolated from 
adventitia of mice. Already, KLF4 has been identified as a negative regulator for 
myocardin induced SMC differentiation [138, 139, 167]. Thus, it was hypothesised 
that KLF4 is inhibiting myocardin gene expression in hSMSPC cells. 
A search for putative binding site for transcriptional repressors within 3.903 
Kb of the myocardin promoter region resulted in the identification of five potential 
KLF4 binding sites within the promoter region with high similarity scores (Fig.4.5).  It 
may be possible that KLF4 binding within these predicted binding sites is 
responsible for KLF4 mediated repression of myocardin gene expression in 
hSMSPC cells. The possibility of KLF4 binding within the human myocardin 
promoter in hSMSPC has been verified using qRT-PCR following the ChIP assay. 
However, there are limitations to use of the qRT-PCR assay as a standalone 
technique to confirm the transcription factors binding within the promoters, due to its 
inevitable errors during the amplification process. Therefore, it requires more 
specific additional studies such as EMSA and site directed mutational analysis to 
further strengthen the direct binding of KLF4 within the human myocardin promoter 
in hSMSPCs. KLF4 is involved in the phenotypic switching of SMCs upon various 
stimuli such as PDGF-BB, oxidised phospholipids and vascular injury. Hence, 
identification of direct KLF4 binding within the myocardin promoter sheds light on a 
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better understanding of molecular mechanisms that regulate myocardin gene 
expression. Further development of small molecules to block the binding of KLF4 
within the myocardin promoter will allow mechanistic studies of KLF4 contributing to 
SMC phenotype switching during development of atherosclerosis.  
The human myocardin promoter activity was studied using a lentiviral 
construct consisting of a human myocardin promoter driving eGFP expression in 
different cell types and found that the myocardin promoter can specifically activate 
eGFP expression in hSMSPC and in HASMC, but not in HUVEC cells, suggesting 
that basic SMC transcriptional machinery exists within hSMSPC. To test whether 
knockdown of KLF4 upregulates myocardin gene expression in response to TGF-β1 
stimulation, the hSMSPC cells were cotransduced with both of LV_shKLF4 B 
lentiviral supernatant and HR-ChMYOCDGW constructs in differentiation media. 
Results from the cotransduction assay showed that TGF-β1 stimulation increases 
myocardin promoter activity, indicating that myocardin transcriptional machinery is 
repressed by the presence of KLF4 in hSMSPC cells. Although, KLF4 has been 
reported to have repressor function via physical association with the myocardin/SRF 
complex [167], there currently exists no direct evidence for KLF4 transcription 
regulation of myocardin gene expression. Based on these results, it was 
hypothesised that KLF4 may physically bind to the human myocardin promoter 
region in hSMSPC cells and repress its expression. 
Binding of KLF4 within human myocardin promoter was verified by ChIP 
assay in hSMSPC cells. The result from KLF4 ChIP assay in hSMSPC strongly 
confirmed for the first time, that KLF4 binds within the human myocardin promoter in 
vitro. This study will need to be expanded to determine the roles of the five putative 
KLF4 binding sites on basal and growth factor induced increase in myocardin gene 
expression in hSMSPC cells. 
To study the functional role of TGF-β1 stimulation on hSMSPC cells that 
have undergone KLF4 knockdown, expression levels of KLF4 were silenced using 
LV_shKLF4 B and subsequently stimulated with TGF-β1. Specific knockdown of 
KLF4 in hSMSPC resulted in loss of their progenitor phenotype and adoption of an 
elongated morphology. Results from TGF-β1 stimulation on KLF4 knockdown 
indicate that TGF-β1 induced SMC differentiation with an increase in SM α actin and 
calponin expression in hSMSPC cells. These data confirm that KLF4 plays a major 
role in maintenance of hSMSPC progenitor phenotype and differentiated phenotype 
repression is mediated by transcriptional suppression of the myocardin gene. This 
result is consistent with previously reported findings showing that KLF4 plays a 
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major role in repression of myocardin induced adult SMC differentiation [167]. In 
these latter cultured cells, PDGF-BB stimulation induced expression of KLF4 which 
in turn decreased SRF binding within the CArG elements and repressed myocardin 
induced SMC gene transcription [167]. This current study identified a direct KLF4 
binding within the myocardin promoter which supports and strengthens the previous 
findings through identification of an additional mechanism through which KLF4 
mediates the repression of myocardin gene regulation by direct physical interaction 
with the myocardin promoter. 
KLF4 is highly expressed in ESC and plays a major role in maintenance of 
embryonic stem cell pluripotency [376]. KLF4 regulates the expression of core 
transcription factors of pluripotency including Oct4, Sox2 and Nanog. The promoters 
of each of these core transcription factors have binding sites for all transcription 
factors and act in a regulatory circuitry with a high degree of autoregulation between 
them. However, the KLF4 promoter has no binding sites for Oct4, Sox2 or Nanog 
genes and KLF4 is exempt from this core regulatory activity. These studies suggest 
that KLF4 is a major regulator for ESC core transcription factors. Therefore, 
downregulation of KLF4 is critical for differentiation of stem cells [338]. Recent 
evidence demonstrates that KLF2 and KLF5 genes are also involved in the 
regulation of the pluripotency transcription factors [376]. Several recent reports 
showed that downregulation of all three KLFs can induce extensive differentiation in 
ESC [376]. Therefore, experiments in the current work should be further expanded 
to analyse the effect of triple knockdown (KLF2\KLF4\KLF5) in induction of SMC 
differentiation in hSMSPC cells. Interestingly, there is already preliminary evidence 
from our group showing binding of KLF5 to the repressor regions within the human 
myocardin promoter in hSMSPC cells (Libby Turner, 2013, personal 
communication). 
To determine whether overexpression of myocardin can induce SMC 
differentiation, hSMSPC cells were transduced with a lentiviral vector encoding the 
myocardin gene.  Results showed that overexpression of myocardin significantly 
increased the stellate cell formation with spindle morphology and induced SMC 
differentiation with expression of myofilamentous SM markers including SM α actin, 
calponin and SMMHC in hSMSPC cells. In addition, nearly 80% of the myocardin 
transduced cells were induced to differentiate into myofilamentous and contractile 
like SMCs, which is consistent with other findings showing that overexpression of 
myocardin is sufficient to induce smooth muscle differentiation in various cell types 
including 10T1/2, NIH3T3 and 3T3 L1 cells [350]. Taken together, these data 
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confirm that myocardin gene expression plays a pivotal role in hSMSPC 
differentiation into SMC. It would be interesting to extend these findings to determine 
contractile function of differentiated hSMSPC cells using calcium signalling and 
angiotensin II responsiveness as described by Simper et al.,[245] and [377]. 
hSMSPC cells from a regenerative medicine perspective are attractive 
cells since they have an unlimited self renewal capability ex vivo, which can be 
expanded outside the body to potentially unlimited quantities. To investigate whether 
rat SMSPC cells expressing eGFP have an ability to integrate into tissue capsules 
formed in the rat peritoneal cavity in vivo and contribute to their smooth muscle 
content, hSMSPCs were injected into peritoneal cavity of rat along with silastic 
tubes. rSMSPC eGFP cells integrated into the tissue capsule structure but with low 
level of efficiency (~1%). Moreover SMSPC treated capsules appeared to contain 
myofibroblasts with more contractile calponin positive immunophenotype compared 
to non cell seed controls. However, this model showed a huge variation in tube 
capsule formation. A possible explanation for this might be due to small numbers of 
animals (n=3) per group. It would be interesting to further extend this work with 
larger numbers of animals per group. Moreover, this model needs to be tested with 
varying numbers of cells, augmenting factors such as chemokines, cytokines, 
chemoattractants, growth factors and differentiation agents. 
Experiments are currently underway to evaluate the in vivo differentiation 
potential of rSMSPC cells to determine whether these cells have the ex vivo ability 
to populate bio matrix-vascular grafts in rats. These studies use biodegradable 
porous 3D poly (L-lactic acid) (PLLA) scaffold seeded with cells prior to implantation 
into artery. Initial preliminary data supports extensive seeding of SMC derived from 
SMSPC in PLLA tubes out to 3 months post implantation as an interposition graft in 
rats (CL- personal communication). Extensive experiments are underway and full 
extent of SMC (derived from SMSPC) engraftment will be verified by 
immunofluorescence analysis for smooth muscle markers and tracer genetic 
studies. However, this study faces some significant challenges, including: how to 
clearly track and identify the undifferentiated rSMSPC cells in vivo? How to eliminate 
the undifferentiated cells in vivo to avoid the formation of teratoma?  This latter 
concern is based on data showing that hSMSPC induce teratoma in nude rats 
(Caplice et al., unpublished data). 
A recent study demonstrated that the introduction of a stem cell specific 
suicide gene including thymidine kinase (tk) into stem cell in combination with 
Ganciclovir (Gan) treatment was effective in killing undifferentiated stem cells [291]. 
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However, the suicide gene approach required genetic manipulation of stem cells, 
which may cause tumorigenicity in animals [291]. Moreover this approach may 
activate the immune system which is counter regulatory in vascular grafting. Another 
recent study reported the use of cytotoxic antibodies directed against cell surface 
antigens such as SSEA-4 [291], or podocalyxin-like protein-1 [378] in hESCs.  
However, so far, too little is known about the specificity and side effects of these 
agents.  Additional purification of undifferentiated and differentiated populations of 
SMSPC and SMC respectively may be achieved by detection of unique FACS 
profiles for these cells and area that is currently being extensively investigated by 
our group. Finally a more complete understanding of the molecular mechanisms 
involved in controlling hSMSPC stemness, self renewal and proliferation will enable 
advances in the development of techniques to control fate determination of 
undifferentiated SMSPC cells with consequences for safer therapeutic application. 
In conclusion, this work has delineated the myocardin signaling pathways 
involved in SMC differentiation of hSMSPC cells. This is the first study to report that 
KLF4 acts as a transcriptional repressor of myocardin gene expression in hSMSPC 
cells mediated through direct binding to the myocardin promoter and requiring a 
consensus sequence at (-3702) on (+) the strand of TSS. Knockdown of KLF4 
resulted in an increase of the myocardin promoter directed reporter genes and in 
combination with TGF-β1 stimulation, induced contractile-like SMC differentiation in 
hSMSPC cells. Moreover, overexpression of myocardin gene alone induced SMC 
differentiation in hSMSPC cells. Of interest, a small number of rSMSPC eGFP cells 
integrated into tube capsules grown within rat peritoneal cavity. Further studies will 
be necessary to determine whether the KLF4 knockdown alone or in combination 
with myocardin gene overexpression in hSMSPC is necessary and sufficient to 
generate large numbers of stably differentiated smooth muscle cells that can be 
manipulated for use in tissue engineered vascular grafts (an area of intense 
research and great clinical need within cardiovascular field).   
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8. Limitations of this study 
The major limitation of this study comes from the use of passaged 
hSMSPC cells isolated from single patients instead from different patients. 
Therefore, it would be interesting to verify the differentiation potential of hSMSPC 
cells isolated from different patients. 
Another limitation of this study is that the sequencing of cloned 3.925Kb 
fragment has detected one point mutation within the human myocardin promoter. 
These mutations may have affected transcription factor binding within the human 
myocardin promoter. Hence, the promoter mutation and their contribution to 
transcription factor binding should be tested in future experiments 
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Figure 10-1. PCR amplification and TA cloning of 3.925 Kb human myocardin 
promoter regions from human genomic DNA. 
 A) PCR amplification of human myocardin promoter. Lane L- Sigma 1 Kb ladder, lane 2 is 
PCR amplified 3.925 kb human myocardin promoter region. B)  TA cloning vector –pGlow 
TOPO vector map. C) Electrophoresis of colony PCR screening of transformed E.coli colony 
1-11 to identify human myocardin promoter positive clone. Colony 11 is positive for human 
myocardin promoter. D) Agarose gel electrophoresis of recombinant plasmid pGlow TOPO 
after restriction with EcoRI/BamHI restriction enzymes on 1% agarose gel. A fragment size 
of 3.925 Kb in lane 1, 2 and 3 confirms the presence of human myocardin promoter within 
the recombinant pGlow TOPO plasmid. Lane L- Sigma 1Kb ladder. 
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Figure 10-2. Sub-cloning of human myocardin promoter (3.925 kb) into HR-CSGW.  
A) Insert preparation. i) Circular map of the 9259 bp recombinant pGlow TOPO plasmid 
containing 3.925 Kb human myocardin promoter. ii) Electrophoresis of the recombinant 
pGlow TOPO plasmid after restriction digestion with EcoRI/BamHI restriction enzymes (Lane 
1, 2 and 3). The 3.925 Kb fragment was excised, purified and used as insert. Lane L- Sigma 
1 Kb ladder. B) Vector preparation. i) Circular map of the 9666bp pHRSIN-CSGW-dNotI 
plasmid (HR-CSGW).  ii)  Electrophoresis of the plasmid HR-CSGW (lane 1) after restriction 
digestion with EcoRI/BamHI restriction enzymes showing fragment sizes of 9.1 Kb and 510 
bp, vector backbone and the  spleen focus-forming virus (SFFV) promoter, respectively.  
Lane L- Sigma 1Kb ladder, U-uncut plasmid.  
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Figure 10-3. Sub-cloning of human myocardin promoter (3.925 kb) into HR-CSGW. 
 A) Circular map of the 13059 bp recombinant plasmid pHRSIN-CMYOCDGW (HR-
CMYOCDGW) The 9.1Kb HR-CSGW vector backbone was ligated with gel purified 3.925 Kb 
human myocardin promoter insert to yield pHRSIN-CMYOCDGW-dNotI (HR-CMYOCDGW) 
plasmid. B). Electrophoresis of the recombinant plasmid HR-CMYOCDGW (lane 1 and 2) 
after restriction digestion with EcoRI/BamHI restriction enzymes showing fragment sizes of 
9.1 Kb and 3.925 Kb, vector backbone and the human myocardin promoter, respectively. 
Lane L- Sigma 1Kb ladder, U1-uncut HR-CSGW plasmid, RD1- restriction digestion of HR-
CSGW plasmid with EcoRI/BamHI restriction enzymes, U2- Uncut recombinant pGlow 
TOPO plasmid containing human myocardin promoter. RD2- restriction digestion of 
recombinant pGlow TOPO plasmid with EcoRI/BamHI restriction enzymes.  
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A) 
>hMyocardin Promoter (3.925 kb) 
AATTCTATCAATAACCAGTGAACTTGGAAGGGGACACTGAGCTTCTCA
TGGGACTGCCACCCTAGCCAGCGCCTTGAGTGCAGCATTGTTAGACCCTAAGC
AGAGGTCCCAGATAATCCATGCCTGGACTCCTGACCATGAAAACTGTGAGATA
ATAAATATGTGCATTGTTTTAAGCTGCTAAATGTCTAGCAACTTATTACACAGGT
AACTAACAGCAAAGGAGAGAAAGCCAAAATGAAGGGGAAAGGGACAGAATTGC
TTGGAATCTTCATGAATGTTTGGAGATGGTTGGGGCAGGGGAAGTAAAAAGAA
GGGTCCAAAACACACCAGGGCCGGGCACGGTGGCTTACACCTGTAATCCCAG
CACTTTGGGAGGCCAAGGCAGGCAGATCACCTGAGCGCAGGAGTTCAAGACC
AGCTTGGCTGGTCTTGATAGGGGGAAGCCCTATCTCTACTAAAAATACAAAATC
ATCTGGGCGCAGTGGCATGCATCTGTAATCCCAGCTACTCGGGAGGCTGAGG
CAGGGAGAATCTCTTGAACCCAGGAGGCAAGGTTGCAGTAAGCCCAGATCGC
ACCACTGTACTCCAGCCTGGGCAACAGAGCGAGACTCTGTCTCAAAATAATAA
AAAATAATAATAAAAAACACACCAAAATTGTTCTGGGCACCCCACATGTATTCTT
TCATTTAAATATCCCAACTCTTCCTGGAAGTAAATATTTCTAACTCCATTTTACAG
ATAAGACGTTGAGTATCCCAGAGAACTCCAATAATTCACTCCAAAGTACAGGGT
TATCCTGATGGAAAGAAGATCTTTCTCACACTGGAGGCTCATGTCTTGCCTTTG
TGTCACATCACGGGCTTACTCCAAGCCCCAGGAAAAGAAGGTCATGGAGTAGC
CTGGCAAGGAAAACATACTCCAAGGTGGTGGGTGACATTGCAGGACAGAGCCT
GGCAGCATGCCGCTGCTGCATTAGCCTGCTGCTTTTCGAGCCTAGCAGCTTAG
GAGTTCTGTTCTCCTTGAGAACATCTTCTCCAAATTCCACCCCTCTCAAAAATTT
TTTTTGTTTTACCAAAAGTGCTTGGCTAGAGAGGAGAAATGATGAACTTCTTTAT
GAGCATATTTATAACCATAGATATTCCAAGCCATAGGAGGTATAAATTTCAGGAT
ATATGTCAGTAGCTCCACACTGTGATGGGAAAATTGAGGGGGGCTATGGTTAT
TGGCATTTCCCAAACTCACTGAAAAAAAGAAACTGCTTCCCTGCAAACACACAT
ACACACACACACACCACACTCCACACATACACACACGCGCGCACACACACACA
CACACACACACACTCCCCCTAGGCCTGCAGAGAGAAAACAACTTACTCCTGGC
CAGCTCATCTAGGTCATGCAGACCCTACAATCAATGCTGGCTTCAGCTAATTTC
ATCCCAACTTGCACTGAAAAAATAATTCTCTGCCAAGTTGCCATGTATCTCTTCT
CAGCCCCAAAGCCTTCGGGATAAAAATCTGTTTGGCTTTTTCTTTTTTCTTTTTT
TAATGTTGCTCAAAATAGTTTTCTCTGCTCAGATAATTTTGCAATATTCCTTATCC
CACCAATCTCTTCCCTGTAGAGTACCTCCCTGCCACACACATCTCAAAGCCGGT
CAGAGCCCTTCCAGACTCCTGTGTGCACCCGTTCCCAAACCTCCCTCCACTTT
CCTTCTTCTCATTGAAGACCAGGGGGCTGGGGGTTGACTGAAGACCAGGAGA
GGTAGAAGAGAAAGAAAGATCTCAGGCGGAATCATGCCCTCTCCTCCCATGTT
CATGTCCTAATCCCAGGAATCTGTGAATAGGTTACATTATACAGCAAAGGGAAT
CCAGGCAGTGGATGAGATTAGGGAGGATAATAAACTGACTTTATGATAGAGTTT
ATTTTTGCCGTAAGGTTAATGTAGAAGAGGGAAGCAGAAGGTGGGGAAGGGAG
CATTAAAGCGGTAAGATGCAATAGGAACTTGACCCACGATTGCTGGCTTCAAAA
ATGGAGGAAGCGGCCATGAGCCAAGTACTCGGGCGGCCTCTAGAAGCTGGAA
AAGGTGAGGAAATCGATTTTCCCCTAGAGCCTCCAGAAACTAACGCAGCCCCG
CTGACACCTTGATTTTGACCCCCTGAGACCCACTTTGGACTTCTGCCCTCCATA
ACAGCAAGATAATTAATGTGTGCTGTTTTAAGCCACTACATTCGTGGTAATTTGT
TATAGCAGGAATGGGAAAATGATGTTACGTAATCGCTGAGATGCTCCTGCACA
CGAAATCAGCCTATAGACAGGCGCCCAGGCCAGGACTAGATCCCCAAAGGGA
ACATGGATGGATTGTTCTTCCTCGTCTCTGACACATCAGCAAGAAGGTGTCTAT
CCCTGAAGACCTTATTTACAAAATCGCCCCGCTCAGATCCAGAGAGTAAGCTCT
AGGGCTAACCCCTCTAATGTGTTTTCAGCAACAGGGGATGGGGCAGAGGCCG
GGACCAGGACATTAGAGGTTGTCCCCATGAGCTATTGTCACCTCGGGTCTCCA
TCTGTCACCGACTGATCTTTTAAGGACTCGTAGTATGCAGGCAGGCTTGTGTGT
AATAGACGACACCCGGGGTCCACGTGCATATGAAGTTGCAAATAAGCCCTAAT
TATATACGTATACAGAGTGGTTTTTATGTTCTGAGCCACCAACTATTTAACGGG
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CTTCTTGAGAGATGGGTCTTTGTTTTATTTCATTGATCCATGTGCCTATAACACC
TCGGCCAGATGCACAAATAACTCTGGGTCGGTTACGGAATGGATTTTCCCCTA
AGGAGAGACTCATTCGCAGGCAAAGTTTTTGAGCCTTCCCAAGCTAAGCCCAG
CCCGAGCTCTGACTTGCCCCCTGCTCCAGAGCCCCTCCCTATTTAGAGCCCAG
TAGGTTTTTCACTCCAACTCAGGTATCTTTTCCCATTCCCTCGGGGTTGTGAGG
TGGGAGCGTTGTGTCGCAGCTGGATCTCCAGATGCGCCGTGTCACATTTGTCC
CCCCAAAAAGCATATCCTAGAAAATGAAAGCCTTTCCATTTCCCCGTGGAAATG
CATCTAAGTCCAGTATTGGAGCTGCGAGATACAGAATCGTCTCTGCCAGTGCC
CTGAGCCCCTCAAACCGAGGGGAATGCGTGGGCTTCGGTCCGTCGGAAGCTT
TTCTTCTCAGGGGTCCAGCTTATTTCCAAATTGCCCCGCGTGAACTGTCCCGC
GGGCGCGCACGCCCTTTCGCGCAGCCTTTGCAGCCGGCTGGCGGGAGATCC
CGGCCGCTTCCCTTTCGCCGGCAGAAGCCCGGCCGGGGAAGCCCCGGCTGC
GCACGCCCATCCCCAGGACCTCGGAGCTCCCAGCGGCTGCCGCAGCCCCGC
GAACCACCTGCAAGCCCCGCGGCGTCGCAGCCCTTCCTTCTTTCCTCCGGGC
ATCCGCTCTTTAGCTCGCGCCCCTCTCCCAGATTCCCGACCCCTGGCCCTGCT
CCCGCCCTCTGTGCCTCGGCGGCTGCGGGGCCCGCCGCAAAGAGTTAAGAG
CCGGTTCCCGAGACGGCTTCGGCGGCTCCGGGTCCCCAGACCCCGCTCGCC
GCTCCTGATTGGCTGAGCGCCTGTCAGTAGTAAAGGGTATCAGATGGCAAAGT
TGGGACCTTCATAAAGGCGTGGTGGCGATTCTCCGCAATCGCCGGCAGCCTAT
GACATCAGACAGGAACGCCTGGGATGCCGCGCTGCTCCTGGCCAACCTCCGA
GGAGGAGGAGGGTCCCGCCGGCTAAGAGTTAATTAGCCCCGCACGGCGAGG
GGGGAGGCGCCAGTTTTCTGGGGACACTGGCTGCCACTGTACTCCTACCCAG
GGGAGCTCACGGAGAGTTGGATGGATCTGGATCTAAGTAAGCTTG 
B) 
>seq1 
AATTCTATCAATAACCAGTGAACTTGGAAGGGGACACTGAGCTTCTCA
TGGGACTGCCACCCTAGCCACCGCCTTGAGTGCAGCATTGtTAGACCCTAAGC
AGAGGTCCCAGATAATCCATGCCTGGACTCCTGACCATGAAAACTGTGAGATA
ATAAATATGTGCATTGTTTTAAGCTGCTAAATGTCTAGCAACTTATTACACAGGT
AACTAACAGCAAAGGAGAGAAAGCCAAAATGAAGGGGAAAGGGACAGAATTGC
TTGGAATCTTCATGAATGTTTGGAGATGGTTGGGGCAGGGGAAGTAAAAAGAA
GGGTCCAAAACACACCAGGGCCGGGCACGGTGGCTTACACCTGTAATCCCAG
CACTTTGGGAGGCCAAGGCAGGCAGATCACCTGAGCGCAGGAGTTCAAGACC
AGCTTGGCTGGTCTTGATAGGGGGAAGCCCTATCTCTACTAAAAATACAAAATC
ATCTGGGCGCAGTGGCATGCATCTGTAATCCCAGCTACTCGGGAGGCTGAGG
CAGGGAGAATCTCTTGAACCCAGGAGGCAAGGTTGCAGTAAGCCCAGATCGC
ACCACTGTACTCCAGCCTGGGCAACAGAGCGAGACTCTGTCTCAAAATAATaAA
AAATAATAATAAAAAaCACACCAAAATTGTTCTGGGCACCCCACATGTATTCTTT
CATTTAAATATCCCAACTCTTCCTGGAAGTAAATATTTCTAACTCCATTTTACAG
ATAAGACGTTGAGTATCCCAGAGAACTCCAATAATTCACTCCAAAGTACAGGGT
TATCCTGATGGAAAGAAGATCTTTCTCACACTGGAGGCTCATGTCTTGCCtTTGT
GTCACATCACGGGCTTACTCCAAGCCCCAGGAAAAgAAGGTCAtggaGTAGCCT
GGCAAGGaAAACATACTCCAAGGTGGTgGGTGACAtTGCAGGACAGAGcCTGG
CAGCATGCCGCTGCTGCATTAGCCT 
 
C) 
>seq2 
TAAGCTTTTCTTCTCAGGGGTCCAGCTTATTTCCAAATTGCCCCGCGT
GAACTGTCCCGCGGGCGCGCACGCCCTTTCGCGCAGCCTTTGCAGCCGGCTG
GCGGGAGATCCCGGCCGCTTCCCTTTCGCCGGCAGAAGCCCGGCCGGGGAA
GCCCCGGCTGCGCACGCCCATCCCCAGGTCCTCGGAGCTCCCAGCGGCTGC
CGCAGCCCCGCGAACCACCTGCAAGCCCCGCGGCGTCGCAGCCCTTCCTTCT
TTCCTCCGGGCATCCGCTCTTTAGCTCGCGCCCTTCTCCCAGATTCCCGACCC
CTGGCCCTGCTCCCGCCCTCTGTGCCTCGGCGGCTGCGGGGCCCGCCGCAA
189 
 
AGAGTTAAGAGCCGGCTCCCGAGACGGCTTCGGCGGCTCCGGGTCCCCAGAC
CCCGCTCGCCGCTCCTGATTGGCTGAGCGCCTGTCAGTAGTAAAGGGTATCAG
ATGGCAAAGTTGGGACCTTCATAAAGGCGTGGTGGCGATTCTCCGCAATCGCC
GGCAGCCTATGACATCAGACAGGAACGCCTGGGATGCCGCGCTGCTCCTGGC
CAACCTCCGAGGAGGAGGAGGGTCCCGCCGGCTAAGAGTTAATTAGCCCCGC
ACGGCGAGGGGGGAGGCGCCAGTTTTCTGGGGACACTGGCTGCCACTGTACT
CCTACCCAGGGGAGCTCACGGAGAGTTGGATGGATCTGGATCTAAGTAAGCTT
G 
 
D) 
>seq3 
CTCCTGGCcaGCTCATCTAGGTCATGcacnCCcTACaATCAATGCTGGC
TTCAGctAATTTCATCCCAACTTGCACTGAAAAAATAATTCTCTGCCAAGTTGCCA
TGTATCTCTTCTCAGCCCCAAAGCCTTCGGGATAAAAATCTGTTTGGCTTTTTCT
TTTTTCTTTTTTTAATGTTGCTCAAAATAGTTTTCTCTGCTCAGATAATTTTGCAA
TATTCCTTATCCCACCAATCTCTTCCCTGTAGAGTACCTCCCTGCCACACACAT
CTCAAAGCCGGTCAGAGCCCTTCCAGACTCCTGTGTGCACCCGTTCCCAAACC
TCCCTCCACTTTCCTTCTTCTCATTGAAGACCAGGGGGCTGGGGGTTGACTGA
AGACCAGGAGAGGTAGAAGAGAAAGAAAGATCTCAGGCGGAATCATGCCCTCT
CCTCCCATGTTCATGTCCTAATCCCAGGAATCTGTGAATAGGTTACATTATACA
GCAAAGGGAATCCAGGCAGTGGATGAGATTAGGGAGGATAATAAACTGACTTT
ATGATAGAGTTTATTTTTGCCGTAAGGTTAATGTAGAAGAGGGAAGCAGAAGGT
GGGGAAGGGAGCATTAAAGCGGTAAGATGCAATAGGAACTTGACCCACGATTG
CTGGCTTCAAAAATGGAGGAAGCGGCCATGAGCCAAGTACTCGGGCGGCCTC
TAGAAGCTGGAAAAGGTGAGGAAATCgATTTTCCCCTAGAGCCTCCAGAAACTA
ACGCAGCCCCGCTGACACCTTGATTTTGACCCCCTGAGACCCACTTTGGACTT
CTGCCCTCCATAACAGCAAGATAATTAATGTGTGCTGTTTTAAGCCACTACATT
CGTGGTAATTTGTTATAGCAGGAATGggaAAATGATGTTACGTAATCGCTGAgAT
GCTCCTGCACACGaAATCAGCCTATAGACAGGCGCCCAGGCCAGGACTAGATC
CCCAAagGGAACATGGATGGATTGTTCTTcCTCGTCTCTGnnnCATCAGCaagAA
GgtGTCTATCCCT 
 
E) 
>seq4 
ATCATGCCCTCTCCTCCCATGTTCATGTCCTAATCCCAGGAATCTGTG
AATAGGTTACATTATACAGCAAAGGGAATCCAGGCAGTGGATGAGATTAGGGA
GGATAATAAACTGACTTTATGATAGAGTTTATTTTTGCCGTAAGGTTAATGTAGA
AGAGGGAAGCAGAAGGTGGGGAAGGGAGCATTAAAGCGGTAAGATGCAATAG
GAACTTGACCCACGATTGCTGGCTTCAAAAATGGAGGAAGCGGCCATGAGCCA
AGTACTCGGGCGGCCTCTAGAAGCTGGAAAAGGTGAGGAAATCGATTTTCCCC
TAGAGCCTCCAGAAACTAACGCAGCCCCGCTGACACCTTGATTTTGACCCCCT
GAGACCCACTTTGGACTTCTGCCCTCCATAACAGCAAGATAATTAATGTGTGCT
GTTTTAAGCCACTACATTCGTGGTAATTTGTTATAGCAGGAATGGGAAAATGAT
GTTACGTAATCGCTGAGATGCTCCTGCACACGAAATCAGCCTATAGACAGGCG
CCCAGGCCAGGACTAGATCCCCAAAGGGAACATGGATGGATTGTTCTTCCTCG
TCTCTGACACATCAGCAAGAAGGTGTCTATCCCTGAAGACCTTATTTACAAAAT
CGCCCCGCTCAGATCCAGAGAGTAAGCTCTAGGGCTAACCCCTCTAATGTGTT
TTCAGCAACAGGGGATGGGGCAGAGGCCGGGACCAGGACATTAGAGGTTGTC
CCCATGAGCTATTGTCACCTCGGGTCTCCATCTGTCACCGACTGATCTTTTAAG
GACTCGTAGTATGCAGGCAGGCTTGTGTGTAATAGACGACACCCGGGGTCCAC
GTGCATATGAAGTTGCAAATAAGCCCTAATTATATACGTATACAGAGTGGTTTTT
ATGTTCTGAGCCACCAACTATTTAACGGGCTTCTTGAGAgaTGGGTCtTTGtTTTA
tTTCATTGATCCATGTGCCTATAACACCTCGGCCAGATGcaCAAATAACTCTGGG
TCGGTTACGGAATGGatTTTCCCCTAAGTt 
190 
 
 
 
Figure 10-5. Sequencing of 3.925 Kb cloned human myocardin promoter .  
A) 3.925 Kb length of the human myocardin promoter was extracted from human genome 
using in silico PCR B) Seq-1- Forward sequence obtained from sequencing of cloned human 
myocardin promoter. C) From the forward sequence, the next primer was designed to 
sequence the next segment of cloned myocardin promoter. The sequence was named as 
Seq2. D) Seq 2 was used for designing primer to obtain seq3 and E) Seq3 was used as 
reference sequence for designing primer to get the last segment of cloned myocardin 
promoter sequences and named as Seq4. 
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Table 10-1. List of transcription factors binding within 3.9 Kb human myocardin 
promoter 
  Position   
Sno Matrix from to anchor 
Core 
sim CAPITALS:core sequence 
1 V$HLF.01 2268 2284 2276 1.000 agcgattacGTAAcatc 
2 V$ACAAT.01 1605 1619 1612 1.000 cccaCCAAtctcttc 
3 V$LYF1.01 3485 3497 3491 1.000 atcTGGGagaggg 
4 V$TGIF.01 3634 3650 3642 1.000 gagcgcctGTCAgtagt 
5 V$TFII-IR4.01 1823 1833 1828 1.000 tggGATTagga 
6 V$TGIF.01 1170 1186 1178 1.000 ggatatatGTCAgtagc 
7 V$MZF1.02 241 251 246 1.000 aaGGGGaaagg 
8 V$MASH1.01 3413 3425 3419 1.000 gaaccacCTGCaa 
9 V$MZF1.01 1967 1977 1972 1.000 gtGGGGaaggg 
10 V$KAISO.01 2249 2259 2254 1.000 attcCTGCtat 
11 V$E2F.02 3270 3286 3278 1.000 aggctgcgcGAAAgggc 
12 V$MZF1.02 2101 2111 2106 1.000 taGGGGaaaat 
13 V$NFY.02 3621 3635 3628 1.000 tcagCCAAtcaggag 
14 V$TGIF.01 2376 2392 2384 1.000 gctgatgtGTCAgagac 
15 V$GATA.01 737 749 743 1.000 tacaGATAagacg 
16 V$MZF1.02 2824 2834 2829 1.000 taGGGGaaaat 
17 V$NGN_NEUROD.01 2560 2572 2566 1.000 tctcCATCtgtca 
18 V$ZKSCAN3.01 1958 1980 1969 1.000 gctcccttCCCCaccttctgctt 
19 V$SPI1_PU1.02 294 314 304 1.000 ggggcaggGGAAgtaaaaaga 
20 V$TBX5.01 2136 2156 2146 1.000 tcaaaatcaaGGTGtcagcgg 
21 V$HOXB5.01 3802 3820 3811 1.000 agagtTAATtagccccgca 
22 V$GSH2.02 3800 3818 3809 1.000 cggggctAATTaactctta 
23 V$MZF1.02 3171 3181 3176 1.000 gaGGGGaatgc 
24 V$ZF5.01 1314 1324 1319 1.000 gtgcGCGCgtg 
25 V$ZF5.01 3259 3269 3264 1.000 gtgcGCGCccg 
26 V$S8.01 3797 3817 3807 1.000 ggggcTAATtaactcttagcc 
27 V$ZF5.01 1316 1326 1321 1.000 gtgtGCGCgcg 
28 V$S8.01 2659 2679 2669 1.000 gtataTAATtagggcttattt 
29 V$CABL.01 1063 1073 1068 1.000 aaAACAaaaaa 
30 V$DLX1.02 2193 2211 2202 1.000 acagcaagatAATTaatgt 
31 V$S8.01 2197 2217 2207 1.000 caagaTAATtaatgtgtgctg 
32 V$S8.01 3802 3822 3812 1.000 agagtTAATtagccccgcacg 
33 V$MZF1.01 3041 3051 3046 1.000 ggGGGGacaaa 
34 V$MYT1.02 2854 2866 2860 1.000 gcaAAGTttttga 
35 V$MZF1.01 3827 3837 3832 1.000 ggGGGGaggcg 
36 V$TBX5.01 2771 2791 2781 1.000 atctggccgaGGTGttatagg 
37 V$MZF1.02 438 448 443 1.000 agGGGGaagcc 
38 V$HNF3.01 1264 1280 1272 1.000 tccctgcAAACacacat 
39 V$NFAT.01 3444 3462 3453 1.000 ccggaGGAAagaaggaagg 
40 V$SOX5.01 74 96 85 1.000 gggtctaaCAATgctgcactcaa 
41 V$SALL1.01 625 637 631 1.000 taATAAaaaataa 
42 V$SMARCA3.02 1076 1086 1081 1.000 aagcACTTttg 
43 V$MEL1.02 1876 1892 1884 1.000 ggcagtgGATGagatta 
44 V$IK2.01 1229 1241 1235 1.000 gtttGGGAaatgc 
45 V$YY1.02 2022 2042 2032 1.000 ttcctCCATttttgaagccag 
46 V$MEL1.02 1386 1402 1394 1.000 tgacctaGATGagctgg 
47 V$S8.01 2192 2212 2202 1.000 cacatTAATtatcttgctgtt 
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48 V$HOXA3.01 3799 3817 3808 1.000 ggggcTAATtaactcttag 
49 V$GATA1.06 445 457 451 1.000 tagaGATAgggct 
50 V$S8.01 2664 2684 2674 1.000 agcccTAATtatatacgtata 
51 V$HSF2.02 2358 2382 2370 1.000 cagagacgaggaAGAAcaatccatc 
52 V$CDX1.01 633 651 642 1.000 tgtgtttTTTAttattatt 
53 V$DELTAEF1.01 391 403 397 1.000 agatcACCTgagc 
54 V$MOK2.02 59 79 69 1.000 accctagccagcgCCTTgagt 
55 V$CMYC.01 2636 2648 2642 1.000 ggtccaCGTGcat 
56 V$CDX1.01 620 638 629 1.000 attatttTTTAttattttg 
57 V$HNF3B.01 710 726 718 1.000 tggaagtaAATAtttct 
58 V$SOX5.01 156 178 167 1.000 gcttaaaaCAATgcacatattta 
59 V$RU49.01 1626 1632 1629 1.000 gAGTAcc 
60 V$IK2.01 1688 1700 1694 1.000 gtttGGGAacggg 
61 V$USF.01 2637 2649 2643 1.000 tatgCACGtggac 
62 V$GATA1.01 431 443 437 1.000 tcttGATAggggg 
63 V$DLX1.02 3803 3821 3812 1.000 gtgcggggctAATTaactc 
64 V$ILF1.01 1362 1378 1370 1.000 agagagaaAACAactta 
65 V$ILF1.01 906 922 914 1.000 gcaaggaaAACAtactc 
66 V$ILF1.01 2475 2491 2483 1.000 ttgctgaaAACAcatta 
67 V$RU49.01 2056 2062 2059 1.000 aAGTAct 
68 V$AHRARNT.03 3353 3377 3365 1.000 ctggggatggGCGTgcgcagccggg 
69 V$BSX.01 3800 3818 3809 1.000 taagagttAATTagccccg 
70 V$DLX1.01 2665 2683 2674 1.000 atacgtatatAATTagggc 
71 V$HSF2.02 809 833 821 1.000 gcctccagtgtgAGAAagatcttct 
72 V$ILF1.01 638 654 646 1.000 taataaaaAACAcacca 
73 V$HSF2.02 1766 1790 1778 1.000 ggtagaagagaaAGAAagatctcag 
74 V$HNF3.01 2652 2668 2660 0.971 aagttgcAAATaagccc 
75 V$VMYB.04 2718 2730 2724 1.000 tttAACGggcttc 
76 V$SALL1.01 638 650 644 1.000 taATAAaaaacac 
77 V$NGN_NEUROD.01 489 501 495 1.000 catgCATCtgtaa 
78 V$STAT3.02 700 718 709 1.000 ttacTTCCaggaagagttg 
79 V$HOXA3.01 2194 2212 2203 1.000 cacatTAATtatcttgctg 
80 V$ZFX.01 2323 2333 2328 1.000 ctGGCCtgggc 
81 V$DLX1.02 3798 3816 3807 1.000 gctaagagttAATTagccc 
82 V$PTX1.01 1821 1837 1829 1.000 tgtcCTAAtcccaggaa 
83 V$STAT3.02 702 720 711 1.000 actcTTCCtggaagtaaat 
84 V$DLX2.01 2198 2216 2207 1.000 agcacacattAATTatctt 
85 V$DEC2.01 2635 2649 2642 1.000 tatgcaCGTGgaccc 
86 V$NGN_NEUROD.01 2784 2796 2790 1.000 tgtgCATCtggcc 
87 V$DLX2.01 2660 2678 2669 1.000 aataagccctAATTatata 
88 V$BSX.01 3801 3819 3810 1.000 gcggggctAATTaactctt 
89 V$GATA3.01 147 159 153 1.000 gtgaGATAataaa 
90 V$AREB6.02 349 361 355 1.000 cttaCACCtgtaa 
91 V$SOX5.01 2352 2374 2363 1.000 aggaagaaCAATccatccatgtt 
92 V$IK2.01 2866 2878 2872 1.000 gcttGGGAaggct 
93 V$RORA1.01 1389 1411 1400 1.000 gctcatctaGGTCatgcagaccc 
94 V$IPF1.01 3798 3816 3807 1.000 gctaagagtTAATtagccc 
95 V$SOX5.01 646 668 657 1.000 gcccagaaCAATtttggtgtgtt 
96 O$XCPE1.01 3514 3524 3519 1.000 ggGCGGgagca 
97 V$GSH2.02 3801 3819 3810 1.000 aagagttAATTagccccgc 
98 V$KAISO.01 939 949 944 1.000 tgtcCTGCaat 
99 V$PAX4.02 3803 3817 3810 1.000 gagttAATTagcccc 
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100 V$NMP4.01 1528 1538 1533 1.000 agAAAAagcca 
101 V$DEC2.01 2636 2650 2643 1.000 ggtccaCGTGcatat 
102 V$NFAT.01 2088 2106 2097 1.000 ggtgaGGAAatcgattttc 
103 V$SIX1.01 3650 3664 3657 1.000 taaagggTATCagat 
104 V$ZBP89.01 3820 3842 3831 1.000 actggcgcctCCCCcctcgccgt 
105 V$PTX1.01 2874 2890 2882 1.000 caagCTAAgcccagccc 
106 V$YB1.01 3624 3636 3630 1.000 ctgatTGGCtgag 
107 V$GKLF.01 3439 3455 3447 1.000 aaagaaggaAGGGctgc 
108 V$YY2.01 726 746 736 1.000 taactCCATtttacagataag 
109 V$NFKAPPAB65.01 2819 2831 2825 1.000 aatggattTTCCc 
110 V$SOX9.02 835 857 846 1.000 atgtgacACAAaggcaagacatg 
111 V$CABL.01 2742 2752 2747 1.000 aaAACAaagac 
112 V$AHRARNT.03 3257 3281 3269 1.000 gcgcgaaaggGCGTgcgcgcccgcg 
113 V$CDPCR3HD.01 2754 2772 2763 1.000 tttcattGATCcatgtgcc 
114 V$MAFA.01 966 986 976 1.000 cgcTGCTgcattagcctgctg 
115 V$BSX.01 2196 2214 2205 1.000 cacacattAATTatcttgc 
116 V$MEIS1.01 2561 2577 2569 1.000 ctccatcTGTCaccgac 
117 V$LMX1B.01 2198 2220 2209 1.000 aaacagcacacatTAATtatctt 
118 V$FTF.01 919 931 925 1.000 actcCAAGgtggt 
119 V$VAX1.01 2196 2214 2205 1.000 gcaagatAATTaatgtgtg 
120 V$ZNF35.01 2365 2377 2371 1.000 acgaggAAGAaca 
121 V$SATB1.01 633 647 640 1.000 aatAATAataaaaaa 
122 V$BSX.01 2195 2213 2204 1.000 agcaagatAATTaatgtgt 
123 V$AREB6.01 202 214 208 1.000 tagttACCTgtgt 
124 V$PAX4.02 3802 3816 3809 1.000 gggctAATTaactct 
125 V$NANOG.01 2966 2984 2975 1.000 ccgagggAATGggaaaaga 
126 V$RORA1.01 880 902 891 1.000 ggaaaagaaGGTCatggagtagc 
127 V$ETS1.01 2031 2051 2041 1.000 aaaatggaGGAAgcggccatg 
128 V$CEBPB.01 1583 1597 1590 1.000 ataattttGCAAtat 
129 V$ZNF35.01 701 713 707 1.000 tccaggAAGAgtt 
130 V$SMARCA3.01 3036 3046 3041 0.960 tcACATttgtc 
131 V$GATA1.03 1578 1590 1584 1.000 ctcaGATAatttt 
132 V$SMARCA3.01 1171 1181 1176 0.960 tgACATatatc 
133 V$SMARCA3.01 3081 3091 3086 1.000 ttCCATttccc 
134 V$IPF1.01 3803 3821 3812 1.000 gtgcggggcTAATtaactc 
135 V$ZF5.01 3261 3271 3266 1.000 gcgtGCGCgcc 
136 V$TEF.01 2267 2283 2275 1.000 tgatgttacGTAAtcgc 
137 V$GKLF.02 216 232 224 1.000 cagcAAAGgagagaaag 
138 V$CEBPB.01 1229 1243 1236 1.000 gagtttggGAAAtgc 
139 V$CEBPB.01 2268 2282 2275 0.940 gatgttacGTAAtcg 
140 V$CMYB.02 2805 2817 2811 1.000 cgTAACcgaccca 
141 V$FAC1.01 641 651 646 1.000 taaaaAACAca 
142 V$SATB1.01 623 637 630 1.000 aatAATAaaaaataa 
143 V$HOXC8.01 2197 2215 2206 1.000 caagataATTAatgtgtgc 
144 V$GATA1.03 108 120 114 1.000 cccaGATAatcca 
145 V$CDP.02 3618 3636 3627 1.000 ctcagcCAATcaggagcgg 
146 V$MSX2.01 2662 2680 2671 1.000 taagccCTAAttatatacg 
147 V$HSF2.02 3122 3146 3134 1.000 gctgcgagatacAGAAtcgtctctg 
148 V$ARNT.01 2634 2650 2642 1.000 ggggtccaCGTGcatat 
149 V$BARX2.01 2663 2681 2672 1.000 acgtataTAATtagggctt 
150 V$NF1.03 1223 1243 1233 1.000 gagtttgggaaatGCCAataa 
151 V$SPI1_PU1.02 1963 1983 1973 1.000 gaaggtggGGAAgggagcatt 
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152 V$LMX1B.01 622 644 633 1.000 aaataataaaaaaTAATaataaa 
153 V$E4BP4.01 2265 2285 2275 1.000 cagcgattacGTAAcatcatt 
154 V$GATA3.02 1779 1791 1785 1.000 gaaAGATctcagg 
155 V$CRX.01 1881 1897 1889 1.000 ctcccTAATctcatcca 
156 V$HIC1.01 3458 3470 3464 1.000 gcggaTGCCcgga 
157 V$CEBPA.01 1553 1567 1560 1.000 tattttgaGCAAcat 
158 V$ELF2.01 697 717 707 1.000 tacttccaGGAAgagttggga 
159 V$GSH2.01 1428 1446 1437 1.000 ttcagcTAATttcatccca 
160 V$DEC2.01 2760 2774 2767 0.903 taggcaCATGgatca 
161 V$SMARCA3.01 1479 1489 1484 1.000 tgCCATgtatc 
162 V$GSH2.01 2469 2487 2478 1.000 cccctcTAATgtgttttca 
163 V$ZNF219.01 3817 3839 3828 1.000 ggcgcctCCCCcctcgccgtgcg 
164 V$MEL1.03 1024 1040 1032 1.000 tggagaaGATGttctca 
165 V$NANOG.01 2250 2268 2259 1.000 tagcaggAATGggaaaatg 
166 V$ARNT.01 2635 2651 2643 1.000 catatgcaCGTGgaccc 
167 V$SPI1_PU1.02 434 454 444 1.000 tgatagggGGAAgccctatct 
168 V$FAC1.01 319 329 324 1.000 tccaaAACAca 
169 V$MAZ.01 1803 1815 1809 1.000 atggGAGGagagg 
170 V$RBPJK.02 2255 2267 2261 1.000 ggaaTGGGaaaat 
171 V$ZF5.01 3258 3268 3263 1.000 gcggGCGCgca 
172 V$MAZ.01 3821 3833 3827 1.000 cggcGAGGgggga 
173 V$E4BP4.01 2266 2286 2276 1.000 atgatgttacGTAAtcgctga 
174 V$CREL.01 1225 1237 1231 1.000 attggcatTTCCc 
175 V$VAX1.01 2195 2213 2204 1.000 acacattAATTatcttgct 
176 V$SPZ1.01 3783 3793 3788 1.000 aGGAGggtccc 
177 V$NKX61.01 3802 3816 3809 1.000 agagTTAAttagccc 
178 V$STAT3.02 1823 1841 1832 1.000 cagaTTCCtgggattagga 
179 V$AARE.01 801 809 805 0.885 tTTCCatca 
180 V$ISRE.01 1245 1265 1255 1.000 ctgaaaaaaaGAAActgcttc 
181 V$HIC1.01 662 674 668 1.000 tggggTGCCcaga 
182 V$SATB1.01 636 650 643 1.000 aatAATAaaaaacac 
183 V$IRF1.01 3063 3083 3073 1.000 cctagaaaatGAAAgcctttc 
184 V$STAT.01 2821 2839 2830 1.000 ctccttaggGGAAaatcca 
185 V$LMX1B.01 2189 2211 2200 1.000 cataacagcaagaTAATtaatgt 
186 V$OCT1.03 2196 2212 2204 1.000 gcaagataATTAatgtg 
187 V$RBPJK.02 1195 1207 1201 1.000 gtgaTGGGaaaat 
188 V$NFAT.01 800 818 809 1.000 ctgatGGAAagaagatctt 
189 V$NKX61.01 2198 2212 2205 1.000 cacaTTAAttatctt 
190 V$SIX4.01 2137 2151 2144 1.000 atcaagGTGTcagcg 
191 V$NBRE.01 883 897 890 1.000 aaagAAGGtcatgga 
192 V$SIX.01 2956 2968 2962 1.000 aacTCAGgtatct 
193 V$VBP.01 1846 1862 1854 1.000 ctgtataatGTAAccta 
194 V$ZF5.01 2318 2328 2323 1.000 ctggGCGCctg 
195 V$GSH2.01 2662 2680 2671 1.000 cgtataTAATtagggctta 
196 V$AHRARNT.03 3170 3194 3182 1.000 cgaggggaatGCGTgggcttcggtc 
197 V$HNF4A.01 773 797 785 1.000 taattcactcCAAAgtacagggtta 
198 V$ZF5.01 3632 3642 3637 1.000 ctgaGCGCctg 
199 V$NANOG.01 2200 2218 2209 1.000 gataattAATGtgtgctgt 
200 V$HHEX.01 1540 1558 1549 1.000 ttttcttttttTAATgttg 
201 V$LHX6.01 3798 3820 3809 1.000 gctaagagtTAATtagccccgca 
202 V$NANOG.01 270 288 279 1.000 cttcatgAATGtttggaga 
203 V$BRN2.03 2196 2214 2205 0.929 cacacattaATTAtcttgc 
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204 V$MTBF.01 1039 1047 1043 1.000 tggaATTTg 
205 V$GATA1.03 2196 2208 2202 1.000 gcaaGATAattaa 
206 V$TH1E47.01 1662 1682 1672 1.000 agagcccttCCAGactcctgt 
207 O$PTATA.02 1121 1135 1128 1.000 tggtTATAaatatgc 
208 V$ZF5.01 3260 3270 3265 1.000 gggcGCGCacg 
209 V$GSH2.01 2663 2681 2672 1.000 aagcccTAATtatatacgt 
210 V$WHN.01 3430 3440 3435 1.000 gcgACGCcgcg 
211 V$GSH2.01 2234 2252 2243 1.000 tcgtggTAATttgttatag 
212 V$LMX1B.01 612 634 623 1.000 ctctgtctcaaaaTAATaaaaaa 
213 V$HSF2.02 300 324 312 1.000 ggggaagtaaaaAGAAgggtccaaa 
214 V$CEBPB.01 2086 2100 2093 1.000 aaggtgagGAAAtcg 
215 V$IRF4.01 1534 1554 1544 1.000 attaaaaaaaGAAAaaagaaa 
216 V$CDPCR3HD.01 2088 2106 2097 0.886 gaaaatcGATTtcctcacc 
217 V$RBPJK.02 1230 1242 1236 1.000 agttTGGGaaatg 
218 V$BRN2.04 3800 3818 3809 1.000 taagagtTAATtagccccg 
219 O$DINR.01 2572 2582 2577 1.000 gaTCAGtcggt 
220 V$PTX1.01 2461 2477 2469 1.000 agggCTAAcccctctaa 
221 V$BRIGHT.01 2196 2214 2205 1.000 gcaagataATTAatgtgtg 
222 V$NFAT.01 3220 3238 3229 1.000 aatttGGAAataagctgga 
223 V$P53.03 2896 2918 2907 0.922 ctctggagcagggggCAAGtcag 
224 V$PEA3.01 3437 3457 3447 1.000 ggaaagaAGGAagggctgcga 
225 V$IRF3.01 3073 3093 3083 1.000 cggggaaatgGAAAggctttc 
226 V$SOX2.01 2734 2756 2745 1.000 aaataaaACAAagacccatctct 
227 V$TWIST.01 665 685 675 0.952 aagaataCATGtggggtgccc 
228 V$CDP.02 1216 1234 1225 1.000 aaatgcCAATaaccatagc 
229 V$SMAD4.01 837 845 841 1.000 tGTCTtgcc 
230 V$SREBP.03 391 405 398 1.000 agaTCACctgagcgc 
231 V$HLF.01 2809 2825 2817 1.000 atccattccGTAAccga 
232 V$AREB6.01 2957 2969 2963 1.000 aagatACCTgagt 
233 V$CEBPB.01 3226 3240 3233 1.000 gcaatttgGAAAtaa 
234 V$YY1.02 276 296 286 1.000 cccaaCCATctccaaacattc 
235 O$VTATA.01 1156 1172 1164 1.000 aggtaTAAAtttcagga 
236 V$E47.02 348 364 356 1.000 ggattacaGGTGtaagc 
237 V$CDP.02 1604 1622 1613 1.000 tcccacCAATctcttccct 
238 V$OCT1.03 2197 2213 2205 1.000 acacattaATTAtcttg 
239 V$NANOG.01 3170 3188 3179 1.000 cgaggggAATGcgtgggct 
240 V$CDP.02 2749 2767 2758 1.000 atggatCAATgaaataaaa 
241 O$VTATA.01 1118 1134 1126 1.000 ggttaTAAAtatgctca 
242 V$NANOG.01 2812 2830 2821 1.000 gttacggAATGgattttcc 
243 V$MYT1L.01 3891 3903 3897 1.000 ggagAGTTggatg 
244 V$HOXA3.01 2664 2682 2673 1.000 agcccTAATtatatacgta 
245 V$SIX3.02 352 372 362 1.000 acacctgTAATcccagcactt 
246 V$RBPJK.02 2967 2979 2973 1.000 ggaaTGGGaaaag 
247 V$TEAD.01 2251 2263 2257 1.000 tccCATTcctgct 
248 V$HOXC8.01 2661 2679 2670 1.000 gtatataATTAgggcttat 
249 V$NEUROG.01 3657 3669 3663 1.000 ttgCCATctgata 
250 V$NFKAPPAB.01 3300 3312 3306 1.000 gcGGGAgatcccg 
251 V$HOXD10.01 620 636 628 1.000 caaaataaTAAAaaata 
252 V$CRX.01 494 510 502 1.000 atctgTAATcccagcta 
253 V$IRX5.01 670 682 676 1.000 aataCATGtgggg 
254 V$LHX6.01 3799 3821 3810 1.000 gtgcggggcTAATtaactcttag 
255 V$SP1.03 3513 3527 3520 1.000 agaGGGCgggagcag 
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256 V$LEF1.02 1644 1660 1652 1.000 cacatctCAAAgccggt 
257 O$DINR.01 3066 3076 3071 0.969 ttTCATtttct 
258 V$NFKAPPAB.01 3301 3313 3307 1.000 ccGGGAtctcccg 
259 V$OCT1.03 2664 2680 2672 1.000 cgtatataATTAgggct 
260 V$IPF1.01 2198 2216 2207 1.000 agcacacatTAATtatctt 
261 V$TST1.01 3217 3235 3226 0.900 ttggaAATAagctggaccc 
262 V$ZBP89.01 1338 1360 1349 1.000 cacacacactCCCCctaggcctg 
263 V$LHX6.01 2193 2215 2204 1.000 acagcaagaTAATtaatgtgtgc 
264 V$OCT1.03 3801 3817 3809 1.000 aagagttaATTAgcccc 
265 V$IRX5.01 671 683 677 1.000 cccaCATGtattc 
266 V$HIC1.01 3712 3724 3718 1.000 taggcTGCCggcg 
267 V$RFX1.01 1474 1492 1483 1.000 agagatacatgGCAActtg 
268 V$IRF7.01 2252 2272 2262 0.937 gcagGAATgggaaaatgatgt 
269 V$CREL.01 3346 3358 3352 1.000 gccggggcTTCCc 
270 V$LMX1B.01 625 647 636 1.000 taataaaaaataaTAATaaaaaa 
271 V$MEF3.01 126 138 132 1.000 tggTCAGgagtcc 
272 V$MYF5.01 3390 3406 3398 1.000 ctgcggCAGCcgctggg 
273 V$USF.04 2762 2774 2768 0.915 taggCACAtggat 
274 V$NKX12.01 3801 3817 3809 1.000 ggggctAATTaactctt 
275 V$INSM1.01 434 446 440 1.000 tgataGGGGgaag 
276 V$HOXD10.01 633 649 641 1.000 aataataaTAAAaaaca 
277 V$SCX.01 2758 2778 2768 1.000 attgatccatgTGCCtataac 
278 V$XFD1.01 2414 2430 2422 1.000 attttgTAAAtaaggtc 
279 V$HIC1.01 3275 3287 3281 0.869 aaggcTGCGcgaa 
280 V$GATA.01 1597 1609 1603 1.000 gtggGATAaggaa 
281 V$HIC1.01 1680 1692 1686 0.889 acgggTGCAcaca 
282 V$ESRRB.01 880 898 889 1.000 ggaaaagaAGGTcatggag 
283 V$MARE.02 964 984 974 0.875 gcaGGCTaatgcagcagcggc 
284 V$LHX3.02 3794 3816 3805 1.000 gccggctaagagtTAATtagccc 
285 V$ER.04 1395 1413 1404 1.000 ctagGTCAtgcagacccta 
286 V$OCT3_4.02 1394 1410 1402 1.000 ggtctGCATgacctaga 
287 V$INSM1.01 25 37 31 1.000 tggaaGGGGacac 
288 V$BRN2.03 679 697 688 1.000 tattctttcATTTaaatat 
289 V$WT1.01 3821 3837 3829 0.837 cggcgAGGGgggaggcg 
290 V$GATA3.01 1510 1522 1516 1.000 tcggGATAaaaat 
291 V$E47.01 3412 3428 3420 1.000 ggcttGCAGgtggttcg 
292 V$NFY.04 1219 1233 1226 1.000 aatgCCAAtaaccat 
293 V$HMX3.01 2163 2181 2172 1.000 gaagtccaAAGTgggtctc 
294 V$MYT1L.01 3244 3256 3250 1.000 ggacAGTTcacgc 
295 V$GFI1.02 2141 2155 2148 1.000 caaAATCaaggtgtc 
296 V$SRY.01 1055 1077 1066 1.000 tggtaaaACAAaaaaaatttttg 
297 V$MIT.01 2760 2774 2767 1.000 tgatcCATGtgccta 
298 V$HOXD10.01 2745 2761 2753 1.000 caatgaaaTAAAacaaa 
299 V$NMYC.01 3239 3251 3245 1.000 gccccgCGTGaac 
300 V$CETS1P54.01 703 723 713 0.843 ctcttcCTGGaagtaaatatt 
301 V$DLX3.01 1425 1443 1434 1.000 ggcttcagcTAATttcatc 
302 V$BRN4.01 2667 2685 2676 1.000 gtatacgtataTAATtagg 
303 V$HMGA.01 765 787 776 1.000 ctttggagtgAATTattggagtt 
304 V$NFKAPPAB.01 3344 3356 3350 1.000 cgGGGAagccccg 
305 V$OCT1.03 3802 3818 3810 1.000 cggggctaATTAactct 
306 V$ZNF219.01 1341 1363 1352 1.000 acacactCCCCctaggcctgcag 
307 V$PCE1.01 3801 3817 3809 1.000 ggggcTAATtaactctt 
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308 V$VMYB.05 1684 1696 1690 1.000 gggAACGggtgca 
309 V$IPF1.01 2665 2683 2674 1.000 atacgtataTAATtagggc 
310 V$NFKAPPAB50.01 438 450 444 1.000 aggGGGAagccct 
311 V$AP2.02 1503 1517 1510 1.000 aaaGCCTtcgggata 
312 V$HMGIY.01 1157 1179 1168 1.000 ggtataAATTtcaggatatatgt 
313 V$PAX4.02 2664 2678 2671 1.000 tatatAATTagggct 
314 V$HOXC13.02 1109 1125 1117 1.000 tatgctcaTAAAgaagt 
315 V$TST1.01 167 185 176 0.900 attgtTTTAagctgctaaa 
316 V$MYOD.01 2559 2575 2567 0.931 cggtGACAgatggagac 
317 V$P53.02 1804 1826 1815 1.000 ctctcctcccatgttCATGtcct 
318 V$FAST1.02 157 173 165 1.000 aaataTGTGcattgttt 
319 V$BRIGHT.01 3800 3818 3809 1.000 cggggctaATTAactctta 
320 V$NF1.03 1467 1487 1477 1.000 tctctgccaagttGCCAtgta 
321 V$BACH2.01 2001 2021 2011 0.813 caatcgTGGGtcaagttccta 
322 V$HES1.01 3260 3274 3267 0.944 agggcgtGCGCgccc 
323 V$HES1.01 3356 3370 3363 0.944 tgggcgtGCGCagcc 
324 V$GATA1.04 791 803 797 1.000 tcagGATAaccct 
325 V$IPF1.01 2193 2211 2202 1.000 acagcaagaTAATtaatgt 
326 V$NF1.03 1625 1645 1635 1.000 agagtacctccctGCCAcaca 
327 V$BRN2.03 2744 2762 2753 1.000 ctttgttttATTTcattga 
328 V$AP2.02 1346 1360 1353 1.000 cagGCCTagggggag 
329 V$KAISO.01 2847 2857 2852 1.000 ttgcCTGCgaa 
330 V$HMGIY.01 1046 1068 1057 1.000 aaaaaaAATTtttgagaggggtg 
331 V$LHX6.01 2194 2216 2205 1.000 agcacacatTAATtatcttgctg 
332 V$GSC.02 109 125 117 1.000 ccagaTAATccatgcct 
333 V$ZNF219.01 1731 1753 1742 1.000 cagtcaaCCCCcagccccctggt 
334 V$OCT1.03 2663 2679 2671 1.000 aagccctaATTAtatac 
335 V$LHX6.01 2660 2682 2671 1.000 aataagcccTAATtatatacgta 
336 V$P53.02 1783 1805 1794 1.000 gatctcaggcggaatCATGccct 
337 V$CDX2.02 1119 1137 1128 1.000 gagcatatTTATaaccata 
338 V$ZNF219.01 2897 2919 2908 1.000 tgacttgCCCCctgctccagagc 
339 V$ZNF217.01 766 778 772 1.000 GAATtattggagt 
340 V$BRN5.04 3799 3821 3810 1.000 gtgcggggctaATTAactcttag 
341 V$BRN2.04 2663 2681 2672 1.000 acgtataTAATtagggctt 
342 V$GATA3.01 1894 1906 1900 1.000 ggagGATAataaa 
343 V$MAZ.01 3481 3493 3487 1.000 gggaGAGGggcgc 
344 V$HOXC13.01 1894 1910 1902 1.000 ggaggataaTAAActga 
345 V$GRHL1.01 3565 3577 3571 1.000 agagccGGTTccc 
346 V$MYCMAX.03 2044 2056 2050 0.754 cggccaTGAGcca 
347 V$CAAT.01 11 25 18 0.847 ataaCCAGtgaactt 
348 V$INSM1.01 3843 3855 3849 1.000 tttctGGGGacac 
349 V$CHREBP_MLX.01 2629 2645 2637 1.000 CACGtggaccccgggtg 
350 V$TIEG.01 1339 1353 1346 1.000 agGGGGagtgtgtgt 
351 V$P53.02 2885 2907 2896 0.885 cagcccgagctctgaCTTGcccc 
352 V$RFX1.02 1992 2010 2001 0.882 aagatgcaataGGAActtg 
353 V$INSM1.01 1044 1056 1050 1.000 tgagaGGGGtgga 
354 V$AP2.01 3788 3802 3795 0.881 ttaGCCGgcgggacc 
355 V$E4F.01 848 860 854 0.842 gtgATGTgacaca 
356 V$SP1.03 1734 1748 1741 1.000 aggGGGCtgggggtt 
357 V$CDE.01 3748 3760 3754 1.000 gcagCGCGgcatc 
358 V$PRE.01 1024 1042 1033 1.000 tttggagaagaTGTTctca 
359 V$GC.01 2915 2929 2922 0.877 atagGGAGgggctct 
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360 O$HMTE.01 2421 2441 2431 1.000 tgAGCGgggcgattttgtaaa 
361 V$INSM1.01 289 301 295 1.000 tggttGGGGcagg 
362 V$GATA3.02 808 820 814 1.000 gaaAGATcttctt 
363 V$EN1.01 684 702 693 1.000 ttgggataTTTAaatgaaa 
364 V$HOX_PBX.01 2353 2369 2361 0.944 acatGGATggattgttc 
365 V$DLX5.01 2236 2254 2245 1.000 tgctataacaAATTaccac 
366 V$MAZ.01 3167 3179 3173 1.000 aaccGAGGggaat 
367 V$TLX1.01 1981 1999 1990 1.000 attaaagCGGTaagatgca 
368 V$BACH2.01 2373 2393 2383 0.813 tgctgaTGTGtcagagacgag 
369 V$MEF2.03 1552 1574 1563 1.000 aatgttgctcaaaATAGttttct 
370 V$CP2.01 1421 1439 1430 1.000 tgCTGGcttcagctaattt 
371 V$LHX3.02 2665 2687 2676 1.000 ctgtatacgtataTAATtagggc 
372 V$E2F.03 3257 3273 3265 1.000 cgcggGCGCgcacgccc 
373 V$TEAD.01 3171 3183 3177 1.000 acgCATTcccctc 
374 V$NFKAPPAB.01 1227 1239 1233 1.000 ttGGGAaatgcca 
375 V$OLF1.02 2971 2993 2982 1.000 tcccatTCCCtcggggttgtgag 
376 V$PRE.01 2354 2372 2363 1.000 catggatggatTGTTcttc 
377 V$OCT3_4.02 2782 2798 2790 1.000 tttgtGCATctggccga 
378 V$PAX4.02 2197 2211 2204 1.000 acattAATTatcttg 
379 V$AML3.01 2685 2699 2692 1.000 cagaGTGGtttttat 
380 V$GFI1.02 1412 1426 1419 1.000 tacAATCaatgctgg 
381 V$NKX25.02 2664 2682 2673 1.000 agcccTAATtatatacgta 
382 V$HMBOX.01 7 23 15 1.000 gttcactgGTTAttgat 
383 V$PAX4.02 2665 2679 2672 1.000 gccctAATTatatac 
384 V$TST1.01 970 988 979 1.000 gctgcATTAgcctgctgct 
385 V$TEAD.01 271 283 277 1.000 aaaCATTcatgaa 
386 V$HMGA.01 267 289 278 1.000 aatcttcatgAATGtttggagat 
387 V$NKX12.01 3802 3818 3810 1.000 agagttAATTagccccg 
388 O$VTATA.01 2665 2681 2673 0.892 acgtaTATAattagggc 
389 V$MAZR.01 2916 2928 2922 1.000 tagggaGGGGctc 
390 V$TAL1BETAITF2.01 3653 3673 3663 1.000 agggtatCAGAtggcaaagtt 
391 V$TEF.01 2418 2434 2426 1.000 ggcgattttGTAAataa 
392 V$IPF1.01 2660 2678 2669 1.000 aataagcccTAATtatata 
393 V$CDX2.02 148 166 157 1.000 gcacatatTTATtatctca 
394 V$PLAG1.01 1614 1634 1624 1.000 GAGGtactctacagggaagag 
395 V$MTF-1.01 3356 3370 3363 0.949 ggctGCGCacgccca 
396 V$FHXB.01 1556 1572 1564 0.818 ttgctcAAAAtagtttt 
397 V$HSF1.01 263 287 275 0.857 ttggaatcttcaTGAAtgtttggag 
398 V$TST1.01 1976 1994 1985 1.000 ggagcATTAaagcggtaag 
399 V$CAAT.01 1078 1092 1085 1.000 ctagCCAAgcacttt 
400 V$BRN2.04 2195 2213 2204 1.000 agcaagaTAATtaatgtgt 
401 V$BRN5.04 2660 2682 2671 1.000 aataagccctaATTAtatacgta 
402 V$CDX2.02 1895 1913 1904 1.000 aagtcagtTTATtatcctc 
403 V$MYOGENIN.02 3006 3022 3014 1.000 gagatcCAGCtgcgaca 
404 V$RFX1.02 197 215 206 0.945 ttattacacagGTAActaa 
405 V$OCT3_4.02 160 176 168 1.000 tatgtGCATtgttttaa 
406 O$PTATA.02 1155 1169 1162 1.000 gaggTATAaatttca 
407 V$BRN3.02 766 784 775 1.000 actccaaTAATtcactcca 
408 V$NKX12.01 2663 2679 2671 1.000 gtatatAATTagggctt 
409 V$PLAG1.01 3506 3526 3516 1.000 GAGGgcgggagcagggccagg 
410 V$BRN2.01 2668 2686 2677 0.933 ctAATTatatacgtataca 
411 V$CHOP.01 1587 1599 1593 1.000 ttttGCAAtattc 
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412 V$XFD2.01 1119 1135 1127 1.000 tggttaTAAAtatgctc 
413 V$TST1.01 2230 2248 2239 1.000 aacaaATTAccacgaatgt 
414 V$MTBF.01 2961 2969 2965 0.885 aggtATCTt 
415 V$TAL1ALPHAE47.01 2556 2576 2566 1.000 tcggtgaCAGAtggagacccg 
416 V$NFKAPPAB.01 3783 3795 3789 1.000 gcGGGAccctcct 
417 V$TAL1BETAE47.01 465 485 475 1.000 ctgcgccCAGAtgattttgta 
418 V$BCL6.02 3058 3074 3066 1.000 catatccTAGAaaatga 
419 V$MEF3.01 3149 3161 3155 1.000 ggcTCAGggcact 
420 V$PAX4.02 2198 2212 2205 1.000 aagatAATTaatgtg 
421 V$ZNF217.01 1869 1881 1875 1.000 GAATccaggcagt 
422 O$VTATA.01 2687 2703 2695 1.000 gaacaTAAAaaccactc 
423 V$MTBF.01 2795 2803 2799 1.000 agttATTTg 
424 V$INSM1.01 871 883 877 1.000 ttcctGGGGcttg 
425 V$GABP.01 1660 1680 1670 1.000 aggagtctGGAAgggctctga 
426 V$MSX3.01 2233 2251 2242 1.000 ttcgtggTAATttgttata 
427 V$MEIS1B_HOXA9.01 2140 2154 2147 1.000 TGACaccttgatttt 
428 V$NXF_ARNT.01 3679 3703 3691 1.000 cttcataaaggCGTGgtggcgattc 
429 V$PHOX2.01 2511 2531 2521 1.000 acctcTAATgtcctggtcccg 
430 V$NKX25.02 3802 3820 3811 1.000 agagtTAATtagccccgca 
431 V$OVOL1.01 2715 2729 2722 1.000 aagcccGTTAaatag 
432 V$HOMEZ.01 2092 2106 2099 1.000 aggaaATCGattttc 
433 V$LHX6.01 2661 2683 2672 1.000 atacgtataTAATtagggcttat 
434 V$ATF2.01 3718 3738 3728 0.815 cctgtcTGATgtcataggctg 
435 V$DLX4.01 764 782 773 1.000 gaactccaatAATTcactc 
436 V$REV-ERBA.01 1649 1671 1660 1.000 ctcaaagccgGTCAgagcccttc 
437 V$XFD2.01 150 166 158 1.000 agataaTAAAtatgtgc 
438 V$HSF1.01 262 286 274 0.857 tccaaacattcaTGAAgattccaag 
439 V$JARID2.01 3058 3076 3067 0.850 tttcaTTTTctaggatatg 
440 O$HMTE.01 3403 3423 3413 0.961 gcAGCCccgcgaaccacctgc 
441 V$CKROX.01 3826 3842 3834 1.000 agggGGGAggcgccagt 
442 V$HNF1.04 204 220 212 1.000 tgctgttaGTTAcctgt 
443 V$PHOX2.01 1877 1897 1887 1.000 ctcccTAATctcatccactgc 
444 V$MTF-1.01 3511 3525 3518 0.835 ccctGCTCccgccct 
445 V$LEF1.01 1856 1872 1864 1.000 tatacagCAAAgggaat 
446 V$E4F.01 2268 2280 2274 1.000 attACGTaacatc 
447 V$LEF1.01 212 228 220 1.000 ctaacagCAAAggagag 
448 V$PAX6.04 1603 1621 1612 1.000 atcCCACcaatctcttccc 
449 V$JARID2.01 1056 1074 1065 0.850 aaaaaTTTTttttgtttta 
450 O$VTATA.02 727 743 735 1.000 atctgTAAAatggagtt 
451 V$IRF7.01 2962 2982 2972 0.937 gaggGAATgggaaaagatacc 
452 V$OLF1.02 2336 2358 2347 1.000 ccatgtTCCCtttggggatctag 
453 V$CLOX.01 112 130 121 0.804 gataATCCatgcctggact 
454 V$SL1.01 2919 2941 2930 1.000 cccctccCTATttagagcccagt 
455 V$CDX2.02 2743 2761 2752 1.000 tctttgttTTATttcattg 
456 V$IRF7.01 224 244 234 1.000 gagaGAAAgccaaaatgaagg 
457 V$EGR2.01 3176 3192 3184 1.000 gaatGCGTgggcttcgg 
458 V$PU1.01 2085 2105 2095 1.000 aaaggtgaGGAAatcgatttt 
459 V$NFAT5.02 1198 1216 1207 1.000 atgGGAAaattgagggggg 
460 V$NFKAPPAB.01 2821 2833 2827 1.000 agGGGAaaatcca 
461 V$HOXB9.01 3642 3658 3650 1.000 gtcagtagTAAAgggta 
462 V$SP1.01 292 306 299 1.000 ttgGGGCaggggaag 
463 V$BARBIE.01 980 994 987 1.000 tcgaAAAGcagcagg 
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464 V$GLI3.02 3175 3189 3182 1.000 aagcCCACgcattcc 
465 V$OLF1.02 1341 1363 1352 1.000 acacacTCCCcctaggcctgcag 
466 V$PHOX2.01 2470 2490 2480 1.000 ccctcTAATgtgttttcagca 
467 V$PLZF.01 785 799 792 1.000 aagTACAgggttatc 
468 V$E2F.03 985 1001 993 0.810 gctagGCTCgaaaagca 
469 V$PLAG1.01 3514 3534 3524 1.000 GAGGcacagagggcgggagca 
470 V$PLZF.01 3858 3872 3865 1.000 gagTACAgtggcagc 
471 V$GLIS3.01 1206 1220 1213 1.000 atagCCCCcctcaat 
472 V$HOMEZ.01 2093 2107 2100 1.000 ggaaaATCGatttcc 
473 V$OLF1.02 2400 2422 2411 1.000 tgtctaTCCCtgaagaccttatt 
474 V$GC.01 3827 3841 3834 0.877 ggggGGAGgcgccag 
475 V$E4F.01 2266 2278 2272 0.842 atgATGTtacgta 
476 V$VDR_RXR.04 3234 3258 3246 0.929 cgggacaGTTCacgcggggcaattt 
477 V$LEF1.01 2739 2755 2747 1.000 aataaaaCAAAgaccca 
478 V$RREB1.01 1693 1707 1700 1.000 tCCCAaacctccctc 
479 V$CLOX.01 2093 2111 2102 1.000 ggaaATCGattttccccta 
480 V$BARBIE.01 1703 1717 1710 1.000 aaggAAAGtggaggg 
481 V$HSF2.01 253 277 265 0.917 acagaattgcttgGAATcttcatga 
482 V$PPARG.02 2493 2515 2504 0.892 aggggatggggcAGAGgccggga 
483 V$PPARG.02 3315 3337 3326 1.000 cttctgccggcgAAAGggaagcg 
484 V$STAT1.02 1825 1843 1834 1.000 ctaatcccaGGAAtctgtg 
485 V$EVI1.02 3200 3216 3208 1.000 ctgagAAGAaaagcttc 
486 O$LTATA.01 2663 2679 2671 1.000 gtaTATAattagggctt 
487 V$E4BP4.01 1843 1863 1853 1.000 gctgtataatGTAAcctattc 
488 V$VMYB.01 211 223 217 0.817 actAACAgcaaag 
489 V$DLX4.01 1454 1472 1463 1.000 ctgaaaaaatAATTctctg 
490 V$BNC.01 247 265 256 1.000 caagcaattcTGTCccttt 
491 V$PIT1.02 2199 2213 2206 1.000 acacaTTAAttatct 
492 V$RBPJK.01 2867 2879 2873 1.000 agctTGGGaaggc 
493 V$CTCF.04 3285 3311 3298 0.841 gggatctcccgccagcCGGCtgcaaag 
494 V$BRN2.02 675 693 684 1.000 catgtattcttTCATttaa 
495 V$EVI1.05 2958 2974 2966 1.000 gggaaaaGATAcctgag 
496 V$GLI1.01 420 434 427 0.771 aagaccaGCCAagct 
497 V$HNF6.01 2093 2109 2101 0.786 ggggaaaaTCGAtttcc 
498 V$PPARG.02 235 257 246 1.000 aaaatgaaggggAAAGggacaga 
499 V$MTF-1.01 1681 1695 1688 1.000 gtgtGCACccgttcc 
500 V$NKX12.01 2197 2213 2205 1.000 caagatAATTaatgtgt 
501 V$MYT1.02 3666 3678 3672 1.000 gcaAAGTtgggac 
502 V$HSF2.01 2861 2885 2873 1.000 gggcttagcttggGAAGgctcaaaa 
503 V$MARE.02 3274 3294 3284 0.792 ggcTGCAaaggctgcgcgaaa 
504 O$PTATA.01 685 699 692 0.826 ttcaTTTAaatatcc 
505 V$ZBRK1.01 1246 1270 1258 1.000 gcagggaaGCAGtttctttttttca 
506 V$HOXA10.01 148 164 156 1.000 tgagataaTAAAtatgt 
507 V$SZF1.01 3651 3675 3663 1.000 aaaGGGTatcagatggcaaagttgg 
508 V$PHOX2.01 768 788 778 1.000 tccaaTAATtcactccaaagt 
509 V$NFAT5.01 3218 3236 3227 1.000 tttGGAAataagctggacc 
510 V$VMYB.04 2124 2136 2130 1.000 actAACGcagccc 
511 V$HOXB9.01 2579 2595 2587 1.000 cgagtcctTAAAagatc 
512 V$HOXB9.01 3676 3692 3684 1.000 gaccttcaTAAAggcgt 
513 V$PLAG1.01 3171 3191 3181 1.000 GAGGggaatgcgtgggcttcg 
514 V$PLAG1.01 2902 2922 2912 0.958 GGGGctctggagcagggggca 
515 V$TCFCP2L1.01 940 958 949 0.815 gcCAGGctctgtcctgcaa 
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516 O$HMTE.01 3423 3443 3433 0.961 caAGCCccgcggcgtcgcagc 
517 V$TIEG.01 1337 1351 1344 0.750 ggGGAGtgtgtgtgt 
518 V$GKLF.01 306 322 314 1.000 gtaaaaagaAGGGtcca 
519 V$SL1.01 1553 1575 1564 1.000 gagaaaaCTATtttgagcaacat 
520 V$BRN5.04 188 210 199 1.000 tctagcaacttATTAcacaggta 
521 V$TIEG.01 1285 1299 1292 0.750 gtGTGGtgtgtgtgt 
522 V$GRE.01 2688 2706 2697 1.000 agtggtttttatGTTCtga 
523 V$TIEG.01 1283 1297 1290 0.750 gtGGTGtgtgtgtgt 
524 V$STAT.01 1925 1943 1934 0.769 aaccttacgGCAAaaataa 
525 V$ESRRB.01 1389 1407 1398 1.000 gctcatctAGGTcatgcag 
526 V$BRN2.01 196 214 205 0.967 ctTATTacacaggtaacta 
527 V$HEN1.02 3004 3024 3014 1.000 tgtgtcgcaGCTGgatctcca 
528 O$XCPE1.01 3787 3797 3792 1.000 cgGCGGgaccc 
529 V$GRHL1.01 10 22 16 1.000 ttcactGGTTatt 
530 V$NKX12.01 2196 2212 2204 1.000 cacattAATTatcttgc 
531 V$SOX5.01 2535 2557 2546 1.000 cgaggtgaCAATagctcatgggg 
532 V$HNF6.01 2090 2106 2098 0.786 tgaggaaaTCGAttttc 
533 V$ACAAT.01 2012 2026 2019 0.750 gccaGCAAtcgtggg 
534 V$EVI1.06 2193 2209 2201 1.000 acagcaAGATaattaat 
535 V$NKX63.01 2665 2679 2672 1.000 gtataTAATtagggc 
536 V$NKX63.01 2197 2211 2204 1.000 caagaTAATtaatgt 
537 V$PAX6.02 3008 3026 3017 1.000 tctggagatCCAGctgcga 
538 V$SL1.01 2661 2683 2672 0.803 ataagccCTAAttatatacgtat 
539 V$OCT2.01 1219 1235 1227 1.000 gaaATGCcaataaccat 
540 V$RBPJK.01 815 827 821 0.796 agtgTGAGaaaga 
541 V$PHOX2.01 963 983 973 1.000 caggcTAATgcagcagcggca 
542 V$GLI1.01 3383 3397 3390 1.000 cggagctCCCAgcgg 
543 V$GSH1.01 1574 1592 1583 1.000 tctgctcagaTAATtttgc 
544 V$HBP1.01 2748 2770 2759 1.000 cacatggatcAATGaaataaaac 
545 V$BRN2.04 3801 3819 3810 1.000 gcggggcTAATtaactctt 
546 V$ARP1.01 3495 3519 3507 1.000 ggagcagggccaggGGTCgggaatc 
547 V$HBP1.01 2965 2987 2976 1.000 accccgagggAATGggaaaagat 
548 V$EN1.02 2233 2251 2242 1.000 tataacaAATTaccacgaa 
549 V$CDE.01 3025 3037 3031 0.842 gatgCGCCgtgtc 
550 V$HFH1.01 1917 1933 1925 1.000 caaaaaTAAActctatc 
551 V$HOXC9.01 2197 2213 2205 1.000 caagataaTTAAtgtgt 
552 V$SRF.04 1144 1162 1153 1.000 tatacctccTATGgcttgg 
553 V$HOXC9.01 3801 3817 3809 1.000 ggggctaaTTAActctt 
554 V$HBP1.01 2809 2831 2820 1.000 tcggttacggAATGgattttccc 
555 V$CDE.01 3475 3487 3481 1.000 ggggCGCGagcta 
556 V$PPARG.03 2073 2095 2084 1.000 ctagaagctggaAAAGgtgagga 
557 V$SREBP.02 664 678 671 0.750 tggGCACcccacatg 
558 V$DBP.01 2182 2198 2190 1.000 tgctgTTATggagggca 
559 V$VDR_RXR.04 1382 1406 1394 0.821 ctggccaGCTCatctaggtcatgca 
560 V$NRF2.01 3191 3211 3201 1.000 ggtccgtcGGAAgcttttctt 
561 V$SL1.01 442 464 453 1.000 ggaagccCTATctctactaaaaa 
562 V$HOXC9.01 1121 1137 1129 0.884 tatggttaTAAAtatgc 
563 V$TEF.01 3721 3737 3729 0.818 ctgtctgatGTCAtagg 
564 V$NFY.03 1520 1534 1527 1.000 aaagCCAAacagatt 
565 V$HDBP1_2.01 3319 3337 3328 1.000 cttctgCCGGcgaaaggga 
566 V$GKLF.01 2915 2931 2923 0.826 aaatagggaGGGGctct 
567 V$BRN2.02 151 169 160 0.857 aatgcacatatTTATtatc 
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568 V$GKLF.01 234 250 242 0.826 caaaatgaaGGGGaaag 
569 V$NBRE.01 2082 2096 2089 1.000 ggaaAAGGtgaggaa 
570 V$NFKAPPAB50.01 3460 3472 3466 0.750 gagCGGAtgcccg 
571 V$CLOX.01 2758 2776 2767 0.804 attgATCCatgtgcctata 
572 V$DBP.01 1395 1411 1403 0.808 ctaggTCATgcagaccc 
573 V$BRN3.03 2199 2217 2208 1.000 agataatTAATgtgtgctg 
574 V$ER.03 1395 1413 1404 1.000 tagggtctgcatGACCtag 
575 V$TCF2.01 2710 2726 2718 0.756 accaactaTTTAacggg 
576 V$RP58.01 469 481 475 1.000 aaatCATCtgggc 
577 V$ISL1.01 1891 1913 1902 1.000 tagggaggaTAATaaactgactt 
578 V$EN2.01 767 785 776 1.000 ctccaatAATTcactccaa 
579 V$TCF2.01 3802 3818 3810 0.761 cggggctaATTAactct 
580 V$AIRE.01 1078 1104 1091 0.964 aaagtgcttggctagagAGGAgaaatg 
581 V$IRF7.01 236 256 246 0.821 aaatGAAGgggaaagggacag 
582 V$OCT1.03 633 649 641 1.000 tgttttttATTAttatt 
583 V$FHXB.01 654 670 662 0.818 gtgcccAGAAcaatttt 
584 V$ISL1.01 1971 1993 1982 1.000 ttaccgcttTAATgctcccttcc 
585 V$HNF6.01 2816 2832 2824 0.833 ggggaaaaTCCAttccg 
586 V$AIRE.01 692 718 705 0.917 ttacttccaggaagagtTGGGatattt 
587 V$RP58.01 3020 3032 3026 1.000 ggcgCATCtggag 
588 V$HNF1.04 3797 3813 3805 1.000 ggctaagaGTTAattag 
589 V$OCT1.03 620 636 628 1.000 tattttttATTAttttg 
590 V$GSH1.01 2199 2217 2208 1.000 cagcacacatTAATtatct 
591 V$GSH1.01 970 988 979 1.000 agcagcaggcTAATgcagc 
592 V$HOX1-3.01 965 983 974 1.000 caggcTAATgcagcagcgg 
593 V$PIT1.02 3801 3815 3808 1.000 aagagTTAAttagcc 
594 V$HOXB5.01 1892 1910 1901 0.763 tcagtTTATtatcctccct 
595 V$HDBP1_2.01 3786 3804 3795 1.000 tcttagCCGGcgggaccct 
596 V$NKX26.01 2161 2179 2170 1.000 agtccaaAGTGggtctcag 
597 V$HOXC10.01 1907 1923 1915 1.000 ctctatcaTAAAgtcag 
598 V$OVOL1.01 2121 2135 2128 1.000 ggctgcGTTAgtttc 
599 V$IK3.01 1138 1150 1144 1.000 ggcttGGAAtatc 
600 V$HOXA9.02 2690 2706 2698 1.000 tcagaacaTAAAaacca 
601 V$OCT1.06 1216 1232 1224 0.750 gctatggtTATTggcat 
602 V$HNF6.01 722 738 730 0.833 tttctaacTCCAtttta 
603 V$HOX1-3.01 1938 1956 1947 1.000 aaggtTAATgtagaagagg 
604 V$AML3.01 1287 1301 1294 1.000 gagtGTGGtgtgtgt 
605 V$E2F.03 1312 1328 1320 1.000 cacacGCGCgcacacac 
606 V$OLF1.01 3868 3890 3879 1.000 gtgagcTCCCctgggtaggagta 
607 V$BRN2.04 2662 2680 2671 1.000 taagcccTAATtatatacg 
608 V$PIT1.02 2200 2214 2207 1.000 gataaTTAAtgtgtg 
609 V$GCM1.01 3159 3169 3164 1.000 gcCCCTcaaac 
610 V$NKX63.01 2201 2215 2208 1.000 ataatTAATgtgtgc 
611 V$HOXB6.01 2235 2253 2244 1.000 cgtggtAATTtgttatagc 
612 V$HDBP1_2.01 327 345 336 1.000 ccgtgcCCGGccctggtgt 
613 V$HEN1.02 3003 3023 3013 1.000 ggagatccaGCTGcgacacaa 
614 O$SPT15.01 1120 1136 1128 0.763 atggttaTAAAtatgct 
615 V$TEF1.01 2971 2983 2977 1.000 tccCATTccctcg 
616 V$HOXB5.01 1895 1913 1904 1.000 gaggaTAATaaactgactt 
617 V$CDX2.02 1153 1171 1162 1.000 cctgaaatTTATacctcct 
618 O$MTATA.01 2921 2937 2929 1.000 ggctcTAAAtagggagg 
619 V$CREB2.01 3719 3739 3729 1.000 agcctaTGACatcagacagga 
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620 V$OLF1.01 37 59 48 1.000 tggcagTCCCatgagaagctcag 
621 V$E2F.03 3473 3489 3481 1.000 gagggGCGCgagctaaa 
622 V$COUP.01 2494 2518 2506 0.779 ggggatggggcagAGGCcgggacca 
623 V$OC2.01 109 125 117 1.000 ccagatAATCcatgcct 
624 V$IRF3.01 242 262 252 0.758 aggggaaaggGACAgaattgc 
625 V$NRF1.01 3261 3277 3269 1.000 ggcGCGCacgccctttc 
626 V$MEOX1.01 1578 1596 1587 1.000 ctcagatAATTttgcaata 
627 V$IPF1.01 2231 2249 2240 1.000 cattcgtggTAATttgtta 
628 V$LHX3.02 1450 1472 1461 1.000 tgcactgaaaaaaTAATtctctg 
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